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ABSTRACT 
Huei-Ting Tsai: Association between Tardive Dyskinesia and Dopamine Receptor 
Genes among Patients with Chronic Schizophrenia 
 
 
(Under the direction of Kari E. North, PhD) 
 
 
This dissertation aims to study associations between genetic variants and 
prevalent tardive dyskinesia (TD) among patients with chronic schizophrenia. The 
etiology of TD is largely unknown but dopamine receptors (DR) have been proposed 
as the drug target of anti-schizophrenic effects. In addition, the blockade of the 
dopaminergic pathway from long-term antipsychotic use likely influences the etiology 
of TD. Therefore, this study interrogated the relationship between DR genes (DRD 1, 
2, 3, 4 and 5) and the prevalence of TD. 
 The first study conducted as part of this dissertation was a meta-analysis of 13 
association studies between DRD3 rs6280 and prevalent TD. Results from the 
meta-analysis implied strong publication bias in the studies on the relationship 
between rs6280 and TD. Study characteristics moderately associated with 
heterogeneous effect estimates in the published literature include publication year, 
criteria of subject’s enrollment, TD assessment and diagnosis, age, percent female, 
and ancestry. In contrast, the summary estimate obtained when assuming a 
recessive mode of inheritance was not vulnerable to publication bias or heterogeneity 
 iii
in the published literature and indicated no association between rs6280 and TD 
(POR= 0.93, 95% C.I.= 0.70, 1.23). 
The second study from this dissertation was a cohort study about associations 
between TD susceptibility and 54 single nucleotide polymorphisms (SNPs) in all DR 
genes. Study subjects were 711 participants with chronic schizophrenia in the Clinical 
Antipsychotic Trial of Intervention Effectiveness (CATIE) study. Two hundred and 
seven participants who ever met the Schooler-Kane criteria in any one of Abnormal 
Involuntary Movement Scale (AIMS) evaluations in the CATIE were defined as TD. 
Several DRD1-3 SNPs demonstrated statistically significant associations with TD. 
However, after multiple comparison adjustments, no SNPs or haplotypes in DR 
genes displayed statistically significant association with TD.   
In summary, results from a comprehensive meta-analysis of 13 genetic 
association studies demonstrated no association between polymorphisms of rs6280 
and TD. In addition, no association was detected in a cohort study interrogating the 
relationship between 54 SNPs in DR genes and TD among 711 CATIE participants. 
These findings suggest that SNPs in DR genes do not exert a strong effect on the 
pathophysiology of TD. 
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CHAPTER I. 
 STATEMENT OF SPECIFIC AIMS 
This dissertation aims to study associations between genetic variants and 
prevalent tardive dyskinesia (TD) among patients with chronic schizophrenia. The 
etiology of TD is largely unknown but dopamine receptors (DR) have been proposed 
as the drug target of anti-schizophrenic effects. In addition, the blockade of the 
dopaminergic pathway from long-term antipsychotic use likely influences the etiology 
of TD. Therefore, this study interrogated the relationship between DR genes (DRD 1, 
2, 3, 4 and 5) and the prevalence of TD. Three specific aims include: 
Aim 1. Meta-analyses of published studies to evaluate the association between DRD3 
rs6280 and prevalence odds ratio (POR) of TD.  
Aim 2. Assess the association between TD and 54 single nucleotide polymorphisms 
(SNPs) in all DR genes. 
Aim 3. Investigate the association between TD and haplotype variations in DR genes. 
  
 
Chapter II.  
BACKGROUND 
1. Conceptual framework 
The aim of this study is to understand genetic influence on TD, one of most 
frequent, distressing and persistent side-effects of long-term antipsychotic treatment. 
Below, I provided a conceptual model to illustrate the hypothesized relationships 
between the genes of interest, TD and other relevant covariates (Figure. 2.1). Details 
of TD, genes of interest, and covariates would be further discussed in following text. 
 
2. Background of schizophrenia and TD 
2.1. Schizophrenia 
2.1.1. Public health significance of schizophrenia 
Schizophrenia influences a person’s ability of recognizing what is real, managing 
his or her emotions, thinking clearly, making judgments and communicate with others 
(1). In the US, schizophrenia is estimated to have a 0.7 % lifetime prevalence (2) and 
affects approximately 2 million people. A meta-analysis of 188 studies from 46 
countries concluded a life-time risk of schizophrenia was 4.0 (95% confidence 
interval, CI,= 1.6-12.1) (3). Because schizophrenia usually begins during 
adolescence or early adulthood and has no cure, antipsychotics are prescribed for 
the duration of most patients’ lives. However, the severity of side effects, such as TD, 
has greatly limited the application of antipsychotic therapies (4, 5). Noncompliance 
resulting from intolerable side effect puts patients with schizophrenia at risk of relapse, 
often requiring hospitalization. Relapse and hospitalization have made schizophrenia 
a very costly disease. The total economic burden of schizophrenia in the US was 
estimated at $62.7 billion in 2002 and has likely increase since that time (6). 
 
2.1.2. Suspected risk factors for schizophrenia 
Schizophrenia has been recognized as a complex disease with multiple causes 
and interactions between genetic and environmental factors. Genetic studies, 
including twin, adoption and family studies, have consistently shown that 
schizophrenia is a disease with high heritability. Although the inheritance pattern of 
schizophrenia is not fully understood, studies have reported that concordance rates 
in monozygotic twins and dizygotic twin are 30-65% and 5-15%, respectively (7-9). A 
population-based cohort study of 1.75 million in Denmark reported an increased risk 
of schizophrenia among people with a schizophrenia-affected mother (RR=9.31, 
95%C.I. = 7.24-11.96), father (RR= 7.2, 95%C.I. = 5.1-10.6) and sibling (RR= 6.99, 
95%C.I. = 5.38-9.09), compared with people without schizophrenia-affected parents 
or siblings. Several candidate gene regions have been identified, including 
chromosomal 6p24-22, 1q21-22 and 13q32-34. In addition, several candidate genes 
have also been suggested in the etiology of schizophrenia, including Neuregulin 1, 
Dysbindin, G72 protein, 5-HT2A and catechol-O-methyltransferase genes (10, 11). All 
of above evidences supports the role of genetics in schizophrenia development.  
    Several environmental risk factors have been shown to have a moderate 
association with schizophrenia (OR~2); these risk factors include prenatal infection, 
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famine in pregnancy, obstetric complications during pregnancy and delivery, season 
of birth, disturbance of early development, urbanization and migration in childhood 
and adolescence (12). Prenatal infections, such as maternal influenza A infection 
during the first or the second trimester, have been proposed to increase the risk of 
schizophrenia. For example, Brown et al. conducted a nested case-control study 
among 64 case and 125 control pregnancies with serological documentation of 
prenatal exposure to influenza. This study reported an increased risk of 
schizophrenia among fetuses exposed to maternal influenza A (odds ration, OR=7.0, 
95% C.I. = 0.7-75.3). This study also concluded that current evidence about the 
relationship between prenatal infection and schizophrenia are still controversial and 
have been criticized because they are frequently vulnerable to recall bias and have 
small sample sizes (13).  
    Obstetric complications during pregnancy and delivery and their relationship to 
schizophrenia have generated a great deal of inquiry. Cannon et al. conducted a 
meta-analysis to summarize findings from prospective population-based studies and 
reported significant but modest effects for three types of complications: 1) 
complications of pregnancy (bleeding, diabetes, rhesus incompatibility, and 
preeclampsia); 2) abnormal fetal growth and development: (low birth weight, 
congenital malformations, reduced head circumference), and 3) complications of 
delivery (uterine atony, asphyxia, emergency Cesarean section). The authors 
concluded that evidence from studies examining the association between obstetric 
complications and schizophrenia are limited by insufficient information from the 
prenatal period and low statistical power to detect interactive effects (14).  
4 
    Migration, urbanization and season of birth are important risk factors associated 
with schizophrenia. A meta-analysis of 24 studies reported that the rate of 
schizophrenia was greater among migrants compared to native-born people (RR= 4.6, 
95%C.I.= 1.0-12.8) (15). A population-based cohort of 1.75 million persons in 
Denmark reported that birth in an urban area (the capital) was associated with 
increased risk of schizophrenia compared to births in rural areas (RR= 2.4, 95% C.I.= 
2.13- 2.7) (16). A review study of over 250 studies have reported an access incidence 
rate of schizophrenia by 5-8% among birth in spring-winter compared to birth in 
summer (17). Although these factors have shown to be highly associated with 
schizophrenia, the complex biological and social factors behind these observations 
have not been elucidated (18) and have limited their usefulness in developing 
interventions to prevent schizophrenia.  
    In summary, schizophrenia is a complex disease with multiple causes, including 
genetic and environmental factors. Research to understand schizophrenia has been 
limited by small sample sizes and several methodological shortcomings, such as 
recall bias and other sources of inaccurate exposure assessment. 
 
2.1.3. Pharmacotherapy of schizophrenia 
Before the introduction of antipsychotic pharmacotherapy in the 1950s, 
schizophrenic patients were commonly committed to custodial institutions(19). The 
effectiveness of antipsychotic medications allowed patients with schizophrenia to live 
in the community. These older antipsychotics, now classified as conventional 
antipsychotic medications (CONV), have been shown to greatly reduced symptoms 
5 
such as hallucinations and paranoid thoughts. However, these CONV resulted in 
many distressing side effects, including sexual dysfunction in males, extrapyramidal 
symptoms (EPS), and TD (20). TD, in particular, has contributed to a high frequency 
of noncompliance or discontinued treatment among patients with chronic 
schizophrenia. As a result, noncompliance is the most frequent cause of relapse and 
hospitalization among patients with chronic schizophrenia (21).  
Beginning in the 1990s, a new series of antipsychotics were introduced for public 
use, including clozapine in 1990, risperidone in 1993, olanzapine in 1996, quetiapine 
in 1997, ziprasidone in 2001 and aripiprazole in 2002. These medications were 
classified as “atypical” because of their different side effect profiles in contrast to 
CONV. In particular, atypical antipsychotic medications (ATY) result in movement 
disorders less frequently than CONV (22). With favorable side effect profiles and 
efficacy equivalent to CONV, ATY have become the first-line drug choices in 
schizophrenic treatment (23, 24) although there are increasing data that their efficacy 
is not as good as had been believed (25).  
The pharmacological mechanisms of antipsychotics have not been fully 
explained. Some studies have proposed that the effects of antipsychotics are 
mediated through the combined effect of dopamine D2 receptor (DRD2) and 
5-hydroxytryptamine receptor (HTR-2A). Compared to CONV, ATY have higher 
binding affinity to HTR-2A and lower binding affinity to DRD2. As described in section 
II-4.2, the difference in binding affinity may also explain a lower rate of side effects, 
particular the occurrence of movement disorders observed in atypical antipsychotic 
use compared to conventional antipsychotic use (22, 26-28).  
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 2.2. Tardive dyskinesia (TD) 
2.2.1. TD and its impact on schizophrenia treatment 
TD is an involuntary movement disorder presenting on the face, extremities and 
trunk. TD emerges late in the course of long-term antipsychotic therapy and can have 
profound impacts. In particular, it may cause non-compliance and discontinuation of 
antipsychotic medications, leading to a high risk of relapse of psychotic symptoms. In 
the absence of safe and effective therapies, the primary approach to reduce TD 
symptoms is to discontinue or minimize the use of antipsychotics (29). However, even 
after discontinuing antipsychotic use, the symptoms of TD can endure for months to 
years and influence lives of patients with schizophrenia in profound ways (30-32). For 
example, even though patients with schizophrenia themselves may not sense 
involuntary movements they present, TD could be quite stressful to individuals 
around patients with schizophrenia. As a result, TD may contribute to stigma and 
social segregation of patients with schizophrenia (33). 
Currently, there is no safe and effective treatment for TD among those receiving 
antipsychotic treatment. One main strategy to prevent TD is to prescribe ATY as ATY 
have less risk of TD than CONV. However, atypical antipsychotic use has recently 
been challenged because it causes several serious side effects and also is expensive. 
Specifically, increased risks of serious side effects, such as weight gain and diabetes, 
have been reported in large-scale clinical trials of ATY(4). In addition, ATY are ten 
times more expensive than CONV and dramatically increase the economic burden of 
schizophrenia care. As a result, in developing areas, CONV still play an important 
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role in schizophrenia treatment, which could lead to a higher risk of TD among 
disadvantaged populations. 
 
2.2.2. Understanding of TD pathophysiology is limited 
Our understanding of TD pathophysiology has not progressed beyond 
hypotheses (34). A dominant hypothesis is that blockade of dopamine receptors in 
the nigrostriatal dopamine pathway causes drug-induced movement disorders, such 
as TD. The rationale is that this pathway, part of the extrapyramidal nervous system, 
may be responsible for the control of human movement (35). Following the chronic 
antipsychotic blockade of dopamine receptors, the nigrostraiatal dopamine systems 
in the brain may increase the sensitivity of dopamine receptors (36, 37).  
Some studies suggest that increased dopamine sensitivity may be the result of 
an increase in dopamine D2 receptors (38, 39). Although hypersensitivity of DR has 
been a dominant hypothesis for TD pathophysiology since 1970, there are still no 
direct human data to support this hypothesis of hypersensitivity. Research on rodent 
models provide some evidence that increased dopaminergic activity results in 
movement disorders. In rodent studies, following administration of dopamine agonists, 
rodents exhibited both short- and long-term behavioral responses, including muscular 
disorders (38). All of this evidence supports the role of dopamine receptors on TD 
development. 
 
2.2.3. Research diagnosis criteria of TD 
TD is diagnosed using standardized examination procedures and rating scales 
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(40). The Abnormal Involuntary Movement Scale (AIMS) is currently the most widely 
accepted measurement tool for TD in clinical research (33). AIMS is a 12-item 
questionnaire. Item 1 to item 7 measure the severity of involuntary movements in 
several body regions, including mouth and face, extremities, and trunk. Item 8 is an 
overall judgment on the severity of abnormal movements (41). An AIMS form is 
attached as Figure 2.2.  
Severity of TD was evaluated on a scale ranging from 0 to 4 points with higher 
scores representing greater severity. AIMS is also used to characterize patients’ 
incapacitation, awareness and overall severity in item 8 to item 10 (33). The 
popularity of the AIMS has resulted from its convenience and high concordance with 
other rating scales (42). 
AIMS scores may be interpreted using different criteria for TD diagnosis. For 
example, according to the Glazer-Morgenstern criteria, TD is defined as a total 
AIMS score from item 1 to item 7 greater than 3 points and at least one AIMS item 
score greater than 2 points (43). The other criteria, Schooler-Kane criteria, are 
more restrictive in diagnosing TD, and defines TD as at least one item rated 
greater than 3 or at least two items rated greater than 2 in item 1 to item 7 (44). 
This study will use Schooler-Kane criteria because it is more restrictive and also 
widely accepted. 
Since there is no gold-standard in the diagnosis of TD, sensitivity and specificity 
are less relevant in determining the accuracy of this evaluation tool. Instead, the 
reliability of this tool is more relevant, particularly when considering the scales 
performance across raters or at different measurement time points. Previous studies 
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have assessed the reliability of AIMS (45-47). The reliability of the AIMS instrument is 
typically evaluated across raters using Pearson Correlation Coefficient (PCC). 
Estimates of AIMS reliability using PCC range between 0.46 and 0.87 across items 
for different body regions in AIMS. However, PCC has been criticized because it 
overestimates the correlations when there are greater than 2 raters. With more than 2 
raters, intraclass correlation coefficient (ICC) is the more appropriate statistic (48). 
One well-done study by Lane et al. used 2 experienced psychiatric faculty members 
and 2 relatively inexperienced psychiatric residents as examiners to evaluate the 
reliability of AIMS test among 33 patients with schizophrenia over a 10-month period. 
They obtained intraclass correlation coefficients, ranging from 0.5 to 0.79 (p <0.001) 
across items for different body regions in AIMS (45). 
 
2.2.4. Epidemiology of TD 
TD, an involuntary movement disorder, emerges late in the course of long-term 
antipsychotic therapy and has profound effects to patients with schizophrenia. 
Studies have reported a greater than 20% TD prevalence among patients treated with 
CONV (49-51). For example, Yassa and Jeste reviewed 76 studies with a total of 
39,187 patients and reported an average prevalence of TD was 24.2% (range: 3-62%) 
among schizophrenic patients treated with CONV (51). The incidence of TD varies by 
population, depending on age, sex and type of antipsychotic treatment, with a yearly 
cumulative incidence of 5% reported among adults patients (49) and 25%-30% 
reported among elderly patients (52).  
In addition to antipsychotic exposure, several risk factors have been proposed to 
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increase the risk of TD. These risk factors include advanced age, female gender, 
African-American ethnicity, anticholinergic medication use. Psychiatric diagnosis has 
also been implicated as an independent risk factor for TD, but this association is 
controversial (see section II-2.2.4.7) (29, 53). However, our current understanding of 
risk factors for TD is limited because existing studies rarely controlled for important 
confounders, such as degree of antipsychotic exposure. Details of each of the above 
risk factors for TD are addressed separately in sections below. 
 
2.2.4.1. Antipsychotics 
A. Type of antipsychotics 
Antipsychotic exposure has been the most consistent risk factor for TD 
development, although this risk has been reported to be different for ATY and CONV. 
ATY have been reported to confer a lower risk for TD than CONV in several recent 
large-scale clinical trials. A recent systematic review of 2,769 patients from 11 clinical 
trials investigated the 1-year risk of TD among all ATY, except clozapine. This study 
reported a summarized annual risk of TD for atypical antipsychotic use in different 
age groups: 0% in the children, 0.8% (range: 0 - 1.5%) in the adults, and 5.3% (range: 
0.0% - 13.4%) in patients aged over 54 years old. Overall, the observed annual risks 
were lower than that of the control group using the conventional antipsychotic, 
haloperidol (annual risk= 5.4%, range 4.1% - 7.4%) (22). Studies that report risk of 
TD due to individual atypical antipsychotic medication use were summarized in Table 
2.1. 
Several studies have suggested that clozapine, the first atypical antipsychotic, 
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has a much lower risk of TD development compared to CONV (54-57). For example, 
Tamminga et al. followed up 32 patients with schizophrenia for 12 months to compare 
the risk of TD from clozapine with haloperidol. The group treated with clozapine was 
found to have less motor disorder symptoms than the group treated with haloperidol 
(p<0.001). Povlsen et al. retrospectively investigated 216 patients treated with 
clozapine for up to 12 years and reported no TD cases. 
Risperidone, another atypical antipsychotic, is also reported to have lower risk 
for TD compared to CONV. Several long-term clinical trials have suggested the yearly 
risk of TD from risperidone is one-fifth to one-tenth of that from haloperidol (58-62). A 
very low incident risk (0.23%) among risperidone-treated patients was also supported 
by a meta-analysis of clinical trials, although this analysis was limited by relatively 
short follow-up periods among studies (12 months was the longest follow-up across 
studies) (63). This relationship was also reported among elderly patients with 
schizophrenia. For example, Jeste et al. reported that risperidone-treated elders had 
a lower incidence of TD development than haloperidol-treated elders (5% vs. 30%) 
(64). This finding agreed with an earlier study from Chouinard (65).    
Studies have suggested a low risk of TD from the atypical antipsychotic, 
olanzapine. Beasley et al. conducted a large-scale and double-blind randomized trial 
of 627 patients with 2.6 years of follow-up to compare the yearly risk of TD among 
olanzapine-treated subjects to haloperidol-treated subjects. This study reported that 
the risk of TD observed among olanzapine-treated subjects was much lower than that 
observed among haloperidol-treated subjects (0.52% vs. 7.45%) (27). This finding 
has been replicated (66).  
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Quetiapine use has a similar annual risk of TD as olanzapine. The annual risk of 
quetiapine use is estimated to be 0.7% in adults (mean age: 36) (67) and 2.7% in an 
elderly population (mean age: 76) (68). These risks are about one-twelfth of the risk 
associated with haloperidol. As newly approved ATY, data about ziprasidone’s and 
aripiprazole’s risk of TD are limited. 
 
B. Duration of antipsychotic exposure 
Longer duration of exposure usually results in a larger accumulation of exposure 
and confers a higher risk of disease. However, this relationship has not always been 
observed in medication use because medication exposure can be modified quickly to 
accommodate intolerable side effects. As a result, a higher incidence rate of adverse 
events, such as TD, is usually observed among subjects at first exposure to 
medications compared to chronic users. This phenomenon is called “depletion of 
susceptibility” in medication-mediated side effects.   
Depletion of susceptibility has also been reported in literature dealing with 
antipsychotic exposure to TD. For example, the Yale Tardive Dyskinesia Study 
consisted of a cohort of 398 adults who had maintained antipsychotic use for at least 
3 months and up to 33 years. This study reported an inverse association between the 
duration of antipsychotic exposure and TD. Specifically, the TD incidence rate was 
found to be highest during the first 5 years of antipsychotic treatment and decreased 
afterward. (43).  
In summary, risk of TD increases with time on treatment. However, this 
association may also diminish with the increase of treatment duration, possibly 
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because with time, physicians and patients discover treatment regimens with few 
side-effects. 
 
2.2.4.2. Increased age 
Both cross-sectional and longitudinal studies have reported a positive 
association between age and TD (43, 50, 60, 69-77), but this association was not 
replicated in other studies (78-80). This positive association has been replicated in 
studies that investigated associations between genes and TD. In Leon et al’s study of 
516 patients with schizophrenia, age greater than 45 was identified as a risk factor of 
TD development (adjusted OR=2.0, 95%C.I.= 1.3-3.0, p=0.002) (81). In Hori et al’s 
study of 200 patients with schizophrenia, advanced age was positively associated 
with TD (OR= 1.09, [confidence interval not reported], p<0.01), after adjusting for 
antipsychotic exposure (69).  
Several explanations for the association between age and TD have been 
proposed. Age-related neuronal damage, degeneration (82), and reduction of 
dopamine receptors in the brains (83) may be responsible for the age-TD relationship. 
But these explanations are speculative. Some investigators have proposed that the 
increased risk of advanced age on TD may be confounded by a higher baseline 
prevalence of spontaneous movement disorder among aged participants, i.e. 
participants aged greater than 65 years. As baseline spontaneous dyskinesia may 
mimic the development of TD, the TD incidence among elderly may be overestimated. 
In addition, elderly and chronic patients with schizophrenia are more likely to have a 
higher cumulative antipsychotic exposure than young patients with schizophrenia. 
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Therefore, observed associations between age and TD may also be confounded by 
increasing antipsychotic exposure among elders (84).    
 
2.2.4.3. Female gender 
Studies have observed a higher prevalence of TD among females than males. A 
meta-analysis of 76 selected studies with a total of 39,187 patients reported a higher 
TD prevalence among female (26.6%) than among male (21.6%) patients with 
schizophrenia. This study also found female patients with schizophrenia had a higher 
prevalence of severe TD and spontaneous dyskinesia than male patients with 
schizophrenia (51).  
However, the association between gender and TD has not been conclusive. For 
example, several prospective studies observed greater prevalence of TD among 
women compared to men but this relationship was restricted to elder patients with 
schizophrenia (60, 77, 85, 86). Other studies have found that men have more severe 
TD than women (51) among younger patients with schizophrenia.  
    A biological mechanism explaining the effect of gender on TD is still unclear. 
Some external factors have been proposed to account for the relatively high TD 
prevalence among females. Compared to male patients with schizophrenia, female 
patients with schizophrenia have longer hospitalization, larger dosages of 
antipsychotics (50) and longer duration of antipsychotic treatment (87). All of these 
factors could confound the association between gender and TD. 
 
2.2.4.4. African-American ethnicity 
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Race was once thought to be a risk factor to TD. Morgenstern et al. reported that 
the TD incidence rate among African-Americans was nearly two times that among 
non-Hispanic Caucasians (43). Lacro et al. also reported a higher TD incidence rate 
among African-Americans than among Caucasians (88). However, there has been 
disagreement about whether the observed ethnic effect is confounded by 
treatment-related factors, such as differences in dosage or types of antipsychotic use 
across ethnicity(43). A study of 700 patients with schizophrenia found that 
African-American participants were less likely than White participants to receive 
first-line antipsychotics, supporting the possible confounding role of medications in 
the relationship between race and TD (5). In addition, a biological mechanism 
explaining the association between race and TD has not been established.  
 
2.2.4.5. Substance abuse 
Abuse of alcohol and of cigarettes has both been reported to increase the risk of 
TD. Studies have observed a higher prevalence of TD among subjects with alcohol 
abuse histories. The association between alcohol abuse and TD has been replicated 
in several studies (86, 89-93). In the analysis from the CATIE data, substance abuse 
was associated with baseline TD (adjusted OR= 1.66, 95%C.I.= 1.2~ 2.3, p=0.0032) 
(94). The mechanism of this association is not understood completely. It is possible 
that ethanol alters neurotransmitter activity or increases neurological insults after 
repeated exposure. Yassa et al. reported that smoking was positively associated with 
TD among antipsychotic-treated patients. This association may be explained by an 
increase of dopamine released from nigrostriatal neurons after nicotine stimulation 
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(95). 
 
2.2.4.6. Anticholinergic use 
Anticholinergics comprise a class of medication that selectively blocks the 
binding of the neurotransmitter acetylcholine to its receptors and is used to treat a 
variety of disorders, including parkinsonism, gastrointestinal cramps, asthma and 
urinary bladder spasm (96). Anticholinergics are also a major treatment for essential 
Parkinson’s Disease, a slowly progressive neurological disorder characterized by 
resting tremor, shuffling gait, stooped posture, rolling motion of fingers and drooling 
(97, 98). 
Concomitant use of anticholinergics has been reported to be a risk factor for TD. 
In the CATIE, concomitant anticholinergic use was 28% and 14% among patients with 
schizophrenia with and without TD, respectively (94). Some studies also have noted 
that addition of anticholinergics can exacerbate existing TD (99, 100) and 
discontinuation of anticholiergics could improve TD symptoms. A biological 
explanation for the effect of anticholinergics on TD have been suggested by animal 
models, which show that long-term administration of anticholinergics can induce a 
supersensitivity of dopamine receptors. This increased sensitivity may in turn cause 
the symptoms associated with TD. 
However, the association between anticholinergics and TD may be confounded 
by the indication of anticholinergics, particularly parkinsonism (50). A study found that 
the incidence rate of TD was 40% and 12% among elderly patients with and without 
parkinsonism, respectively (77). Thus, it is not clear whether the vulnerability to TD 
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observed among patients taking anticholinergics is confounded by the indication of 
anticholinergics, i.e. treating patients with higher risk of movement disorder, or if it is 
anticholinergics which lead to a higher risk of TD. 
 
2.2.4.7. Psychiatric disorders 
    Psychiatric disorders and in particular, affective disorder and schizophrenia with 
negative symptoms, have been proposed as risk factors for TD (101-103). This 
association has been found independent of antipsychotic use. Studies report that 
approximately 7% of antipsychotic-naïve patients with schizophrenia present with 
movement disorders at onset of their illness (104, 105). However, other risk factors 
aside from antipsychotics use may confound the association between TD and 
psychiatric disorders. For example, in cross-sectional studies, it may be difficult to 
differentiate between TD symptoms and other spontaneous movement disorders that 
are concomitant to psychiatric illness (33). As a result, the observed association 
between psychiatric disorder and TD could be due to misdiagnosis of TD among 
subjects with other movement disorders.  
In addition to the possibility of misdiagnosis of TD, detection bias could occur 
when TD is not evaluated blindly to medication history. It is widely known that TD 
occurs more frequently in subjects using CONV than in subjects using ATY or 
non-antipsychotics. When a patient has a treatment history of CONV, physicians may 
be predisposed to diagnose any movement disorder as TD. As a result, when 
evaluation of TD symptoms is not blinded to patients’ history of antipsychotic use, a 
detection bias may occur.  
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 2.2.4.8. Summary of non-genetic risk factors for TD 
Overall, several non-genetic risk factors for TD have been proposed, including 
exposure of CONV, increased age, female gender, African-American race, 
anticholinergic use, substance abuse, psychiatric disorders. ATY have a lower risk of 
TD than CONV. However, the relationship between longer duration of antipsychotics 
exposure and higher risk of TD is not so robust. Increased age also increases the risk 
of TD but this relationship may be confounded by a higher incidence of other 
spontaneous movements, rather than TD, or higher cumulative antipsychotic 
exposure among elder populations than among younger populations. Female gender 
has a higher risk of TD but this relationship has been inconclusive. African-Americans 
were suspected to be more susceptible to TD than Caucasians but biological 
mechanisms for this association have not been established. A history of substance 
abuse showed an increased risk of TD. Anticholinergic use is positively associated 
with TD. Although this association has been supported by animal models, the 
relationship may be confounded by the indication of anticholinergics. Psychiatric 
disorders also increased the risk of TD. However, more research is needed to 
eliminate potential biases resulting from difficulties of differentiating TD and other 
movement disorders in schizophrenia progress. 
 
3. Evidence indicating an association between genetics and TD 
A genetic basis for TD has been suggested by the results of both animal and 
human studies. Evidence from each type of study was addressed below: 
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 3.1. Animal studies 
In animal studies in which rats were exposed to antipsychotics, there was 
significant variation in the onset of vacuous chewing movements and repetitive jaw 
movements across different genetic strains of rats (106, 107). 
 
3.2. Human studies 
In humans, individual variation in the susceptibility to adverse effects, particular 
TD, is considerable. While previous studies have identified several non-genetic 
factors associated with an increased risk of TD, these factors can only explain a small 
proportion of the variance in the occurrence of TD (108). 
 
3.2.1. Family aggregation 
Reports of TD aggregated within families indicate that genetic disposition has an 
important role in TD (109-113). For example, Schulze et al. reported 39 out of 222 
schizophrenic or schizoaffective patients with TD had at least one first-degree relative 
affected TD (113). Yassa et al. surveyed 500 inpatients taking long-term 
antipsychotics and found a concordance of the presence or absence of TD among 
eight patients and their first degree relatives (111). Youssef et al. studied 11 relative 
pairs with chronic schizophrenia. This study reported a complete familial 
concordance of presence or absence of TD in the following relationships: 
brother-sister (5 pairs), father-son (3 pairs), brother-brother (2 pairs), and 
mother-daughter (1 pairs) (112). In addition, other extrapyrimidal disorders, such as 
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Parkinson’s disease (114) and dystonia (115), provide indirect evidence for genetic 
components in abnormal movement disorder. Together, these studies suggest a role 
of genetic factors in schizophrenic patients’ susceptibility to TD.  
 
3.2.2. Twin studies 
No twin study conducted on this issue has been found. 
 
3.2.3. Adoption studies 
No adoption study conducted on this issue has been found. 
 
3.2.4. Linkage studies 
No linkage study conducted on this issue has been found. 
 
4. Dopamine receptor genes as the candidate genes in this study 
4.1. Overview 
Selection of candidate genes from the large number of possible genes in the 
human genome has been a fundamental source of difficulty in studies that attempt to 
identify genetic variants associated with susceptibility to complex phenotypes, such 
as TD (116). A reasonable approach to select candidate genes associated with TD is 
to consider the pharmacological mechanisms of antipsychotics as most 
treatment-related side effects are the result of medications acting upon unintended 
mechanisms. As a result, the present study aimed to study genes coding for 
dopamine receptors, most acknowledged drug targets of antipsychotic medications. 
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All subtypes of dopamine receptor genes were included: dopamine receptors 1 to 5 
(DRD1, DRD2, DRD3, DRD4, DRD5). Choice of these dopamine receptor genes are 
informed by our current understanding of the drug targets of antipsychotics.   
 
4.2. Dopamine receptors has been proposed as the drug targets of antipsychotics 
Although antipsychotics provide marked reductions in psychotic symptoms, the 
precise mechanism of action has not been fully understood. The different risks of TD 
between conventional and ATY has led to a predominant hypothesis: the 
antipsychotic effect is mediated through the blockade of dopamine D2 receptor 
(DRD2) in the brain. Since the presence of serotonin can theoretically result in the 
inhibition of dopamine release in the nigrostriatal pathway and impact on the control 
of human movement, studies have proposed that the anti-schizophrenic effects of 
antipsychotics are mediated through the combined effect of dopamine D2 receptor 
(DRD2) and serotonin receptor (HTR-2A). However, several investigative trials have 
reported that several selective serotonin antagonists, such as ritanserin and 
M100906, are not efficacious for anti-schizophrenic purpose. Thus, dopamine 
receptors have been dominantly recognized as the drug targets for antipsychotics. 
This study consulted the Psychoactive Drug Screening Program (PDSP) Ki 
database (http://pdsp.cwru.edu/pdsp.php) to obtain the receptor binding affinities (Ki) 
for the six antipsychotic medications evaluated in CATIE phase 1 and phase 2. It 
should be noted that K  ≤ 100 nM, i.e., log  (Ki 10 i) ≤ 2, indicates physiologically 
significant receptor binding between an agent and a target. Consistent with the Food 
and Drug Administration (FDA)’s clinical trials data 
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(http://www.accessdata.fda.gov/scripts/cder/drugsatfda/), the genes DRD2 and 
DRD3 demonstrate the greatest potential to mediate the effect of these six drugs. 
Medication-receptor binding affinities are summarized in Table 2.2. 
  
4.3. Associations between TD and dopamine receptor genes has been inconclusive 
Several association studies have been publishe reporting the relationship 
between dopaminergic receptor genes and TD among schizophrenic patients, but 
results of these studies are inconclusive. Almost all of these studies used the AIMS 
scale and followed the Schooler-Kane’s criteria for TD. In addition, the study 
populations were predominantly comprised of patients with chronic schizophrenia 
with a mean age ranging from 30 to 55 years old. However, the studies also differed 
in many respects including the number of TD measurements among participants, the 
genetic variants of dopamine receptor genes selected for study, and the distribution 
of study populations’ demographic characteristics such as gender and ethnicity. The 
characteristics of studies that investigated association between TD and dopamine 
receptor genes are summarized in Table 2.3.  
 
4.3.1. Dopamine receptor 1 (DRD1) 
    Literature about the association between DRD1 and TD are limited but animal 
models support a role of DRD1 in oral TD symptoms. For example, one study 
administered male rats the conventional antipsychotic, fluphenazine, to trigger a 
syndrome of vacuous chewing movements. These symptoms were successfully 
suppressed using a selective dopamine D1 receptor antagonist. In addition, 
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experiments also showed that the chewing disorders can also be triggered by acute 
administration of a selective dopamine D1 antagonist among drug-naïve animals. 
This evidence indicates that DRD1 may play a role in TD development (117). 
    A 2006 study consisting of 297 patients with schizophrenia (86 with TD, 211 
without TD) studied 5 markers of DRD1 to investigate the associations between 
polymorphisms in DRD1 and TD. However, none of investigated variations in DRD1 
gene showed a statistically significant association with TD (118). 
 
4.3.2. Dopamine receptor 2 (DRD2) 
Many studies (median of the sample sizes: 249) have investigated the effect of 
several genetic variants on DRD2 but their associations with TD are inconclusive.  
For example, Ser311Cys, the most studied SNP on DRD2, has been reported to 
be both positively and negatively associated with TD across different studies. 
However, none of the findings from these studies reached statistical significance (69, 
71, 80, 118-120). Specifically, one study of 196 Japanese patients with schizophrenia 
reported an increased risk of TD among those with Ser311Cys genotype (adjusted 
OR gly/gly+ ser/gly vs. ser/ser=1.2, p=0.48) (69). In contrast, a study of 419 white and 89 
African-American patients with schizophrenia reported an inverse association 
between TD and Ser311Cys genotype in the univariate analysis (OR ser/gly vs. ser/ser= 
0.46, 95% C.I.= 0.13- 1.6, P=0.21). It is important to note that none of study subjects 
had gly/gly genotype in this study and adjusted OR ser/gly vs. ser/ser was not presented in 
the paper (119).  
Chen et al reported a marginal association between TaqI A genotype and TD 
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(p=0.03). This same study reported that homogeneous mutant TaqIA genotype was 
associated with TD among females (62% in TD and 24% in non-TD, p=0.001) (121). 
However, this association was not replicated in later studies with larger sample sizes 
(69, 80, 118, 120). Studies that investigated associations between other markers on 
DRD2 and TD are summarized in Table 2.3. 
 
4.3.3. Dopamine receptor 3 (DRD3) 
The majority of research to assess the role of dopamine receptor genes in TD 
has focused on the marker Ser9Gly on DRD3, but results from these studies have 
been inconclusive. Several previous studies reported a positive association between 
TD and genotypes of Ser9Gly, i.e. Ser/Ser, Ser/Gly, and Gly/Gly (70, 79, 122-124) but 
this relationship was not replicated in many recent large-scale studies (71, 78, 118, 
119, 125-128). Other studies have reported that patients with schizophrenia carrying 
the Gly/Gly polymorphism have a mild but significant increase for TD risk compared 
to other Ser9Gly genotypes (70, 108, 122-124). However, Liao et al’s study reported 
that the mean AIMS score among patients with schizophrenia carrying Ser/Gly was 
3.6, which is about twice the mean AIMS score among patients with schizophrenia 
carrying other genotypes in their study (79). In Segman et al’s study, the TD group 
had a larger proportion of Ser/Gly genotypes than the non-TD group (122).  
A 2002 “combined-analysis” of eight studies indicated an association between 
Ser9Gly and both binary TD status and AIMS-measured severity. This study pooled a 
sample of 780 subjects with schizophrenia or affective disorder (317 with TD and 463 
without TD) from six research centers. After controlling for age and gender, two 
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associations reached statistical significance: TD and genotypes of Ser9Gly (X2= 7.51, 
degree of freedom=2, p= 0.002); TD and the allele frequency of Ser9Gly, i.e. Ser and 
Gly (X2= 5.02, degree of freedom = 1, p= 0.02). This combined analysis indicated a 
positive association between Gly/Gly genotype and a higher AIMS score compared to 
Ser/Gly (p=0.006) or Ser/Ser (p< 0.001) (108).  
A 2006 meta-analysis, combining 12 studies with 1610 total subjects (695 
patients with TD and 915 without TD), indicated the Gly allele was only mildly 
associated with TD as compared to the Ser allele (OR=1.17, 95% C.I. = 1.01- 1.37). 
However, this study reported a publication bias in allele analyses (bias coefficient= 
-1.82, 95% C.I. = -3.61 - -0.04, p= 0.046). No association was found between 
genotype and TD and this finding was not confounded by publication bias (129). 
 
4.3.4. Dopamine receptor 4 (DRD4) 
    Two human studies have investigated the association between DRD4 and TD 
but the findings on the association from these two studies are inconclusive. An early 
study done in Israel, consisting of 122 patients with schizophrenia (59 with TD and 63 
without TD), reported no association between genetic variants on DRD4 and TD (80). 
However, a recent study of 297 North Indian patients with schizophrenia (86 with TD, 
211 non-TD) found a statistically significant association between TD and 120bp 
dup-T-repeat 3, a haplotype composition on DRD4 (p<0.01) (118).   
 
4.3.5. Dopamine receptor 5 (DRD5) 
    Studies assessing the association between DRD5 and TD are absent from the 
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published literature. 
 
5. Other candidate genes for future gene-TD association studies 
    Although increased dopamine sensitivity has been a dominant hypothesis for TD 
pathophysiology, this hypothesis can only explains some aspects of TD. Hypotheses 
regarding pathophysiological models of other neurotransmitters affected by 
antipsychotics have been proposed, including changes in acetylcholine and 
γ-aminobutyric acid (GABA). For example, studies suggested a reduced activity of 
GABA neurons as the basis of TD based on evidence from animals and patients with 
schizophrenia (130). In addition, a reduction of glutamic acid decarboxylase (GAD), a 
rate-limiting enzyme in the synthesis process of GABA, has been observed in 
monkeys following long-term treatment with antipsychotics (131) and among five TD 
patients with schizophrenia (132).  
    Another hypothesis of TD pathophysiology is through oxidative stress. The 
long-term administration of antipsychotic blocks dopamine receptors, leading to an 
increased dopamine turn over rate and thus to generate free radicals (133). The 
blockade of dopamine receptors also increase the release of glutamate and aspirate 
in the striatum, leading to oxidative damage to cellular proteins, cell membrane and 
DNA. As a result, several oxidative stress-related genes, such as manganese 
superoxide dismutase (MnSOD) and N-methyl-D-aspartate (NMDA) receptor genes, 
have been proposed as potential candidate genes for TD (134). Information about 
potential candidate genes for TD association studies is summarized in Table 2.4. The 
proposed study will focus on all dopamine receptor genes. Skills and perspectives 
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obtained from proposed association studies between TD and all dopamine receptor 
genes can be applied to these other candidate genes in the near future.  
 
6. Essential information about the parent study of study aims 2 and 3 
6.1. Overview 
Briefly, the CATIE study was a double-blinded randomized clinical trial with 
18-month follow-up. The purpose of the CATIE trial was to evaluate the 
effectiveness of antipsychotics among a heterogeneous group of schizophrenic 
patients living in the community. The CATIE recruited 1,493 patients with chronic 
schizophrenia from various sites including public mental health centers, academic 
hospitals, Veterans’ Affairs hospitals, and managed care centers. As opposed to 
most trials, CATIE included schizophrenic patients with substance abuse and 
medical comorbidities so that participants in CATIE would more accurately reflect 
community populations of schizophrenic patients. 
 
6.2. Source of the CATIE population 
    Detailed inclusion and exclusion criteria have been described in a previous 
report (135). A summary of the recruitment guidelines in CATIE is described below: 
Participants with the following criteria were approached for enrollment: 
- age from 18-65 years old 
- schizophrenia diagnosed using Diagnostic and Statistical Manual of Mental 
Disorders - Fourth Edition (DSM-IV).  
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- appropriate candidate for oral antipsychotic treatment based on participants’ 
judgment in consultation with their physicians.  
- decisional capacity to participate in the CATIE program  
    - informed consent provided 
Participants with the following criteria were excluded: 
-  a DSM-IV diagnosis of schizoaffective disorder, mental retardation, 
pervasive developmental disorder, delirium, dementia, amnesia or other 
cognitive disorder.  
- well-documented serious adverse reaction, history of failure of response or 
contradiction to any one of the proposed treatment arms. 
- first episode of schizophrenia. Patients who have first begun antipsychotic 
treatment within the previous 12 months and have had psychotic symptoms 
for less than 3 years were considered as being in their first episode. 
- concomitant use of any investigational drug within 30 days of the baseline 
visit. 
- Women who were pregnant or breastfeeding. 
- cardiac comorbidity history, including recent myocardial infarction (<6 
months), QTc prolongation, sustained cardiac arrhythmia, uncompensated 
congestive heart failure, complete left bundle branch block and first-degree 
heart block with RR interval ≥ 0.22 seconds. 
 
6.3. Design of the CATIE trial 
A schematic diagram of CATIE is illustrated in Figure 2.3 of the article by Stroup 
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et al.(135). In phase I, participants were randomly assigned to one of the investigated 
antipsychotics. If the assigned antipsychotic treatment on phase I failed, participants 
would enter phase II to receive another atypical antipsychotic.  
The antipsychotic intervention in CATIE consisted of the following ATY: 
olanzapine, quetiapine, risperidone, ziprasidone, clozapine, and aripiprazole. The 
control group received perphenazine, a mid-potent conventional antipsychotic 
treatment. All antipsychotics except clozapine were administered in a double-blind 
fashion. All CATIE subjects received antipsychotics through the trial. In addition to 
antipsychotic use, the CATIE study also collected data about treatment responses 
and adverse events, such as TD, in several regular visits during the trial. 
 
7. Justification for not studying metabolizing enzyme genes in this study 
Activities of metabolizing enzymes could affect the duration and concentration of 
medication in the human body. Thus, metabolizing enzyme genes have been 
important candidate genes in pharmacogenetic studies in the past several years.  
However, it is inappropriate to study drug metabolizing enzyme genes in the 
CATIE data for two reasons. First, in the CATIE trial, seven antipsychotics were 
studied across 3 treatment phases to accommodate occurrences of treatment failure 
in assigned antipsychotics. As the proposed study is limited by inadequate statistical 
power to investigate genetic effects within individual antipsychotic regimens, grouping 
antipsychotic exposure into “conventional” and “atypical” groups could increase the 
statistical power. When studying dopamine receptor genes, this grouping strategy is 
appropriate because the pharmacological classification of antipsychotics 
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corresponds to their different binding affinities to dopamine receptors. However, 
classifying antipsychotic exposure into conventional and atypical classes would be 
inappropriate in a study that investigates associations between TD and drug 
metabolizing enzyme genes because each antipsychotic has its own unique 
metabolizing pathway (Table 2.5), which does not follow the pharmacological 
classification.  
Second, drug metabolizing enzymes compete for drugs and other environmental 
hazards that need to be metabolized and eliminated from the body, particularly 
alcohol and cigarette consumption. As the CATIE trial only collects a broad indicator 
of substance use, i.e. user or non-user of alcohol or cigarettes in the past five years, 
this indicator is too blunt to be useful in controlling for substance use as a confounder. 
Thus, in order to improve the validity and statistical power in the proposed study, 
investigating drug receptor genes are more appropriate than studying metabolizing 
enzyme genes in exploring genetic influence on TD.
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8. Tables 
Table 2.1 Comparisons of tardive dyskinesia (TD) risk and pharmacokinetics of antipsychotics studied in the 
CATIE trial. 
 Initial 
Dose 
(mg/d)
Dose 
Range 
(mg/d)
    Freq. of 
dosing 
Relative 
potency 
__(mg)_
  Major route of 
Metabolism
 Max 
_DoseAntipsychotic Elimination
32 
 Risk of TD 
(%) 
  (per day)  
~ 0 (54-57)Clozapine 50 25-50 300-600 900 Once- 
twice 
12 CYP1A2, 3A4, 
2E1 
Olanzapine 0.52 (27) 4 5-10 15-30 40 Once 30 CYP1A2 
Glucuronidation 
Quetiapine 0.7- 2.7 (68) 80 25-50 300-800 1000 Twice 6-7 CYP3A4 32 Risperidone 0.23- 5 (63, 
68) 
1 2 2-6 8 Once 20 CYP2D6, 3A4 
Ziprasidone --- 20 40 80-160 160 Twice 7 CYP3A4 
Aldehyde oxidase
Aripiprazole --- 6 10-15 10-15 30 Once 75 CYP2D6, 3A4 
Perphenazine --- 8 8-18 8-64 64 Twice 9 CYP2D6 
 
 Table 2.2 List of candidate genes for strength of binding affinity to investigated antipsychotics in the CATIE  
study in the human model 
  CATIE Phase 1 & 2 Medications
33 
 
_C_Gene Description   O_ _P_ _Q_ _R_ _Z_ 
Receptor Binding Targets Binding affinity in log10(K  in nM) i
aDopamine receptor 1 2.2 1.5 -- 3.1 2.7 2.2 DRD1 
bDRD2 Dopamine receptor 2 1.7 1.1 -0.8 1.9 0.0 0.7 b
 bDopamine receptor 3 2.5 1.6 -0.9 2.7 1.0 0.8 (0.9 ) DRD3 
Dopamine receptor 4 1.4 1.0 1.2 3.4 0.5 -0.1 DRD4 
Dopamine receptor 5 2.4 1.9 -- 3.2 2.8 -- DRD5 
C=clozapine, O=olanzapine, P=perphenazine, Q=quetiapine, R=respiridone, and Z=ziprazidone. 
“--”=no data. “a”=no human data. “b” = also documented in FDA approved labeling.  
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Table 2.3 Association studies between tardive dyskinesia (TD) and genetic variants in dopamine receptor genes 
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Sample size_ _________________Main findings_________________   
 
Genetic 
__variants_ 
 
 
Rating  
_scale 
 
 
Repeat 
rating ? 
Mean 
age (SD) 
(TD-Y/ 
TD-N)
Female 
(%)  
 
      RefEthnicity 
 
(TD-Y/ 
TD-N) (country) TD-Y TD-N From categorical analysis From continuous analysis 
 
 
I. Studies that investigated dopamine receptor 2 (DRD2) 
Kaiser 
et al. 
2002 
-241A>G AIMS 2-4 days 38.3 (12) M: 54 Caucasian
(Germany)
Total n  NO significant association 
between mean AIMS score 
and any DRD2 genotype 
was identified no matter 
the effect was evaluated 
before or after adjusting for 
covariates (i.e. age, 
gender, chlorpromazine 
adjusted dose, dose of 
anticholinergic agents, no. 
of recurrent exacerbations 
and smoking). 
-141Cins/del 12-16 d (18~70) F: 46 = 584  
TagI B 26-30d (2-4 days) 
TagI D (acute 
schizoph
renics) 
= 518  
Val Ala (12-16 days) 99
Leu Leu = 384 (26-30 
days) 
141
Pro Ser 310
Ser Cys 311
TaqI A 
 
 
Correlations between 
AIMS-score and age was 
0.3 and 0.2 for AIMS 
evaluated in 2-4 days and 
12-30 days, respectively. 
 
Correlations between 
AIMS-score and Sex are 
non-significant. 
  
-141Cins/del 
Ser311Cys 
TaqI A 
AIMS w 
S-K 
criteria 
 
No 
(chronic 
schizoph
renics) 
55 (9.5) M: 52.5
F: 47.5
Asian 
(Japan) 
44 156 No. of Ser/Ser, Ser/Cys, 
Cys/Cys 
= 40, 4, 0 (cases);  
= 145, 10, 1 (controls) 
The association b/w -141C 
ins/del and total AIMS is 
significant before adjusting 
for covariates (p=0.037) 
Hori et 
al. 
2001 
34 
but not significant after 
covariates adjustment 
(p=0.14).  
(Fisher’s exact test, p= 0.622).
No significant association 
between allelic and genotypic 
distribution and TD status.  
Ps. Covariates in this study 
included age, gender, 
duration  
 
This study provided adjusted 
OR for each genotype but did 
not show how genotype is 
compared within each marker: 
of illness, and 
antipsychotic use. 
Ser Cys: OR=1.22 (p= 0.48);311
-141Cins/del: OR=0.69 (p= 
0.28); 
TaqI A: OR= 1.55 (p= 0.43) 
 
Age(years): OR= 1.09 
(p<0.01) 
 
 Inada  
et al. 
1999 
-141Cins/del AIMS w 
S-K 
criteria 
Valid by 
videotyp
e 
62 
(21-82) 
 Asian 31 108 No. of Del/Del, Del/Ins, Ins/Ins
35 
 
 
 (chronic 
schizoph
renics) 
vs. 55 
(28-78) 
(Japan) = 1,12, 18 (case);  
= 0, 32, 76 (control) 
(Fisher’s exact test: p= 0.121)
 
No associations between TD 
status and the -141 Del/Ins 
genotype frequency was 
found  
 
Ps. This study did not adjust 
for confounding variables.   
 
TaqI A AIMS w 
S-K 
criteria 
 
N 
(chronic 
schizoph
renics) 
43 vs. 42 45.2 vs. 
48.8 
 
Asian 
(Taiwan) 
93 84 Marginal significance b/w 
genotype distributions and TD 
stauts (X2 = 6.8, p= 0.03).  
 
Among female, excess A2A2 
proportion was associated 
(62% in TD, 24% in non-TD, p 
 Chen  
et al. 
1997 
35 
= 0.001).  
 
Ps. Matched case-control 
design by age, duration of 
illness and current 
antipsychotic dosage. 
 
II. Studies that investigated Dopamine receptor 3 (DRD3)  
Liou  Ser9Gly was not 
significantly associated 
with total AIMS score 
(p=0.080), score on 
orofacial regions 
(p=0.957), and on 
limb-trunk regions 
(p=0.312).  
Ser9Gly AIMS w 
S-K 
criteria 
Y: 3 mo 
later 
47.5 
(9.8) vs. 
46.9(9.5)
40.2 
vs. 
42.1 
Asian 102 114 No. of Ser/Ser, Ser/Gly, 
Gly/Gly et al. Val66Met (Taiwan) 
2004  (chronic 
schizoph
renics) 
= 51, 41, 10 (cases);  
 = 61, 41, 13 (controls) 
(Wald = 0.843, p= 0.656, 
df=2) 
 
No sig. asso. before and after 
adjusting for dosage, duration 
of antipsychotic exposure, 
smoking.  
 
Ps. The conclusion was 
obtained from a ANCOVA 
analysis adjusting for age 
but only in TD group?! 
36 
 
Ps. This study reported some 
factors  are significantly 
associated with TD, including 
“Duration of antipsychotic 
exposure” (p= 0.024); “mean 
daily drug dosage” (p= 
<0.001) 
 
Ser9Gly AIMS w 
S-K 
criteria 
Y: 4 mo 
later 
(chronic 
schizoph
renics) 
56.1 
(10.4) 
vs.55.1 
(7.3) 
0:0 
(all are 
male) 
Asian 
(China) 
42 52 No. of Ser/Ser, Ser/Gly, 
Gly/Gly 
= 19, 22, 1 (cases);  
= 30, 17, 5 (controls) 
(Fishers’ test: p= 0.098) 
No findings reached statistical 
sig. No regression analysis 
which adjusted confounding 
 Zhang 
et al. 
2003 
36 
effects. 
 
Woo et 
al. 2002
The mean (SD) AIMS 
score in each genotypic 
group was: 13.8 (9.3) for 
Ser/Ser, 18.0 (8.9) for 
Ser/Gly and 9.7 (4.6) for 
Gly/Gly group. But this 
study only compared the 
mean AIMS score among 
TD group. 
Ser9Gly AIMS w 
S-K 
criteria 
Not clear 42.3 
(10.7) 
vs.38.3 
(8.8) 
25.4 
vs. 
22.2 
Asian 59 54 No. of Ser/Ser, Ser/Gly, 
Gly/Gly  (chronic 
schizoph
renics) 
(Korean) 
 = 25, 28, 6 (cases);  
= 21, 33, 0 (controls)  
(X2= 0.288,  Fishers’ test: p= 
0.028)   
Gly/Gly was positively 
associated w TD  
 
 No regression analysis which 
adjusted confounding effects. No significant difference 
b/w the three classes by 
ANOVA (p= 0.071, d.f.=2) 
 
Other significant factors with 
TD: 
Age (years) (p= 0.038) 
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Ser9Gly AIMS w 
S-K 
criteria 
Not clear 
(chronic 
schizoph
renics) 
57.2 
(12.3) vs. 
45.6 
(10.5) 
38.5 
vs. 
31.8 
Asian 
(Hong 
Kong) 
65 66 No. of Ser/Ser, Ser/Gly, 
Gly/Gly 
= 36, 23, 6 (cases);  
= 42, 18, 6 (controls) 
( X2= 1.064, df=2, p= 0.588) 
 
Regression analysis was 
done but no any result was 
mentioned in the text or 
shown by tables.  
 
Non-genetic risk factors for 
TD identified in this study 
include: 
Age (years) (p= <0.0001);  
Duration of illness (p= 0.047)
 
 Garcia-
Barcelo 
et al. 
2001 
 
Ser9Gly AIMS w 
6 or 
Not clear 
(chronic 
40.7 
(9.3) 
M: 62.6
F: 37.4
Asian 
(Taiwan) 
21 94 No. of Ser/Ser, Ser/Gly, 
Gly/Gly 
The mean (SD) AIMS 
score in each genotypic 
Liao 
et al. 
37 
group was: 1.9 (6.3) for 
Ser/Ser, 3.6 (5.8) for 
Ser/Gly and 1.7 (5.4) for 
Gly/Gly group.  
2001 above 
as the 
cut-off 
point for 
TD 
schizoph
renics) 
(18~ 65) = 6, 14, 1 (cases);  
= 55, 29, 10 (controls) 
38 
( X2= 9.41, df=2, p=0.009) 
 
Multiple regression analysis 
indicated age (p=0.009) and 
DRD3 genotypes (p=0.01) as 
risk factors for TD. 
The AIMS score was 
higher among patients 
carrying Ser/Gly than other 
genotype (p= 0.014). 
 
 Rietsch
el et al. 
2000 
Ser9Gly TDRS Y: 3 mo 43.9 
(8.7) 
M: 48 Caucasian 79 78 No. of Ser/Ser, Ser/Gly, 
Gly/Gly  w S-K 
criteria 
(chronic 
schizoph
renics) 
F: 52 (Germany)
vs. 42.2 
(7.9) 
= 39, 37, 3 (cases);  
= 37, 35, 6 (controls) 
(OR: 0.47 (95% CI= 0.11- 2.0, 
p=0.328) 
 
Stratification by duration of 
psychotic illness but no trend 
observed.  
 
Data analyses in this study 
were not very appropriate. 
For example: no regression 
analysis which adjusted for 
confounding effects.  
 
Ser9Gly AIMS w 
4 or 
above 
as the 
cut-off 
point for 
TD 
Not clear 
(chronic 
schizoph
renics) 
53 (18) 
vs. 41 
(12) 
M: 73 
F: 27 
Caucasian
(UK) 
32 39 No. of Ser/Ser, Ser/Gly, 
Gly/Gly 
= 11, 14, 7 (cases);  
= 17, 18, 4 (controls) 
(Fisher-Freeman-Halton test, 
p= 0.37) 
 
Allele frequency: (Gly vs.Ser)
= 44% vs. 56% (case) 
= 33% vs, 67% (control) 
(ORgly = 1.56, 95% C.I.= 
 Lovlie  
et al. 
2000 
38 
0.74-3.26, p= 0.23) 
 
Segma
n  et 
al. 1999
Positive association 
between Association 
between total AIMS and 
ser/gly+gly/gly genotypes 
was identified (p=0.02). 
Ser9Gly AIMS w 
S-K 
criteria 
N 
(chronic 
schizoph
renics) 
52.1 
(11.6) vs. 
49.6 
(10.7) 
47.2  
vs. 
46.0 
Jewish 53  63 No. of Ser/Ser, Ser/Gly, 
Gly/Gly  (Israel) 
 = 13, 37, 3 (cases);  
 = 29, 29, 5 (controls) 
(Fisher’s exact test: p=0.032)
 TD was associated with the 
genotype of Ser9Gly When looking at AIMS by 
body regions, observed 
positive associations 
between regional AIMS 
score and ser/gly+gly/gly 
genotypes still held.  
 
Allele frequency: (Gly vs.Ser)
= 41% vs. 59% (case) 
= 31% vs. 69% (control) 
( X2= 2.4, df=1, p> 0.1) 
  
Non-genetic risk factors for 
higher AIMS score 
identified: 
Multiple regression showed 
OR ser/gly+gly/gly was 1.16 (p= 
0.006) and OR(age at first 
antipsychotic treatment) = 1.0 (p = 
0.01). Overall r
39 
2 of the model 
is only 0.12.   
 
Ps. This is a matched 
case-control study, matching 
on age, sex, duration of 
illness, antipsychotic dosage 
et al. 
 
Age at first antipsychotic 
treatment (p= 0.01) 
Ser9Gly AIMS or 
Simpso
n 
Dyskine
sia 
scale 
 
N 
(chronic 
schizoph
renics) 
32.9 
(9.6) 
(16~ 58) 
M: 72.4
F: 27.6
Caucasian: 
85 (76%) 
 
African A: 
25 (22%) 
 
Asian: 
2 (2%) 
(USA) 
N/A N/A  Mean AIMS score for 
African Americans (10.7, 
SD= 12.2) was higher than 
Caucasians (4.7, SD= 6.6) 
and Asians (5.4. SD= 8.0).
 
Patients w Gly/Gly 
genotypes had higher 
AIMS score in both 
Basile 
et al. 
1999 
39 
Caucasians (n= 85, F[2, 
75]= 3.85, p= 0.026) and 
African Americans (n= 25, 
F[1, 23]= 8.10, p= 0.009) 
 
Ser9Gly 
 
 
AIMS w 
S-K 
criteria 
N for 
cross-se
ction 
cases 
Y for 
longitudi
nal cases 
(chronic 
schizoph
renics) 
M: 
50(14) 
F: 57 
(16) 
M: 54 
F: 44 
 
(Scotland)
51 49 In cross-sectional TD cases:  Steen, 
1997 No. of Ser/Ser, Ser/Gly, 
Gly/Gly 
= 23, 17, 11 (cases);  
= 28, 19, 2 (controls) 
OR= 6.46 (95%CI=1.28- 
62.38, p=0.018) 
 
Allele frequency: (Gly vs. Ser)
= 38% vs. 62% (case) 
= 23% vs. 77% (control) 
OR= 2.02 (CI= 1.05- 3.93, p= 
0.035).   
 
In TD cases identified by 
longitudinal assessment (3 
times):   
No. of Ser/Ser, Ser/Gly, 
Gly/Gly 
= 10, 9,6 
(TD-developed/persistent);  
= 24, 23, 3 
(TD-never/fluctuating) 
OR= 4.95 (CI: 0.92- 32.92, 
p=0.066) 
 
Allele frequency: (Gly vs. Ser)
= 42% vs. 58% in 
TD-developed/persistent 
group; 
= 29% vs. 71% (control) 
OR= 1.77 (CI= 0.82-3.81, p= 
40 
40 
0.16). 
 
 
III. Studies that investigated multiple genes including dopamine receptor genes 
AIMS w 
S-K 
criteria 
N 
(chronic 
schizoph
renics) 
34.5 
(12.6) vs.
38.5 vs. Asian 86 211 This study examined 24 
markers on DRD1-DRD4, 
DAT and COMT. However, 
only markers that showed sig. 
association were reported. 
They were 120bp duplication 
on DRD4, 408 C>G and 472 
G>A on COMT.  
No any association was 
found in following analysis 
by linear and logistic 
regressions. 
Srivast
ava  
et al. 
2006 
DRD1 
(rs5330, 
rs5331, rs 
13306309, 
rs686, -48 
A>G) 
48.5 (India) 
31.4 
(10.2) 
 
 
 
DRD2 
 (-141ins/del 
C; G>A 1kb 
upstream 
from exon 8; 
Ser311Cys; 
T>C 10kb 
downstream 
from exon 8) 
No. of 549/549, 549/429, 
429/429 
= 35, 44, 7 (cases);  
= 120, 68, 23 (controls) 
41 
 
DRD3 
(rs324026, 
rs6280, 
rs1503670, 
rs905568, 
intron 3 of 
ZnF80) 
 
DRD4  
(120bp 
duplication, 
1.2kb 
upstream 
from 
initiation 
(X2= 9.29, df=2, p=0.009) 
(allele freq: X2= 2.67, df=1, 
p=0.1) 
 
Among participants who had 
all the markers on the 
haplotype been genotyped, 
the proportion of the 
haplotype on DRD4 (120 bp 
dup-T-repeat 3) was 0.31 and 
0.36 on TD and non-TD 
group, respectively (p=0.00, 
not typo!).  
 
When counting the proportion 
of all individuals genotyped in 
this study, proportion of the 
haplotype on DRD4 (120 bp 
dup-T-repeat 3) was 0.41 and 
41 
codon, -521 
C>T, 48bp 
VNTR in 
exon 3.) 
0.27 on TD and non-TD 
group, respectively. 
AIMS w 
S-K 
criteria 
Not clear 
(chronic 
schizoph
renics) 
42.4 
(12.8) 
M: 53 White: 162 354 No data about the distribution 
of patients’ demographics, 
allele and genotype.  
 Leon, 
2005 
DRD2 
F: 47 N= 419 
(81.2%)
(Ser311Cys, 
-141C del)  
   
African 
A: 
DRD2 and DRD3 were not 
selected into final models. So, 
only results from univariate 
reg. were presented in the 
paper:  
DRD3 
(Ser9Gly) 
N= 89  
(17.2%)CYP2D6 
 CYP3A5 
(USA) Ser311Cys (in DRD2): PgP  
OR= 0.46, (95%CI=0.13-1.6, 
p= 0.21) 
GSTM1 
GSTT1 
  
42 
 -141 Del (in DRD2):  
ORwt/wt vs. others= 0.9 (95%CI= 
0.6-1.5) 
 
Ser9Gly (in DRD3): 
ORwt/m vs. wt/wt= 1.0 
(95%CI=0.68-1.5) 
ORm/m vs wt/m= 0.81 
(95%CI=0.46- 1.4) 
 
Other non-genetic risk factors
for TD were identified in 
multivariate regressions: 
Age> 45: OR= 2.0 
(95%CI=1.3-3.0, p=0.002) 
 
Female sex: OR= 1.5 
(95%CI=1.0-2.3, p= 0.04)  
 
Taking typical anticholinergic 
42 
> 5 years: OR= 2.4  
(95%CI=1.4- 3.9, p=0.001) 
 
Taking anticholinergic: 
OR=2.0 (95%CI=1.2-3.4, p= 
0.008) 
 
No antipsychotic exposure: 
OR= 0.25  
(95%CI=0.07- 0.87, p=0.02) 
    
No significant association 
between genotypes and 
total AIMS were found.  
Chong 
et al, 
2003 
DRD2 AIMS w 
S-K 
criteria 
N  M: 85 Asian 117 200 No. of Ser/Ser, Ser/Gly, 
Gly/Gly (Ser311Cys) (not 
clearly 
specified
. 
F: 232 (Singapo
re)  = 60, 46, 11(cases);  
DRD3 = 89, 88, 23(controls) 
43 
(Ser9Gly) (X2 = 1.409, df= 2, p= 0.495).
 Probably 
chronic 
schizoph
renics 
 
 Allele frequency: (Gly vs. Ser)
= 29% vs. 71% (case) 
= 34% vs. 66% (control) 
 
No. of Ser/Ser, Ser/Cys,Cys 
/Cys 
= 19, 52, 46(cases);  
= 42, 92, 66(controls) 
(X2 = 1.742, df= 2, p=0.419) 
 
Allele frequency: (Cys vs. 
Ser) 
= 62% vs. 38% (case) 
= 56% vs. 44% (control) 
 
Risk factors for TD were 
identified in multivariate 
regressions: 
Age (p<0.005) 
Ser/Ser on DRD3 (p= 0.012)
43 
 
 Segma
n 2003
59 63 In DRD2: AIMS w 
S-K 
criteria 
N 54.3 (13) 
vs. 50.4 
(10) 
49.2 
vs.47.6 
Ashkena
zi 
DRD2 
No. of Ser/Ser, Ser/Cys,Cys 
/Cys 
(chronic 
schizoph
renics) 
(Tap-1 A,  
(57.6% 
vs. 
60.3%) 
-141Cins/del 
= 52, 2, 0 (cases);  Ser311Cys) 
= 52, 3, 0 (controls)  
(Fisher’s exact test: p=1.000) DRD4 
 non-Ash
kenzai 
(exon 3 vntr, 
No association between 
genotype frequency or allele 
frequency with TD status was 
found among all markers 
investigated in this study. 
promoter 
120bp 
repeat) 
(42.4% 
vs.  
39.7%)  
 DAT 
 (Israel) 5-HT6 
Non-genetic risk factors for 
TD identified in this study: 
5-HTTLPR 
TPH  
Cigarette pack years (p= 
0.01) 
44 
DRD3 
(Ser/Gly) 
 
CYP1A2 
 
 
AIMS N 
(chronic 
schizoph
renics) 
32.9 
(9.6) 
(16~ 58) 
M: 72.4 
F: 27.6 
Caucasia
n: 85 
(76%) 
African 
A: 
25 (22%)
Asian: 
2 (2%) 
 
(USA) 
 
N/A N/A Nothing here. 
This study was conducted 
among same subjects as the 
article published by Basile et 
al. in 1999 for the Ser9Gly on 
DRD3. 
Mean AIMS score in each 
genotype: 
Ser/Ser: ~ 3.8, n=34 
Ser/Gly: ~ 4, n=53 
Gly/Gly: ~ 14, n=25  
 
The severity of TD was 
greater among subjects w 
Gly/Gly genotype than 
among subjects with the 
other two kinds of 
genotypes. 
  
Ozdem
ir, 2001
DRD3 
(Ser/Gly) 
 
AIMS w 
S-K 
criteria 
N 
(chronic 
schizoph
52.1 
(11.6) vs. 
49.6 
47.2  
vs. 46.0
 
Jewish 
(Israel) 
55  60 The data about DRD3 was 
published in another article in 
1999 by same author. This 
This study concluded that 
DRD3gly and 5-HT2Cser 
contributed 4.7% and 4.2%, 
Segma
n, 2000
44 
5-HT2C  renics) (10.7) study mainly addressed the 
5-HT2C
respectively, to the variance 
in orofacial dyskinesia 
scores in the AIMS. 
(Cys/Ser) ser data added to the 
same subjects in previous 
study.  
 
 Inada 
et al. 
1997 
DRD2 AIMS w 
S-K 
criteria 
(chronic 
schizoph
renics) 
65 (13) 
(22~ 89) 
vs. 
44.9  Asian 49 56 No. of A1/A1, A1/A2, A2/A2 
on DRD2  (Nco I site) vs. 55.4 (Japanes
e)  = 4, 29, 15 (cases);  
DRD3 57 (10) = 8, 32, 15 (controls) 
45 
 
(Bal I site) 
 
 
(34~ 77) (X2 = 1.010, df= 2, p=0.604).
 
No. of A1/A1, A1/A2, A2/A2 
on  
DRD3  
= 25, 17, 7 (cases);  
= 33, 19, 4 (controls) 
(X2 = 1.573, df= 2, p= 0.455).
 
Non-genetic risk factors for 
TD identified in this study: 
Age(years): OR= 1.07 
(p<0.01) 
Sex: OR= 0.43 (p= 0.058) 
(ps. not clear which gender 
was the comparison group) 
 
45 
Table 2.4 Summary of SNP number, pathway and presence of literature of possible candidate genes to TD 
  
   ______Medline search*_____
46 
   
     Animal Human  
Gene name SNPs no. ____Pathway____  ____________Product___________ChromosomestudyLiterature  study 
ACHE 6 acetylcholine N   7 acetylcholinesterase (Yt blood group) 
BCHE 9 acetylcholine N   3 Butyrylcholinesterase 
CHAT 22 acetylcholine N   10 choline acetyltransferase 
CHRM1 10 acetylcholine N   11 cholinergic receptor, muscarinic 1 
CHRM2 31 acetylcholine N   7 cholinergic receptor, muscarinic 2 
CHRM3 55 acetylcholine N   1 cholinergic receptor, muscarinic 3 
CHRM4 2 acetylcholine N   11 cholinergic receptor, muscarinic 4 
CHRM5 11 acetylcholine N   15 cholinergic receptor, muscarinic 5 
CHRNA10 
7 acetylcholine N   11 
cholinergic receptor, nicotinic, alpha 
10 
46 
cholinergic receptor, nicotinic, alpha 2 
(neuronal) CHRNA2 16 acetylcholine N   8 
CHRNA3 4 acetylcholine N   15 cholinergic receptor, nicotinic, alpha 3
CHRNB3 8 acetylcholine N   20 cholinergic receptor, nicotinic, alpha 4
CHRNA5 12 acetylcholine N   15 cholinergic receptor, nicotinic, alpha 5
CHRNA6 4 acetylcholine N   8 cholinergic receptor, nicotinic, alpha 6
CHRNA7 18 acetylcholine N   15 cholinergic receptor, nicotinic, alpha 7
CHRNA9 13 acetylcholine N   4 cholinergic receptor, nicotinic, alpha 9
cholinergic receptor, nicotinic, beta 2 
(neuronal) CHRNB2 10 acetylcholine N   1 
CHRNB3 11 acetylcholine N   8 cholinergic receptor, nicotinic, beta 3 
CHRNB4 8 acetylcholine N   15 cholinergic receptor, nicotinic, beta 4 
solute carrier family 18 (vesicular 
monoamine), member 1 SLC18A1 15 acetylcholine N   8 
ADORA2A 9 dopamine N   22 adenosine A2a receptor 
 
DBH 27 dopamine Y (136-140) 9 
dopamine beta-hydroxylase 
(dopamine beta-monooxygenase) 
DRD1 8 dopamine receptor Y  (118) 5 dopamine receptor D1 
dopamine receptor (69, 71, 
80, 
118-121, 
DRD2 25 Y  141) 11 dopamine receptor D2 
dopamine receptor (70, 71, 
78, 79, 
118, 119, 
122-128, 
DRD3 17 Y  3 dopamine receptor D3 141-143) 
DRD4 4 dopamine receptor Y  (80, 118) 11 dopamine receptor D4 
DRD5 3 dopamine receptor N   4 dopamine receptor D5 
RGS9 12 dopamine Y (144)  17 regulator of G-protein signalling 9 
SLC6A3 
47 
19 dopamine N   5 
solute carrier family 6 
(neurotransmitter transporter, 
dopamine), member 3 
47 
TH 7 dopamine Y 
(145-1
47)  11 tyrosine hydroxylase 
dopamine 
Response ACE 19 Y  (148) 17 
angiotensin I converting enzyme 
(peptidyl-dipeptidase A) 1 
dopamine 
Response COMT 23 Y  (149-151) 22 catechol-O-methyltransferase 
DDC 20 dopamine serotonin N   7 
dopa decarboxylase (aromatic 
L-amino acid decarboxylase) 
MAOA 9 dopamine serotonin Y  (152, 153) 23 monoamine oxidase A 
MAOB 19 dopamine serotonin Y  (150) 23 monoamine oxidase B 
SNAP25 28 dopamine serotonin N   20 
synaptosomal-associated protein, 
25kDa 
(154) 
PPP1R1B 3 
dopamine serotonin 
glutamate Y  17 
protein phosphatase 1, regulatory 
(inhibitor) subunit 1B (dopamine and 
cAMP regulated phosphoprotein, 
DARPP-32) 
48 
GAD1 13 GABA glutamate Y 
(131, 
155) 
glutamate decarboxylase 1 (brain, 
67kDa) (132) 2 
GAD2 22 GABA glutamate N   10 
glutamate decarboxylase 2 
(pancreatic islets and brain, 65kDa) 
GLS 19 GABA glutamate Y (131)  2 glutaminase 
GLUL 8 GABA glutamate N   1 
glutamate-ammonia ligase (glutamine 
synthetase) 
CACNG2 47 glutamate N   22 
calcium channel, voltage-dependent, 
gamma subunit 2 
GLUD1 12 glutamate N   10 glutamate dehydrogenase 1 
GLUD2 4 glutamate N   23 glutamate dehydrogenase 2 
GRIA1 48 glutamate N   5 
glutamate receptor, ionotropic, AMPA 
1 
GRIA2 
14 glutamate N   4 
glutamate receptor, ionotropic, AMPA 
2 
48 
GRIA3 86 glutamate N   23 
glutamate receptor, ionotrophic, 
AMPA 3 
GRIA4 42 glutamate N   11 
glutamate receptor, ionotrophic, 
AMPA 4 
GRIN1 7 glutamate N   9 
glutamate receptor, ionotropic, 
N-methyl D-aspartate 1 
GRIN2A 75 glutamate N   16 
glutamate receptor, ionotropic, 
N-methyl D-aspartate 2A 
GRIN2B 114 glutamate N   12 
glutamate receptor, ionotropic, 
N-methyl D-aspartate 2B 
GRIN2C 8 glutamate N   17 
glutamate receptor, ionotropic, 
N-methyl D-aspartate 2C 
GRIN2D 16 glutamate N   19 
glutamate receptor, ionotropic, 
N-methyl D-aspartate 2D 
GRIN3A 42 glutamate N   9 
glutamate receptor, ionotropic, 
N-methyl-D-aspartate 3A 
GRIN3B 10 glutamate N   19 glutamate receptor, ionotropic, 
N-methyl-D-aspartate 3B 
GRM1 52 glutamate N   6 glutamate receptor, metabotropic 1 
GRM2 4 glutamate N   3 glutamate receptor, metabotropic 2 
GRM3 33 glutamate N   7 glutamate receptor, metabotropic 3 
GRM4 32 glutamate N   6 glutamate receptor, metabotropic 4 
GRM5 76 glutamate Y (156)  11 glutamate receptor, metabotropic 5 
GRM6 14 glutamate N   5 glutamate receptor, metabotropic 6 
GRM7 200 glutamate N   3 glutamate receptor, metabotropic 7 
GRM8 275 glutamate N   7 glutamate receptor, metabotropic 8 
SLC17A6 15 glutamate N   11 
solute carrier family 17 
(sodium-dependent inorganic 
phosphate cotransporter), member 6 
SLC17A7 
9 glutamate N   19 
solute carrier family 17 
(sodium-dependent inorganic 
phosphate cotransporter), member 7 
SLC1A1 51 glutamate N   9 
solute carrier family 1 
(neuronal/epithelial high affinity 
glutamate transporter, system Xag), 
member 1 
SLC1A2 37 glutamate N   11 
solute carrier family 1 (glial high affinity 
glutamate transporter), member 2 
SLC1A3 28 glutamate N   5 
solute carrier family 1 (glial high affinity 
glutamate transporter), member 3 
SLC1A6 9 glutamate N   19 
solute carrier family 1 (high affinity 
aspartate/glutamate transporter), 
member 6 
SLC18A2 17 
monoamines, 
histamine N   10 
solute carrier family 18 (vesicular 
monoamine), member 2 
SOD1 8 SOD1 N   21 
superoxide dismutase 1, soluble 
(amyotrophic lateral sclerosis 1 
(adult)) 
SOD2 7 SOD2 Y  (125, 134, 6 superoxide dismutase 2, mitochondrial
49 
49 
157, 158) 
 
*Medline search was implemented using MeSH term for (tardive dyskinesia OR TD) AND (gene name OR gene) abbreviation in full text 
 
 
50 
50 
Table 2.5 List of drug metabolizing enzymes with its importance in metabolizing the six antipsychotics in the 
CAITE in human models  
51 
CATIE Phase 1 & 2 Medications Gene Drug Metabolizing 
Enzymes C O P Q R Z A 
CYP1A2 Cytochrome P450 1A2 Major Major Minor   Minor  
CYP2A6 Cytochrome P450 2A6 Minor       
CYP2C8 Cytochrome P450 2C8 Minor  Minor     
CYP2C9 Cytochrome P450 2C9 Minor  Minor     
CYP2C19 Cytochrome P450 2C19 Minor  Minor     
CYP2D6 Cytochrome P450 2D6 Minor minor Major  Major  Major
CYP3A4 Cytochrome P450 3A4 Minor  Minor Major Major Major Major
 
C=clozapine, O=olanzapine, P=perphenazine, Q=quetiapine, R=respiridone, and Z=ziprazidone. A=Aripiprazole 
“*” = also documented in FDA approved labeling.  
 
 51 
9. Figures 
Figure 2.1 Conceptual model to illustrate relationships between TD, dopamine 
receptor genes and covariates 
Genetic variants in
DRD1, 2, 3, 4, 5
Tardive Dyskinesia
(TD)
Sex Ancestry Age
Antipsychotic
use
Duration of 
antipsychotic use Schizophrenia
Substance 
abuse
Anticholinergic
use
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Figure 2.2 Evaluation form of Abnormal Involuntary Movement Scale (AIMS).  
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Figure 2.3 Flow diagram of the CATIE study design. (Source: (135)) 
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Chapter III. 
METHODS 
 
1. Meta-analyses of associations between DRD3 rs6280 and POR of TD 
1.1. Overview of the meta-analysis between DRD3 rs6280 and TD 
The purpose of this meta-analysis was to evaluate the evidence for a widely 
suspected but inconclusive association between prevalence of TD and rs6280 in 
DRD3. Meta-analysis has been recognized as an important tool to summarize 
scientific knowledge explicitly and objectively (1). However, in contrast to 
meta-analyses of randomized clinical trials, summary estimates based on 
meta-analyses of observational studies may be vulnerable to mistaken conclusions if 
methodological considerations limit study findings (2). Therefore, this meta-analysis 
of observational studies only reported summary estimates that were not vulnerable to 
publication bias and heterogeneous findings from the literature.  
This meta-analysis included three components: 1) a systematic search of several 
bibliographic systems; 2) statistical testing for symmetry of funnel plots and 
homogeneity of effect sizes among studies; and 3) stratified analyses by study 
characteristic to identify sources of inconclusive findings in the literature. We reported 
the summarized effect estimate when assuming a recessive model of inheritance, 
which was not vulnerable to publication bias and heterogeneity across studies, and 
concluded no association between DRD3 rs6280 and prevalence of TD. 
 1.2. Rationale for the meta-analysis study 
This meta-analysis study was motivated by several factors. The first reason was 
to reconcile conflicting results. The rs6280 in DRD3 is the most widely studied 
genetic variant that has been associated with TD. However, the reported effect 
estimates were inconclusive, ranging from OR=0.76 (95%C.I. = 0.48- 1.20) to OR= 
3.53 (95%C.I. = 1.26- 9.89). A 2002 combined analysis of 708 patients with chronic 
schizophrenia in seven groups concluded that the rs6280 polymorphism in DRD3 
significantly contributes to susceptibility of TD (3). However, two large studies 
published since that time found conflicting results. The heterogeneous findings could 
be due to methodological limitations inherent in several of these studies, for example 
small sample sizes (median of total samples: 116 over 13 studies).  
Second, heterogeneous findings in the literature may result from differences in 
study characteristics that may strongly influence the effect size of prevalence TD 
across studies. However, this important information has not been noted in prior 
studies. A 2006 meta-analysis of 1,610 patients with chronic schizophrenia reported 
an increased susceptibility to TD among patients with chronic schizophrenia carrying 
the Gly allele in comparison to those carrying the Ser allele; however, no association 
between rs6280 and TD was identified (4). Although notable heterogeneity of effect 
sizes across the literature was identified in this study, no further analyses were 
implemented to tackle this concern before relying on the summarized effect estimates. 
In addition, this study set an alpha value of 0.05 for heterogeneity tests and Egger’s 
tests. As both tests are known to be statistically under-powered, meaningful 
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heterogeneity and publication bias may have been overlooked in this study.  
Lastly, two large studies were published since the publication of the 
meta-analysis study in 2006. Therefore, this meta-analysis study aimed to examine 
the association between genotype in rs6280 and TD, while improving an earlier 
meta-analysis by including recent publications and implementing a more 
comprehensive evaluation of heterogeneity and publication bias.  
 
1.3. Method of meta-analysis  
1.3.1. Literature collection  
A systematic search of literature was conducted using several databases, 
including Pubmed (1966-2006), CINAHL, Web of Science (1955-2006), BIOSIS 
Previews (1969-2006), and The Cochrane Library, by using keywords: (tardive 
dyskinesia OR TD) AND (dopamine receptor 3 OR DRD3). No language criterion was 
set. All types of publications were considered in the first search, including original 
articles with and without full texts, conference proceeding and preliminary reports. 
Publications were further screened to identify studies which investigated associations 
between TD and DRD1, 2, 3, 4 and 5 genes. A study was included in this 
meta-analysis if it met the following criteria: 1) the outcome of interest is TD; 2) 
genetic variants of interest includes rs6280; and 3) in human. A summary of 
publication on associations between TD and DR genes is tabled in Table 2.3. 
 
1.3.2 Data abstraction  
Data abstracted from selected association studies included information of TD 
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measurement, genotype data, and study characteristics in methodology and study 
population. 
 
1.3.2.1. Outcome: TD status 
As addressed in section II-2.2.3, TD is mainly defined using Schooler-Kane 
criteria to AIMS evaluation but a few studies applied different criteria. Information 
abstracted about TD assessment included: 1) whether TD was evaluated using AIMS; 
2) whether the Schooler-Kane criterion was adopted as the diagnosis criterion for TD; 
and 3) whether TD was measured repeatedly. 
 
1.3.2.2. Genotype in DRD3 rs6280      
Counts of rs6280 genotype, including AA, AG and GG, by TD status were 
abstracted in each study.    
 
1.3.2.3. Study characteristics 
Examining study characteristics can help us understand potential reasons for 
heterogeneous effect sizes across studies. I identified study characteristics from two 
perspectives: methodological factors and study population factors. Study 
characteristics identified from each perspective were listed below: 
Methodological factors: 
1. study design (cohort, matched cohort, case-control, matched case-control); 
2. recruiting source (hospital, community, mix);  
3. enrollment criteria (only required patients with chronic schizophrenia, only 
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required on antipsychotic treatment; and require patients with chronic 
schizophrenia and with history of antipsychotic exposure);  
4. year of publication. 
 
Study population factors: 
1. ethnicity (European, Asian, African, mixed);  
2. age (mean and standard error), which were calculated using total population 
and control group in crosesstional and case-control studies, respectively; 
3. percent female, which were calculated using total population and control 
group in crosesstional and case-control studies, respectively; 
4. Hardy-Weinberg equilibrium p-value in non-TD populations; 
5. type of schizophrenia (chronic, acute, mix);  
6. type of antipsychotic medication (conventional antipsychotic, atypical 
antipsychotic, mix). 
 
1.3.2.4. Validation of data abstraction and data entry 
Validation of data abstraction and data entry is an important step in 
meta-analysis because typos in data entries can lead to misleading effect estimates 
(5, 6). I first abstracted data into a table and then verified the data in the table a few 
weeks later. The validation work was executed by using another blank working table 
with the same study characteristics that I abstracted the first time. I performed data 
abstraction work again and compared the consistency between the new data 
abstraction results and the prior working table. A few inconsistencies were noted and 
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I consulted with the initial articles to resolve these discrepancies. 
 
1.3.3. Author contacts 
    Authors were contacted to obtain information missing in their publications. For 
example, some studies only provided count data of rs6280 when its association with 
TD was statistically significant.  
I contacted authors systematically by email, making polite requests for further 
information on their study. When the author did not respond to my first inquiry, I 
contacted them again a few weeks later to remind them of my request. When no 
response was obtained from the second email, I worked with Dr. Sullivan to send 
another request. Up to three author contacts were made.   
 
1.3.4. Analysis plans 
1.3.4.1. Overview  
I first assessed symmetry of funnel plots among collected publications using 
symmetry tests and trim-and-fill approaches. I then performed overall heterogeneity 
tests to determine whether effect estimates across studies were heterogeneous. In 
order to understand potential sources of heterogeneous findings in the literature, 
meta-regression and stratified analysis were also performed using 13 study 
characteristics.   
Meta-analysis can be conducted assuming a fixed effect model or random 
effects model. Both models apply different approaches in estimating a summary 
estimate and its variance. A fixed effect model computes its summary estimates using 
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a precision-weighted average of effect sizes in studies. In contrast, random effects 
model assumes that the true effect estimate is normally distributed with a different 
mean and variance in each given study. As we think a single summary estimate is 
appropriate and not an oversimplification of the literature only when heterogeneity of 
effect estimates does not exist, we used a fixed effect model when estimating 
summary estimates in this meta-analysis (7). 
 
1.3.4.2. Symmetry tests of funnel plots to detect potential publication bias 
Meta-analyses may provide summary effect estimates across published studies. 
However, summary effects obtained from meta-analyses may not be reliable, 
particularly when several published studies were not included in the meta-analysis.  
Publication bias is caused by multiple sources, including investigators, 
employers, funding sources, reviewers and also editors. In most situations, study 
findings in plausible directions with small p-value are highly favored for publication. In 
contrast, study findings in an implausible direction and with very small p-values are 
often not published. Therefore, publication bias may be particularly strong when prior 
knowledge about direction of the association is commonly accepted in the research 
community. 
Three procedures were implemented to examine funnel plot symmetry, an 
important sign in indicating potential publication bias among articles of interest. First, I 
graphed a funnel plot, a scatter plot which graphs effect measures by inverse 
standard error, using the metabias command in STATA 8. In a funnel plot, less 
precise estimates from studies with small sample sizes are expected to spread out 
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more than scatters from more precise estimates. As a result, if there is no publication 
bias, the shape of a funnel plot would be close to symmetry. The first assessment of 
symmetry of funnel plot was made by visually examining graphs  
Second, I calculated a p-value for  Begg and Mazumdar’s log rank test (8) 
and Egger’s regression test (9) using the metabias commend in STATA. These two 
tests provide quantitative assessments of the symmetry of a funnel plot. It is 
important to note that both Begg’s and Egger’s tests have low statistical power. As a 
result, we used a high alpha-value, such as 0.1, in evaluating the evidence of 
asymmetry of funnel plots in the literature.  
 Third, I used Duval and Tweedie’s trim-and-fill imputation (10) procedure as an 
additional analysis of funnel plot symmetry. The trimmed-and-filled procedure 
imputes effect estimates in three steps: 1) remove estimates that made the funnel 
asymmetry, forming a trimmed dataset; 2) use the trimmed dataset to compute a 
presumptively less biased summary effect and standard error; and 3) return trimmed 
estimates into the dataset and fill the datasets with estimates that had the same 
standard error as the summary effect obtained from the trimmed dataset but an 
opposite sign of the effect from the trimmed estimates. Summary estimates from the 
final trimmed-and-filled dataset was more valid than summary estimates computed 
from existing publications.  
 
1.3.4.3. Overall Heterogeneity  
     After examining the degree of publication bias in the literature, I assessed the 
heterogeneity of effect estimates among published studies. The rationale of 
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heterogeneity assessment is to assure observed study-specific estimates were not 
too inconsistent or heterogeneous to be over-simplified as one summary estimate. 
Heterogeneity assessment was implemented by computing a p-value of Cochran’s Q 
statistics in a homogeneity test (11) using the metan command in STATA. As 
homogeneity testing is known to have low statistical power, a higher than usual alpha 
value of 0.1 was applied. 
 
1.3.4.4. Meta-regression 
Meta-regression analyses were performed in order to explore potential sources 
of heterogeneous estimates in literature. In meta-regression analyses, the outcome 
was the magnitude of the effect estimate in each study and the independent variables 
were the study characteristics of interest. Therefore, the meta-regression of study 
characteristics provided us information regarding the strength of each study 
characteristic for explaining potential sources of heterogeneity among studies. 
Meta-regression was implemented using the metareg command in STATA.  
It is important to note that the unit of analysis for the meta-regression was the 
collection of all the studies examined in the meta-analysis. Therefore, the sample size 
of the meta-regression was up to 13 studies, depending on the study characteristic 
investigated.  As a result, each meta-regression was performed to examine one 
study characteristic at a time. Study characteristics identified from meta-regression 
were factors that may have contributed to heterogeneity of effect sizes in the 
literature. 
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1.3.4.5. Stratified analysis 
We performed stratified analysis when a study characteristic was suspected to 
have an important influence on the observed heterogeneity or when the 
stratum-specific summary estimates were of interest. As long as a suspected study 
characteristic was presented in at least two studies for each of its categories, 
stratified analyses were performed, including 1) examination of heterogeneity of 
effect estimates in a subgroup; 2) assessment of Begg’s and Egger’s tests for 
symmetry of funnel plots, and 3) comparison between imputed effect estimates with 
summary estimates of published studies.   
 
2. Association study between single nucleotide polymorphisms (SNPs) in 
dopamine receptor genes and POR of TD 
 
2.1. Overview 
This study aimed to investigate SNPs in DR genes and the prevalence of TD 
using 711 CATIE subjects. Fifty four SNPs in DRD1-5 genes were selected to 
implement both SNP-based and haplotype-based analysis.  An illustration of the 
relationship between TD, DR genes, and several important risk factors for TD was 
presented Figure 2.1. Associations were assessed applying a minimum-adjusted 
model, in which adjustment was made for ancestry only (Figure 3.1) and a final model, 
which adjusted for all covariates with significant effects on TD in the CATIE dataset 
(Figure 3.2).  
 
2.2. Study design 
The closest description of the study design is a cohort study of prevalent TD. The 
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TD group was composed by all individuals with TD, either those observed at baseline 
or those that identified over the course of the CATIE trial period. The non-TD group 
consisted of participants who never met TD criteria in any of their AIMS evaluations. 
The measure of effect was POR of TD across different genotypes of selected SNPs 
in DR genes.  
The rationale of including TD detected at any time point during the CATIE study 
as TD group was to accommodate the complicated detecting force for the presence 
of TD. The presence of TD can be masked or revealed by change of antipsychotic 
use, including both type and dosage. For example, TD symptoms can be temporarily 
suppressed when increasing the dosage of typical antipsychotics or starting an 
antipsychotic treatment.  However, TD symptoms could also be revealed shortly 
after patients discontinued antipsychotic medications and be mistaken as an incident 
TD. Moreover, TD symptoms could also be transient without changes of antipsychotic 
therapy. Therefore, this study included all TD at any time point to assure we capture 
all participants genetically predisposed to TD.  
 
2.3. Outcome Definition 
This study utilized the Schooler-Kane’s criteria for probable TD, which required 
at least one item in the AIMS evaluation rated greater than 3 (moderate) or at least 
two items are rated greater than 2 (mild). Participants who ever showed an AIMS 
evaluation that met Schooler-Kane’s criteria were classified with TD. Participants 
were classified as non-TDs if none of their AIMS evaluations throughout the CATIE 
study met the Schooler-Kane’s criteria. 
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 2.4. Selection of genetic markers 
    Given the large number of genetic variants on the human genome and the high 
degree of redundancy involved in densely spaced genotyping, SNP tagging has been 
proposed as an effective strategy to reduce the cost of genotyping (12). Several 
selection methods for tagging SNPs have been proposed, each using different criteria 
for evaluation. These methods can be broadly split into two types: capturing the 
diversity of original haplotypes present in the known SNP set; and demonstrating a 
strong association between proposed SNPs s (13). Among these two types of 
selection criteria, the second method measured the direct relevance to association 
between tag SNPs and with the original SNP sets and has been accepted as the 
more appropriate selection strategy in population association studies.  
2 Our study used the multiple-marker haplotype r statistic to select tag SNPs on 
DRD1-DRD5. Haplotype r2 is equivalent to the one-way analysis of variance of locus i 
among the SNP-defined groups and has been widely used to measure association 
between a reduced tag SNPs set and the known SNPs set K. A minimum r2 of ≧0.85 
between the SNPs set and the known SNP set K was required. The minimum r2 of 
≧0.85 criteria assure only a modest loss of power when genotyping tag SNPs 
exclusively. In addition, the tag SNPs were selected using the HapMap data, which 
includes European and African populations. The tag SNPs identified from HapMap 
should be representative of the tag SNPs in the proposed study population, given the 
predominant white and African-American ancestry of participants from the CATIE 
study. SNP selection was implemented using TagIT software (13). 
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In addition to tag SNPs, several functional SNPs were also interrogated in the 
proposed study. Functional SNPs are genetic variants that could potentially change 
protein characteristics such as physical properties, stability, and folding kinetics, 
leading to an altered protein. A total of 54 tag and functional SNPs in DRD1-DRD5 
were selected for the second part of this dissertation work. These SNPs are listed in 
Table 3.1. 
 
2.5. Genotyping method and quality control 
Genotyping was conducted using Illumina Golden Gate technology 
(http://www.illumina.com). This choice was dictated by high genotype call rates 
(>99.6%), high reproducibility (>99.59%) and competitive pricing (14). All genotyping 
was conducted according to protocol at the Duke University core facility directed by 
Dr. Kevin Shianna (15). Illumina Bead Studio software (version 2.0) was used for 
genotype calling. 
 
2.5.1. Genotyping method 
These assays are based on an array of wells (usually in 96 well format) 
patterned into an optical imaging fiber bundle (14). The optical imaging fiber bundles 
used by Illumina consist of ~50,000 individual fibers fused into a hexagonally packed 
matrix that can hold up to ~50,000 beads. Each bead has a distinct oligonucleotide 
capture probe. Since the assembly of beads into wells is a random process, the 
location and identity of beads in the array must be decoded post-assembly (16). 
Highly multiplexed genotyping (up to 1,536 SNPs per well) is based on allele-specific 
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extension with read-out on random arrays of universal capture probes. There are 
three probes per SNP (two allele-specific oligos and one locus-specific oligo). 
Allele-specific extension followed by ligation joins the allele-specific and 
locus-specific oligos to create a PCR template that can be amplified with universal 
primers. The extension reaction provides allele selectivity. The fluorescently labeled 
PCR products are hybridized to capture probes on beads in the array. The signal ratio 
from the two allele-specific extension products indicates the genotype.  
 
2.5.2. Quality control  
As all CATIE participants were unrelated, genotyping error proceeded as follows: 
First, I performed Hardy-Weinberg Equilibrium (HWE) tests in the whole study 
population separately by ancestry. Second, I referred to the resources listed below as 
external sources to compare allele frequencies among CATIE samples and existing 
datasets to detect potential signals for genotyping error. [dbSNP 
(http://www.ncbi.nlm.nih.gob/SNP); NHLBI/SeattleSNPs 
(http://pga.mbt.washington.edu); NIEHS/geneSNPs (http://www.genome.utah.edu); 
NCI/SNP500Cancer (http://snp500cancer.nci.nih.gov)]. 
 
2.6. Measurement of potential confounding factors 
2.6.1. Ancestry 
In the CATIE study, self-reported race was collected by a closed-ended 
questionnaire. Respondents could select one (or maybe more than 1) of the following 
five categories: White, Black or African-American, American-Indian or Alaska Native, 
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Asian, Native Hawaiian or other Pacific Islander. Among these five categories, White 
and Black categories are the two largest groups, counting for 85% of the total study 
population (Table 3.2). However, validity of self-reported ancestry might be a concern 
in most studies. Therefore, this study performed Structure Analysis, using software 
Structure (http://pritch.bsd.uchicago.edu/structure.html) (17) to obtain 
Structure-allocated proportion for ancestry. The computing process generated a set 
of estimated proportions for each participant’s ancestry in each of three main 
ancestries: Europe, Africa and Asia, rather than categorized ancestry origins. This 
study adjusted for Structure-allocated ancestry proportion in regression models to 
more precisely control population stratification and also to obtain better statistical 
power than stratified analyses by ancestry. The population stratification issue is 
further addressed in section III-2.8.6.1.  
 
2.6.2. Anticholinergic use at baseline 
“ANTICHOL”, a variable indicating participants’ anticholinergic use within 14 
days prior to randomization, was the only available information about anticholinergic 
use in the CATIE study. Therefore, this study used “ANTICHOL” in evaluating 
confounding by anticholinergic use. 
 
2.6.3. Substance use 
Substance use implies alcohol and/or illicit drug use. Several indicators were 
used to dichotomize substance use into categories characterized by abuse and/or 
dependence on substances. These indicators included: (1) clinicians’ rating using the 
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Structured Clinical Interview for DSM-IV (SCID) in the screening step. Participants’ 
alcohol or drug abuse/ dependence presented in the past month are indicated as 
“Current substance abuse or dependence”. (2) hair assay for illicit drug use including 
cocaine, opiates, phencyclidine (PCP), Methamphetamine, and marijuana at 
screening, every 6 months, and at the end of each phase of the trial; (3) urine assay 
for illicit drug use (cocaine, cannabinoids, ethanol, dextroamphetamine, 
methamphetamine, hydrocodone, morphine, codeine, hydromorphone, 
propoxyphene, heroin) at baseline screening and every three months during the trial. 
Participants with substance abuse records on the SCID form or testing positive for 
any of the above illicit substances were classified as having a substance abuse or 
dependence disorder.   
 
2.6.4. Duration of schizophrenia illness and antipsychotic treatment 
Lifetime antipsychotic exposure is very difficult to measure due to the lack of 
long-term follow-up data and also the low reliability of patients’ self-reported exposure 
of antipsychotic medications. This study explored the use of a variable, “yrspres0”, 
which indicated “year since first prescribed antipsychotic” to approximate 
accumulated duration of schizophrenia illness and prior antipsychotic use.  
We understand that “year since first prescribed antipsychotic” may not 
approximate lifelong treatment duration well as it assumed all antipsychotics are 
comparable in the same duration of use and also assumed discontinuation of 
antipsychotics was not of great concern. The first assumption may be acceptable as 
atypical antipsychotics constitute over 90% of antipsychotic prescriptions, and current 
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data indicate that all ATY have equivalent efficacy in schizophrenic treatment and 
remission maintenance after a psychotic episode (18). The second assumption may 
be of concern because TD may affect participants’ willingness for continued use of 
antipsychotic, i.e. depletion of susceptibility in long term medication users. As a result, 
this study explored the control of “years since first antipsychotic use” with caution.  
 
2.7. Assessment of confounders 
    Principally, confounders would be identified using the following criteria: 1) the 
variable is a risk factor of TD development; 2) the variable is differentially distributed 
across different genotypes on most SNPs; 3) after adjusting for the varible of interest 
there is a 10% or greater change in the effect of the main exposure variable, 
measured by |ln(crude OR)-ln(adjusted OR)|, and 4) clinical plausibility. To ease the 
interpretation of genetic effects of 54 SNPs studies in this study, we identified a set of 
confounders by considering biological plausibility, forward model selection (entry 
level=0.2) and expert opinions. 
When a covariate is a continuous variable, such as baseline age and years since 
first antipsychotic prescription, I compared their group means using student’s t test 
and analysis of variance. When the covariate is a categorical variable, such as sex, 
anticholinergic use and substance use, I used Person’s X 2 test to estimate a potential 
confounders’ relationship with SNP distribution and TD. More details about the 
analysis strategies were addressed in sections III-2.8.3 and III-2.8.4. 
 
2.8. Statistical analysis 
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2.8.1. Overview 
The present study estimated genotype-phenotype associations among 711 
unrelated CATIE participants. We implemented analysis of SNPs and haplotype in 
DR genes to assess their associations with TD. Details of these analyses are 
addressed in section III-2.8. Specifically, we used STRUCTURE-inferred ancestry to 
address the concern of population stratification in a genotype-phenotype study. 
Details of STRUCTURE allocated ancestry would be addressed in sections 
III-2.8.6.1. 
Although specific antipsychotic use may modify the association between TD and 
genetic variants in DR genes, literature about existence and strength of the 
interaction is missing. This study, therefore, decided not to implement stratified 
analyses by 5 specific antipsychotic in a concern of limited statistical power to detect 
genotype-antipsychotic interactions and preference to reduce unnecessarily for 
multiple comparisons. In addition, cluster effects among clinical sites was not a 
concern in the present study as participants were recruited from many clinical sites 
but were randomized by individual, not by sites.   
 
2.8.2. Data exploration and quality control  
Before analyzing the data, the following steps were implemented for quality control of 
the dataset:  
1ST: remove CATIE participants whose genetic data were missing for more than 10% 
of all genetic markers.  
2nd: remove those genetic markers that have an allele frequency of less than 1% so 
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that all strata are sufficiently large to produce stable estimates 
3rd: apply Fisher’s exact test to examine HWE separately by European-only and 
African-only participants (19). We examined HWE in the total population in this 
crossectional study. When tests for HWE were not rejected, the possibility of 
genotyping errors was small. Otherwise, an inquiry to the lab was sent to verify 
the validity of the genetic data. 
4th: check the range of continuous covariates such as age, duration of prior 
antipsychotic use in the total population to detect any outliers. For data outside 
the plausible range of values, I verified the value with assistance from the CATIE 
data coordinating center. 
5th: check the distribution of categorical variables such as sex, ancestry, baseline 
anticholinergic use, status of substance abuse, in TD and non-TD group. 
6th: compare prevalence of missing data in each variable by TD status. This 
comparison aimed to examine whether missing data is related to participants’ 
outcome status.  
  
2.8.3. Single marker analysis 
2.8.3.1. Overview 
Single marker analysis was implemented to estimate the association between 
each tSNP and POR of TD. Several main steps included contingency test, regression 
analysis only adjusting for ancestry and regression analysis adjusting for all 
meaningful confounders identified.  
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2.8.3.2. Rationale  
    Given the extensive genetic variation in the human genome, the probability of 
any single marker being the cause of a disease, including TD, is very low. However, it 
is still important to begin the analytic process by estimating the effect of each 
selected SNP. The purpose of this analysis is to determine whether any tSNP is a 
disease-causing locus or whether there is strong linkage disequilibrium with the real 
casual allele. This step provides us an overview of effect sizes of associations 
between TD and each tSNP with ancestry adjustment. 
 
2.8.3.3. Contingency testing between a SNP and TD  
I first performed contingency tests to compare the distribution of three 
genotypes (e.g. AA, Aa, aa) across TD status using Fisher’s exact tests. The 
contingency test is valuable because it does not set any strong assumptions in 
testing the proportionality of genotype distribution across disease groups. 
Findings from contingency tests provided me a crude overview of all investigated 
SNPs-TD associations.  
  
2.8.3.4. Estimating effects of SNPs using univariate models 
    The univariate model contained three components: a) outcome: TD status; b) 
genotype information; and c) Structure-inferred proportion of ancestry in Europe and 
Asia. Thus, the univariate model presented as ln (π /(1-πij ij)=β0 + β1 (g=1,1)+ β (g=1,0)2  
+ β  (% of European ancestry)+ β3 4 (% of Asian ancestry). As described in section 
III-2.6.1., Structure computed and allocated each participant’s ancestry into admixture 
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proportions of European, African and Asian ancestry. As proportion of European and 
African ancestry showed a strong inverse correlation (correlation coefficient< -0.6), 
we selected proportions of European and Asian ancestry in the regression 
adjustment.  
 
    Among four genetic models of inheritance (dominant, additive, recessive and 
general model), we implemented general model as it does not assume any 
relationship between any two of three genotypes, e.g. AA, Aa, aa. I assumed the 
most common genotype, i.e. the wide type, as the reference group, thereby 
maximizing statistical efficiency. When the genotype count of a SNP was smaller than 
or equal to 5, I implemented Fisher’s exact test between homozygous and 
heterozygous variants by TD status to examine if the genotypic distribution by TD 
were similar in both genotypes. When the Fisher’s exact test was not rejected, I used 
the dominant model to assess their associations with TD. By assuming the dominant 
model of inheritance, I pooled the heterozygous variant and homozygous variant 
together to obtain more informative estimates of SNP effect on the PORs of TD than 
effect estimates when assessing the genetic effects in the general model of 
inheritance.  
 
2.8.3.5. Estimating SNPs effects using covariates-adjusted model 
A covariate-adjusted model was used to control confounding effects when 
estimating the SNP-TD association (Figure 3.2). As a result, each regression model 
contained three components: a) outcome: TD status; b) exposure: genetic 
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polymorphisms; c) potential confounders, including age, sex, ancestry, year since first 
antipsychotic prescription, baseline antipsychotic use, substance use and baseline 
PANSS. The full regression model before model selection processes was 
parameterized as below: ln (π /(1-πij ij)=β + β (g=1,1)+ β (g=1,0) + β0 1 2  3 (baseline age)+ 
β (sex)+ β  (year since first antipsychotic use) +β4 5  6 (only use atypical antipsychotic 
medications)+ β  (use conventional antipsychotic medications)+ β 7 8 (baseline 
PANSS)+ β (% of inferred European ancestry)+ β9 10 (% of inferred Asian ancestry) 
+β (anticholinergic use)+ β  (substance use)+ their interaction terms.  11  12
The model building processes involved several steps: 1) using forward model 
selection strategy; 2) exploring different formats of covariates in the model, and 3) 
referring psychiatrists’ suggestions. A forward model selection process in the initial 
parameterized model identified four important covariates: participants’ baseline age, 
ancestry, total PANSS at baseline, and anticholinergic use.  
The investigator then explored the model building process by excluding the 
“years since first antipsychotic prescription” covariate in a concern of poor 
approximation of this measurement to lifelong antipsychotic exposure and also its 
incompleteness with 4% missing data. After excluding “year since first antipsychotic 
prescription” from the initially parameterized model, forward model selection 
procedure was performed again. The model selection process at this step only 
identified participants’ baseline age, ancestry, and baseline total PANSS as important 
covariates for the odds of TD. 
I discussed the model selection results with psychiatrists, statisticians and 
epidemiologists. As anticholinergic medications have wide indications, including 
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controlling movement disorders such as Parkinsonism, anticholinergic use may be 
reflecting a treatment purpose in the early onset of the TD symptoms. Therefore, we 
decided to exclude this variable from the final model.  
In addition, antipsychotic use was included in the final model because of 
biological plausibility. The model selection process did not identify status of 
antipsychotic use as an important factor for TD. However, we decided to include 
antipsychotic status (2 dummy variables for the 3 levels of the covariate) in the final 
model because previous studies have sbowed a higher rate of TD among patients 
using conventional antipsychotic medications than using atypical antipsychotics. 
As a result, covariates included in the final model were participants’ baseline age, 
ancestry (proportion in European and Asian ancestry), baseline total PANSS, sex and 
type of antipsychotic use (3 levels).  
 
2.8.4. Haplotype-based analysis 
2.8.4.1. Overview 
    It has been argued that evidence from single-SNP-association studies is 
inadequate because of the growing belief that most clinical outcomes are mediated 
through complex genetic traits. Haplotypes are a specific combination of nucleotides 
on the same chromosome. In contrast to SNP-based analysis, haplotype-based 
analyses investigate effects of multiple linked-SNPs on TD.  
 
2.8.4.2. Rationale 
Haplotype-based analysis can be informative for several reasons (20). First, 
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haplotypes reflect multilocus mutations on a chromosome. The multiple mutations 
may be required in order to change proteins’ physical properties, stability and folding 
kinetics, leading to functional disorders. As a result, variations of haplotypes could 
have a stronger impact on a phenotype than a single variant. This hypothesis has 
been supported in many studies. For example, a combination of multiple mutations 
have been shown to influence the function of various genes including lipoprotein 
lipase (21), actions of catecholamines which influence bronchodilation (22), intestinal 
lactase activity (23), and prostate cancer(24).  
Second, haplotypes consider the dependence among SNPs on the same 
chromosome rather than viewing each SNP independent of one another. By 
considering haplotype effects, multiple association testing may be reduced, resulting 
in a gain of statistical power (20). Third, studies have found the numbers of 
haplotypes are much smaller than all possible allele combinations, suggesting that 
variations among population genetics are intrinsically organized in haplotype format. 
For example, Drysdale et al. found 13 SNPs were organized into 12 haplotypes out of 
8,192 possible combinations among 13 SNPs (22), supporting haplotype structure to 
genetic variations.  
 
2.8.4.3. Strategies for haplotype analysis 
    This study used score test methods developed by Schaid et al (25) and Lake et 
al (26) for haplotype-based analysis. Schaid et al’s method has been widely used 
through the operation of haplo.stat software in R. This method implements 
generalized lineal models (GLMs) to adjust for environmental factors when estimating 
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genetic effects.  
Haplo.stat applies the score test to examine associations between disease traits 
and haplotypes, regardless of whether the phase of the haplotype is confirmed or 
ambiguous. In contrast to other methods, such as EM algorithm method, this method 
provides a global score statistic and also haplotype-specific score statistics, which 
enable me to compare haplotype-specific effects. In addition, the score statistics are 
more efficient in the computing process than the conventional EM algorithm method. 
This haplotype-based analysis includes two main steps:  
1st: use haplo.em to estimate haplotype frequencies and obtain posterior probabilities 
of haplotype pairs for each subject, conditional on observed genotype data in the 
CATIE. In this step, I set a command to exclude haplotype less or equal to 1% as 
no informative inference can be drawn in rare haplotype frequency. The haplotype 
with the highest frequency was set as the baseline group in subsequent analyses.  
2nd: use haplo.glm program to run regressions for TD on simple haplotype-specific 
effects and covariate-adjusted haplotype effects. For haplotypes with a low 
frequency, we set 5 as the minimum expected count in TD and non-TD group for 
haplo.glem analysis. In this step, I obtained a global score statistic for loci that is 
composed of haplotypes and haplotype-specific score statistics. I used empirical 
p-values obtained from simulation for a reliable p-value in significance testing.  
 
2.8.5. Examinations of statistical assumptions for logistic regression models 
2.8.5.1. Overview 
We also examined the statistical assumptions of the logistic regression model, 
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particularly the assumptions of adequate responses across discrete variable levels 
and no multicollinearity between independent variables.  
 
2.8.5.2. Ratio of cases to discrete variables 
    Adequate responses across levels of discrete variables in a logistic regression 
model are important in order to obtain valid effect estimates and standard errors. 
Discrete variables in our models were genotype, sex, baseline substance abuse/ 
dependence, baseline antipsychotic use, and baseline anticholinergic use. By 
referring to Table 4.2.1, we knew case number in every given category of the discrete 
covariates were not small. Regarding small cell count in a given genotype category, 
we combined that with the heterogeneous variant after Fisher’s exact tests. Therefore, 
this study met this assumption for logistic regression analyses. 
 
2.8.5.3. Collinearity between markers and covariates   
    Collinearity between independent variables in a regression could result in biased 
estimates of regression coefficients, inflated coefficients of variance, and p-value. I 
examined the collineraity between genetic markers and the covariates age, year 
since first antipsychotic prescription, baseline PANSS, percentage of European 
ancestry, percentage of African ancestry, percentage of Asian ancestry, sex, 
substance use and anticholineargic use. I first checked the correlation matrix 
between markers and covariates. When a strong (i.e. >=0.6) correlation between a 
marker and a covariate was identified, I examined the variance inflation factors (VIF) 
of the marker and the covariate. A VIF greater than 10 was further investigated and 
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the covariate was removed from the multiple covariates-adjusted models.  
 
2.8.6. Special considerations in genetic analysis 
2.8.6.1. Adjusting for empirical ancestry to reduce confounding by population 
stratification  
Population stratification could confound findings of genetic association studies 
when subpopulations have different risk to the disease and also when the allele 
frequencies are fairly different across the subpopulations (27). In order to control 
confounding from population substructure, 75 ancestry informative markers selected 
using HapMap panels were included in the Illumina genotyping runs and genotyped 
in CATIE participants. HapMap samples were then used as the prototypes for 
continental ancestry to which CATIE subjects can be compared. We then used the 
Structure program, (http://pritch.bsd.uchicago.edu/structure.html) (17), which use a 
Bayesian approach and Markov chain Monte Carlo (MCMC) method, to determine 
the posterior probability for each study subject being classified into one of three main 
sources of human ancestry (African, East Asian, and European). These three 
probabilities sum to 1.0 and subjects could have had substantial ancestry from each 
source. Detailed steps to generate Structured-allocated admixture fraction and the 
results are listed below: 
Step 1: Identify SNPs with high Fst values for use with STRUCTURE 
- Considered Caucasian (CEU), African (YRI), and Asian (CHB+JPT) HapMap 
panels. Used ALL SNPS genotyped in HapMap.  
- Selected SNPs with allele frequencies in the [0.05 - 0.95] range in all panels 
 100
- Calculated Fst values 
- Formulas from Weir and Hill (28), three pairwise combinations of HapMap 
populations 
- Ranked each of the three pairwise comparisons 
- Dropped SNPs that were within 50 kb of each other 
- Selected 100 SNPs with high pairwise Fst values (CEU-YRI & CEU-ASI given 
priority given the demographics of CATIE).  
 
Step 2: genotype these SNPs in all of CATIE.  
- Done at Duke core facility 
- 75 of 100 SNPs requested were successfully genotyped.  
- Genotyping was successful in only N=719 (of 745) 
- No evidence of the “allele flip problem” in HapMap1 
- Pretty divergent – the minimum difference between allele frequencies in 
“Black” versus “White” was 0.49 
 
Step 3: use STRUCTURE 
 
Step 3a: use HapMap populations as a guide 
- All SNPs in Step 2 were genotyped in HapMap 
- Use the HapMap samples as “exemplars”, as the prototypes for continental 
ancestry to which CATIE subjects can be compared.  
- HapMap data (N=270)  
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- used Hapmap sets (CEU 30x3, JPT+CHB 45x2, YRI 30x3) 
- kept founders (210=60 CEU, 90 JPT and 60 YRI) 
- dropped NA19012 who had missing for 43/75 (other missings 0-4 range) 
- Ran STRUCTURE 3 times (settings – burnin 25K, run length 200K, use pop 
info, correlated allele frequency, all others defaults) 
- Some people were not well classified based on these SNP data and were 
dropped 
- Final numbers: 60 YRI, 80 ASI, and 58 EUR 
 
Step 3b: use STRUCTURE in a supervised way. I want to determine posterior 
probability for each CATIE subject being classified into one of three human 
continental ancestries using HapMap data as exemplars.  
- Goal is to classify CATIE into groups defined by HapMap exemplar groupings 
- NOT to discover new classifications (number of SNPs insufficient for this task) 
- Checks – allele calls very similar in CATIE and HapMap 
- N=917 individuals (HapMap=198 and CATIE=719) and 75 SNPs 
- Details: 
o K=3.  
o For HapMap, popID (or popdata)=1-2-3 for pop of origin & popflag=1. 
This tells STRUCTURE to use this person for pop learning 
o For CATIE, popID=0 & popflag=0 
o Burnin 25K, run length 200K, use pop info (advanced, use defaults 
admixture model, gensback=2 & migrprior=0.05), correlated allele freqs 
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o advanced - I turned on update allele freqs with POPFLAG=1 data 
(PFOMPOPFLAGONLY), manual p19 
o all others defaults 
- Ran STRUCTURE four times. Results highly similar across runs.  
 
Preliminary data generated by Dr. Sullivan have suggested that 
misclassifications of ancestry based on self-reported ancestry in the CATIE study 
population are unusual (Table 3.3). In addition, the preliminary data also demonstrate 
that the posterior probabilities inferred from Structure are sensible, particularly among 
CATIE participants who reported more than one ancestry. A summary of CATIE 
subjects by their self-reported race and the inferred posterior probabilities from 
Structure is listed in Table 3.4. These findings were important because they 
demonstrate the validity of using Structure-referred ancestry admixture proportion to 
represent population substructure. Therefore, I used Structure-allocated admixture 
fraction to assess confounding and control for population stratification. The 
distribution of Structure-allocated ancestry proportions are shown in Figure 3.3.  
 
2.8.6.2. Controlling positive false discovery rate (pFDR) in multiple testing 
Multiple comparisons are an unavoidable issue in genetic association studies, 
particularly in studies investigating a large number of genetic variants. This is a 
problem because multiple testing may lead to increased type I error and generate a 
certain amount of false-positive findings. Two strategies have been commonly used 
to adjust for multiple testing: controlling family-wise error rate (FWER) and controlling 
the false discovery rate (FDR). Using methods for FWER control, such as a 
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Bonferroni correction, assures the probability of any single false positive testing is 
less than 0.05 in all loci testing. However, this strategy has been criticized to be too 
conservative in genotype-phenotype association testing because it is reasonable to 
expect a sizeable proportion of genetic markers could be truly significant findings 
when examining a large amount of genetic markers.  
Instead of using Bonferroni method and setting a very restrictive p-value for all 
tests, this study applied Storey et al’s method to control positive false discovery rate 
(pFDR) in multiple tests (29). pFDR is defined as minimum expected proportion of 
errors among rejected hypothesis. Controlling pFDR method enables proposed study 
to balance the opportunistic cost between generating false positive findings and 
missing truly positive findings. 
In operating the control of pFDR, I first performed statistical tests for each 
variant to obtain a variant-specific p-value. Second, I ordered the p-values from 
each testing in the same model in ascending fashion. Third, I entered all the 
p-values into the QVALUE software 
(http://faculty.washington.edu/~jstorey/qvalue/) to calculate the q-value.  I set a 
q-value of 0.05 as a tolerable pFDR, which means this study accepts 5% 
erroneous rejections among all rejected hypotheses from individual testing. So, 
only statistical testing that obtained a q-value less than 0.05 would be interpreted 
SNP with statistically significant association with TD after adjustment of multiple 
comparisons.  
 
2.9. Power calculation 
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    In order to obtain an overview of statistical power in this genotype-phenotype 
association study, we performed power calculation across a range of effect sizes 
and minor allele frequencies in SNPs in this study. We set 15% of TD prevalence, 
alpha-value equal to 0.001, and additive model of genetic inheritance in power 
calculation using software Quanto version 1.1.1 (30).  
 
2.10. Human Subject 
2.10.1. Type of subjects 
    The present study was involved with 711 CATIE participants who agreed to 
provide their DNA sample for genetic studies. To enter the trial, a subject must be a 
patient with schizophrenia, aged between 18 to 65 years old, non-pregnant, 
non-breastfeeding, and with decisional capacity in study participation. In addition, 
subjects who were in their first episode of schizophrenia, with contraindication or 
history of treatment failure to any proposed antipsychotic treatment were not 
recruited in this study.  
 
2.10.2. Method of recruitment 
Participants were enrolled from various recruitment sites, including managed 
care centers, public mental health, and Veteran’s Affairs, regardless of their 
race/ethnicity, sex and disease severity. This study did not enroll patients under 18 
years old as the development of chronic schizophrenia is less common among 
persons under 18 years of age. Only participants who consented with DNA samples 
when entering the trial were eligible in the study about DR genes and TD.    
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 2.10.3. Informed consent 
Participants must have the decisional capacity in the participation of the 
CATIE and would like to sign the informed consent to be recruited. Participants 
consented DNA samples through an additional informed consent for CATIE HGI 
(Human Genetics Initiative) study with an agreement for research purpose to 
improve etiological understanding of schizophrenia and its treatment.  
 
2.10.4. Risk to participants 
The present study was involved with genotyping work of existing DNA samples 
and linking the genetic data to the parent study. No additional physical damage would 
cause to participants due to this study.  
 
2.10.5. Confidentiality of data 
The genotyping work was blinded to subjects, investigators and health care 
providers. In order to reduce the risk of disclosure of participants’ confidentiality, all 
datasets were processed and stored without coding of personal identification, such 
as name. Each participant was assigned a pseudo unique identifier by the CATIE 
study and be traced by the psueo-ID for data link purpose. Password was configured. 
Therefore, access to the datasets was available to limited study personnel. In 
addition, participants’ names and the name of clinical sites from which participants 
were recruited were also excluded from future publications. When the study is 
completed, I would return the data to the CATIE committee.  
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 3. Tables 
Table 3.1 List of tag single neucleotide polymorphisms (SNPs), functional and 
structural SNPs in dopamine receptor genes. 
Location  
Chromosome no. Length  tagSNP
Gene (Start- End position) (base pair) __no._ _____________SNPs___________
rs2453737, rs265973, rs265974, 
rs265976,  
 brs686, rs5326 , rs2168631, 
rs267418 
chr5  
(174,828,959- 
 43,128 8174,872,086) DRD1 
DRD2 
chr11 
(112,797,968- 
112,903,544 105,577 23
rs1079594 b, rs1079596 b, 
rs12364283, rs17115461 b, 
rs1799978a, rs1800497 b, rs1800498 
b  b  b, rs2234690 , rs2587548 , 
rs2734836 b, rs2734848a b, 
rs4581480 b, rs4586205 b, 
rs4648317 b, rs4648318 b, 
rs4986918a b, rs6275a b a b, rs6277 , 
rs6279 b  b, rs6589377, rs7103679 , 
rs7109897 b, rs7125415 b
 
rs6808291, rs1486012, rs2399496, 
rs9824856b, rs2134655 b, 
rs2251177a b, rs963468 b, rs3773678 
b  a b  b, rs2630349 , rs167771 , 
rs167770 b, rs324029 b, rs10934256 
b  b  b, rs1486009 , rs3732783 , rs6280 
b
chr3 
, rs9825563 (115,148,457- 
90,201 17  115,238,657) DRD3 
chr11 rs3758653, rs11246226, rs936465, 
rs1800443a b (607,536- 
650,933) 43,398 4DRD4 
DRD5 
chr4 rs2867383, rs4516717a
(9,514,485- 
9,556,515) 42,031 2
a: SNPs predicted in silico to be functional (i.e. functional SNPs) 
b: SNPs in basic structural elements (i.e. structural SNPs) 
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Table 3.2 Distribution of self-reported ancestry by tardive dyskinesia (TD) 
classification in 711 participants in the present study. 
_____Anytime TD____ 
Self-reported race _Non-TD_ ____TD___ __Total (%)_ 
Africa only 140 (28%) 69 (33%) 209 (29%) 
287 (57%) 112 (54%) 399 (56%) Europe only 
77 (15%) 26 (13%) 103 (15%) Other 
504 207 711 Total 
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Table 3.3 Consistency comparison between self-reported race and 
Structured-inferred ancestry with inconsistent data marked in bold.  
 Inferred best class of continental  
_Self-reported ancestry_ ___________ancestry by Structure___________ _Total_ 
 ____AFR____ _____ASI____ ____EUR____  
213 Africa only 210 (98.59%) 0 (0%) 3 (1.41%) 
400 (99.5%) 402 Europe only 1 (0.25%) 1 (0.25%) 
Other 11 (10.58%) 20 (19.23%) 73 (70.19%) 104 
Total 222 21 476 719 
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Table 3.4 Summary of CATIE subjects by their self-reported race and the 
inferred posterior probabilities from Structure. 
 Structured-allocated No. of 
subjects__Self-reported race among CATIE participants_ admixture fraction 
NATIVE PACIFIC 
ISLANDER
HISPANIC
WHITE BLACK AMERICAN ASIAN LATINO P-AFR P-ASI P-EUR N
1 0 0 0 0 0 0.01 0.03 0.95 402
1 0 0 0 0 0 0.80 0.06 0.10 213
1 1 0.74 0 0 0 0 0.10 0.14 69
1 0.93 0 0 0 0 0 0.02 0.05 15
1 1 0 0 0 0 0.68 0.09 0.18 6
1 1 0.71 0 0 0 0 0.25 0.04 3
1 1 0.610 0 0 0 0.07 0.32 3
0 0 0 0 0 1 0.18 0.05 0.78 1
0 0 0 0 1 0 0.03 0.92 0.05 1
0 0 1 0 0 0 0.18 0.05 0.77 1
1 0 0 1 0 0 0.04 0.38 0.58 1
1 0 1 0 0 0 0.02 0.02 0.96 1
1 0 1 0 0 1 0.02 0.04 0.94 1
1 0 1 0 1 1 0.01 0.03 0.96 1
1 1 1 0 0 0 0.43 0.06 0.51 1
* P-AFR: posterior probability of African origin; P-ASI: probability of East Asian origin, P-EUR: 
probability of European continental ancestry. 
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4. Figures 
Figure 3.1 A Directed Acyclic Graph (DAG) that models genetic effect to 
prevalent tardive dyskinesia (TD), adjusting for ancestry. 
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Figure 3.2 A Directed Acyclic Graph (DAG) that models genetic effect to TD 
among prevalent TD, adjusting for multiple covariates. Covariates filled with 
blue color were covariates identified as confounders in final model. 
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Figure 3.3 Ternary plot to present Structured-inferred proportion of African 
ancestry (P1), Asian ancestry (P2) and European ancestry (P3) in the CATIE 
study participants. Every dot represents self-report ancestry of each 
participant as “African-American” (red dot), "White" (blue dot), or “Other" 
(green dot).  
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Chapter IV.  
RESULTS 
 
 
1. Paper I: The DRD3/Ser9Gly polymorphism and prevalence of tardive 
dyskinesia: A meta-analysis 
 
1.1 Abstract 
To elucidate a widely suspected but inconclusive association between rs6280 in 
the dopamine receptor 3 gene (DRD3) and prevalence of tardive dyskinesia (TD), we 
conducted a meta-analysis of results obtained in a systematic search of several 
bibliographic systems. We conducted several analyses of funnel plot asymmetry, 
overall heterogeneity, and study characteristics in analyses analogous to general, 
dominant and recessive inheritance models with the prevalence odds ratio (POR) as 
the measure of association. Thirteen eligible studies were identified with publication 
dates between 1997 and 2007. Evidence of reporting bias was discerned from funnel 
plot asymmetry in the dominant and general model analyses, but not in the recessive 
model analysis. Stratified analyses indicated that publication year, TD assessment 
method (Schooler-Kane criteria or other) and TD assessment frequency (single or 
repeated) were moderately associated with average PORs in the literature. Study 
population factors, such as average age, gender (percent female) and ancestry 
(Asian or European) also presented a moderate influence in the average PORs in the 
literature. Summary effect estimates under the dominant and general inheritance 
models were not warranted due to funnel plot asymmetry and heterogeneity. These 
contraindications were not present under the recessive model, for which the 
summary estimate was POR= 0.93 (95% CI 0.70, 1.23). We conclude that there is no 
association between DRD3 rs6280 polymorphisms and prevalence of TD. 
 
1.2 Introduction 
Tardive dyskinesia (TD), an involuntary movement disorder affecting the face, 
extremities and trunk, is a frequent, distressing, and potentially persistent side effect 
of long-term antipsychotic therapy (1). In the absence of safe and effective therapies 
for TD, understanding risk factors for prevalent TD is important for TD prevention in 
long-term schizophrenia care. Several risk factors have been proposed for TD, 
including antipsychotic exposure (particularly conventional agents), advanced age, 
female sex, African-American ancestry, substance abuse and anticholinergic use (2). 
However, these risk factors explain only a small portion of differential susceptibility to 
TD among patients with schizophrenia exposed to antipsychotics. Strong aggregate 
genetic effects on TD have been recognized across multiple populations (3-7), 
although the identification of specific and highly replicated sequence variation has 
thus far been lacking.   
Biological plausibility has motivated studies to investigate the association 
between TD and rs6280, a polymorphic site in the dopamine receptor 3 gene (DRD3). 
The DRD3 gene is positioned at chromosome 3q13.3 and has been hypothesized as 
a strong candidate gene for TD because DRD3 receptors densely distribute in the 
human ventral striatum and DRD3 mRNA is widely expressed in regions that are 
responsible for motor function (8). The single nucleotide polymorphism (SNP) rs6280 
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is located 25 base pairs downstream from the starting ATG codon in DRD3. A 
transition from adenine (A) to guanine (G) in rs6280 results in a serine to glycine 
substitution at position 9 in the extracellular N-terminal part of the receptor (9). 
Studies have demonstrated that replacement of the A allele (serine) with the G allele 
(glycine) increases the binding affinity of dopamine, which may result in differential 
susceptibility to TD (10). 
However, literature on the association between rs6280 and TD has been 
inconclusive with prevalence odds ratios (PORs) ranging from 0.76 (95% confidence 
interval (C.I.)= 0.48- 1.20) (11) to 3.53 (95%C.I.= 1.26- 9.89) (12) when assuming a 
dominant model of inheritance. In 2002, a combined analysis of 780 patients with 
schizophrenia in seven groups reported an increased susceptibility to TD among 
subjects carrying at least one Gly allele in comparison to those carrying Ser/ Ser in 
rs6280 (OR= 1.33, 95%C.I.= 1.04, 1.70) (13). In 2006, a meta-analysis of 1,610 
patients with schizophrenia indicated a slightly elevated risk of TD among those 
carrying the Gly allele in comparison to those with the Ser allele (OR= 1.17, 95%C.I.= 
1.01- 1.37) but no association between rs6280 genotype and TD was identified (14).  
Inconclusive findings in the literature may be due to small sample sizes in 
individual studies (median sample size= 116 of 13 studies) or differences in study 
characteristics. The 2006 meta-analysis study identified heterogeneity of effect sizes 
(14) but did not explore factors associated with the heterogeneous findings. 
Therefore, this study aimed to examine the association between genotypes in rs6280 
and TD, while improving upon the earlier meta-analysis by including recent 
publications and implementing a more comprehensive evaluation of heterogeneity 
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and funnel plot asymmetry. 
 
1.3 Methods 
A systematic literature search was conducted in several bibliographic systems, 
including PubMed (1966-2007), CINAHL, Web of Science (1955-2007), BIOSIS 
Previews (1969-2007), and the Cochrane Library, using keywords: (tardive 
dyskinesia OR TD) AND (dopamine receptor 3 OR DRD3). No language criterion was 
set. All publications that met the following criteria were included: 1) TD as an outcome; 
2) data on rs6280; 3) in human, and 4) not an abstract. We contacted authors up to 
three times by email in an attempt to acquire missing information. 
TD outcome, genotype data and study characteristics were abstracted from all 
studies. The study characteristics were: 1) study design (cohort, matched cohort, 
case-control, matched case-control); 2) whether the Abnormal Involuntary Movement 
Scale (AIMS) (15) was implemented for TD assessment; 3) whether the 
Schooler-Kane criteria were employed that defined a subject as a probably TD if he/ 
she showed at least one 3 or 4 point item or at least two 2 point items among AIMS 
items 1 to 7 (16); 4) whether TD was evaluated repeatedly; 5) enrollment source 
(hospital, community, mix); and 6) publication year; 7) enrollment criteria of subjects’ 
diagnosis (only schizophrenia, schizophrenia and other mental disorders); 8) average 
age; 9) sex (percent female); 10) ancestry (European, Asian, African, mixed); 11) 
Hardy-Weinberg equilibrium (HWE) p-value; 12) type of schizophrenia (chronic, 
acute, mix); 13) history of antipsychotic use (Yes, No); 14) current or past 
conventional antipsychotic use (Yes, No). 
 119
For cell counts of 2 or fewer persons, we conducted a sensitivity analysis of the 
six sparse-data smoothing or continuity correction methods described by Sweeting et 
al. (17). Statistical analyses included a standard heterogeneity test (18), and the 
funnel plot symmetry tests of Begg and Mazumdar (19) and Egger et al. (20). Duval 
and Tweedie’s trim-and-fill imputation procedure was used as an additional analysis 
of funnel plot symmetry (21).  
Stratified and random-effects meta-regression analyses (5) were conducted to 
identify study characteristics associated with effect measure estimates. A restricted 
maximum likelihood method was used to estimate the among-population variance 
and, for each study characteristic, the stratum with the largest number of studies was 
used as the referent. Continuous study characteristics were grouped as below in 
stratified analyses: average age (≤ 50 and > 50 years), percent female (< 0.4 and ≥
0.4), HWE p-value (< 0.1 and ≧0.1), and publication year (1997-2001; 2002-2007). 
All statistical analyses were implemented in three genetic models of inheritance: 
general, dominant, and recessive model, using STATA 8.0 (Stata Corporation, 
College Station, TX, USA.). In the general model, the three groups (Gly/Gly, 
heterozygotes, and Ser/Ser) are treated as three distinct groups, two of which are 
contrasted with a single referent (Ser/Ser). In the dominant model, the heterozygotes 
are grouped with those who are homozygous Gly/Gly and contrasted with those who 
are homozygous Ser/Ser. In the recessive model, those who are homozygous 
Gly/Gly are compared with the union of the heterozygotes and those who are 
homozygous Ser/Ser.  
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1.4 Results 
A total of 13 studies met inclusion criteria from 120 PubMed, 97 ISI, 183 BIOSIS 
and 7 The Cochrane Library citations identified as of Jun 2007. There were 16 
citations that assessed the association between TD and DRD3 Ser9Gly. One study 
was excluded because the TD outcome was only examined continuously using the 
AIMS score (22). Another study was excluded because it was a repeat analysis from 
a prior study (23). Two conference abstracts (24, 25) were excluded because the 
majority of contextual information needed for the stratified analyses was missing. An 
additional study was identified when reviewing the references of the original studies 
(26). The study information from the 13 studies included in this meta-analysis is 
summarized in tables 4.1.1 and 4.1.2.  
All studies assessed were cross-sectional investigations of prevalent TD among 
chronic patients with schizophrenia. Only one study did not use AIMS in TD 
assessment (27). Two studies used AIMS but did not adopt Schooler-Kane criteria for 
TD diagnosis (12, 28). Ten studies reported experience of typical antipsychotic use in 
their study populations, while 3 studies did not specify types of antipsychotic use in 
their study populations. All studies were conducted among patients with a history of 
antipsychotic medications. Four studies had a cell count of 2 or smaller in the 
cross-classification of TD in the homozygous genotype cell (12, 29-31). In the 
sensitivity analysis, the meta-analytic results were very similar across the different 
approaches to smoothing or continuity correction (17). Therefore, we followed 
convention by allowing the “metan” macro in STATA to add 0.5 to all cell counts for 
each study with a zero cell count.  
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In the analysis of these 13 studies, small p-values of symmetry tests were noted 
mainly when implementing a dominant model of inheritance (Table 4.1.3). The funnel 
plot shows that after including 5 imputed estimates obtained from the trim-and-fill 
procedure, the summarized effect was reduced from 1.16 to 1.02 (Figure 4.1.1). 
Heterogeneity of POR estimates was moderately indicated when comparing those 
participants with the Ser/Gly genotype to those with the Ser/Ser genotype and while 
assuming a general model of inheritance. The POR of each study, assuming a 
recessive model and a general model are presented in Figures 4.1.2 and 4.1.3, 
respectively. No significant relationship between rs6280 genotypes and TD was 
noted. The summarized POR in a recessive inheritance model was the only estimate 
for which heterogeneity and asymmetry of funnel plots were not detected.  
Several study characteristics showed an association with PORs across these 13 
studies (Table 4.1.4). Methodological factors associated with TD PORs were 
publication year, TD diagnostic criteria, and requirement of repeated TD evaluations. 
Studies published between 1997-2001 reported a stronger association than studies 
published between 2002-2007. Two studies that did not apply the Schooler-Kane 
criteria for TD diagnosis reported ~ 2 times stronger PORs than studies using the 
Schooler-Kane criteria. Studies that required repeated TD evaluations reported 
smaller PORs than studies that identified TD based on one AIMS evaluation.   
Percent female, average age and ancestry also showed an association with 
PORs. Studies with fewer female participants or with older subjects had stronger 
PORs than studies with higher numbers of female participants or who with younger 
subjects. In contrast to those studies that included Asian populations, studies with 
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European subjects reported a consistent increase of PORs for all genetic models 
examined. The association between ancestry and PORs of TD was particularly 
strong when contrasting Gly/Gly genotypes with other genotypes. Prevalence odds 
ratio reported in the literature were not associated with either the HWE p-value or the 
inclusion of subjects with mental disorders other than schizophrenia. Most small 
p-values in the symmetry tests occurred when implementing a dominant model of 
inheritance. After trim-and-fill imputation, estimates with small p-values in the 
symmetry test were almost reduced to the null (Appendix 1). 
 
1.5 Discussion 
Overall, the results from this study do not support an association between rs6280 
and TD. This conclusion of no association was most convincing when applying the 
recessive model of inheritance because no evidence for heterogeneity or asymmetry 
of funnel plots was noted. However, the null results extended to the dominant and 
general models.  
Symmetry tests of funnel plots in overall and stratified analyses indicated that the 
PORs obtained when implementing a dominant model of inheritance were more likely 
to be inflated than estimates obtained when implementing other inheritance models. 
Moreover, when using the trim-and-fill imputation, the majority of summary estimates 
decreased to near the null. The observed asymmetry of funnel plots when 
implementing a dominant model (Figure 4.1.1.) could be due to publication bias, to 
important study characteristics that are associated with study size, or both and also 
chance (32). As the frequency of homozygous genotypes was small in the majority of 
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studies, researchers tended to examine the relationship between genotype and TD 
using a dominant model of inheritance to increase their statistical power. Therefore, 
the number of possible unpublished studies that would have implemented a dominant 
model of inheritance was probably higher that the number that would have 
implemented some other model of inheritance. This may partially explain why an 
asymmetric funnel plot was more obvious when implementing the dominant model 
rather than either the general or recessive models. We also found a strong 
association between publication year and strength of the TD POR, indicating that 
“statistically significant estimates” found in earlier studies were not supported in later 
publications, a common occurrence in genetic epidemiology studies (33).   
A moderate to strong association between rs6280 and TD was noted among 
studies applying the Schooler-Kane criteria for TD diagnosis or in studies that did not 
require repeated TD evaluations. However, the elevated association diminished in 
the contrast group, implying that different TD diagnosis criteria may partially explain 
heterogeneous estimates across studies. Although these observations were 
consistently noted when applying different models of inheritance, informative 
confidence intervals of the PORs were not obtained due to the small number of 
studies that were available for consideration. In addition, the association between 
rs6280 and prevalent TD may be modified by age, sex and ancestry as a moderate 
rs6280 TD association was observed in studies with fewer female, aged, and 
European subjects, but not in their contrasting groups. 
As TD is a common outcome and we were obliged by the design of the 
case-control studies to use the POR as the measure of association, it would lend 
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context to translate even some of the higher summary PORs in our analysis into 
absolute differences in prevalence (34).  With typical baseline TD prevalences on the 
order of 40% to 50% in the available cohort studies (11, 12, 26-28, 30, 35-39), a POR 
of 1.2 (e.g., the Ser/Gly vs. Ser/Ser summary estimate from all studies without 
imputation, Table 4.1.3) would correspond to a prevalence difference in the range of 
2% to 5%.  A POR of 1.8 (e.g., the Gly/Gly vs. Ser/Ser summary estimate in 
European patient populations, Table 4.1.4) would correspond to a prevalence 
difference of about 15%. 
Some limitations of this meta-analysis should be noted. First, we were unable to 
adjust our PORs for the effects of confounders because information on many 
covariates was missing in the majority of earlier studies. However, the degree of 
confounding effect by environmental factors may not be of great concern as literature 
has not supported an association between the rs6280 polymorphisms and 
environmental factors (40). Second, this meta-analysis did not include two recent 
conference abstracts, which may affect the completeness of the literature we 
assessed. However, as our conclusions were consistent with study findings in both 
abstracts, excluding the abstracts should not strongly affect results of this 
meta-analysis. Third, symmetry and heterogeneity tests in this study may only have 
moderate statistical power due to the small number of studies included in this 
meta-analysis.  
This meta-analysis was strengthened by an extensive search of the literature in 
several bibliographic systems and also by the use of secondary references to 
supplement the initial search. Particularly, two recent large studies were added in this 
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updated meta-analysis. Second, we refrained from using summary estimates when 
asymmetry of funnel plots was present. This avoided misleading conclusions for the 
rs6280 prevalent TD association because of a biased sample of publications. Third, 
this study implemented stratified analysis of many study characteristics to explore 
sources of heterogeneity in studies. We suggested important methodological factors 
and population features which may have affected the strength of the association 
between rs6280 and TD.  
Study findings in this meta-analysis indicated some directions for future studies. 
First, the association between rs6280 polymorphisms and prevalence of TD may be 
subtle. Large studies that carefully consider environmental factors and that 
comprehensively explore the relationship between TD and other genetic variations 
are needed to elucidate the role of genetics in TD etiology. In addition, the effect of 
genetic variants on TD may differ by criteria for TD assessment and diagnosis, age, 
sex ratio and ancestry of a study population. Information on these study 
characteristics should be clearly described in a TD genetic association study. Lastly, 
reporting bias was indicated in this meta-analysis, particularly when we examined the 
association when assuming a dominant model of inheritance. Mechanisms to 
minimize the underreporting of studies with “no statistically significant findings” must 
be encouraged.
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1.6 Tables 
 
Table 4.1.1 Summary of association studies between DRD3 rs6280 and tardive dyskinesia (TD) 
 
____________TD (N=928)__________ __________non-TD (N=1098)_________ First author 
(publication year) 
Ethnicity (country) 
Total Ser/Ser Ser/Gly Gly/Gly Total Ser/Ser Ser/Gly Gly/Gly 
Steen (1997) European (Scotland) 45% 33% 22% 57% 39% 4% 51 49 
Inada (1997) Asian (Japan) 51% 35% 14% 59% 34% 7% 49 56 
Segman (1999) European (Israel) 24% 70%  6% 46% 47% 8% 53 63 
Lovlie (2000) European (UK) 34% 44% 22% 44% 46% 10% 32 39 
Rietschel (2000) European (Germany) 49% 47%  4% 47% 45% 8% 79 78 
Liao (2001) Asian (Taiwan) 28% 67%  5% 58% 31% 11% 21 94 
Garcia (2001) Asian (Hong Kong) 55% 35% 10% 64% 27% 9% 65 66 
Woo (2002) Asian (Korean) 42% 48% 10% 39% 61% 0% 59 54 
Chong (2003) Asian(Singapore) 51% 39% 10% 45% 44% 11% 117 200 127
Zhang (2003) Asian (China) 45% 53%  2% 58% 33% 9% 42 52 
Liou (2004) Asian (Taiwan) 50% 40% 10% 53% 36% 11% 102 115 
Leon (2005) Mixed (US)* 43% 43% 14% 42% 42% 16% 162 354 
Srivastava (2006) Asian (India) 28% 57% 15% 33% 49% 18% 96 238 
*Study population in the study was a mix of European and African-ancestry. 
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Table 4.1.2 Characteristics of 13 studies of DRD3 rs6280 and tardive dyskinesia (TD) prevalence  
_______________Methodological factors*_______________ _____Study population factors_____First author 
Chronic 
schizoph
(publication  TD classification Enrollment Average PercentAIMS Repeated TD Enrollment  HWE*
year) Design _in S-K criteria_ __source_ __age_ female _use __evaluation__  _criteria_ Ancestry  p-value renia 
No Steen (1997) cohort Yes Yes community SCZ EUR 52.1    1 0.44 Yes 
Yes (12 
months) 
Yes Yes Inada (1997) cohort Yes hospital Rx ASI 60.7   0.7 0.50 
Segman (1999)** cs-cn Yes No Yes hospital SCZ+ Rx EUR 49.6   0.8 0.47 Yes 
Lovlie (2000) cohort Yes No No hospital SCZ+ Rx EUR 46.4     1 0.27 Yes 
Rietschel (2000) cohort No Yes (3 months) Yes hospital Rx EUR 43.1   0.8 0.52 Yes 
Liao (2001) cohort Yes No No hospital SCZ+ Rx ASI 40.7  0.06 0.37 Yes 
Garcia (2001) cohort Yes No Yes hospital SCZ ASI 51.3  0.08 0.35 Yes 
Woo (2002) cohort Yes No Yes hospital SCZ+ Rx ASI 40.4 0.001 0.24 Yes 
Chong (2003) cohort Yes Yes (3 months) Yes hospital SCZ ASI 65.9   0.9 0.73 Yes 
Zhang (2003)** cs-cn Yes Yes (4 months) Yes hospital SCZ+ Rx ASI 55.1   0.3 0.00 Yes 
Liou (2004) cohort Yes Yes (3 months) Yes hospital SCZ+ Rx ASI 47.2   0.2 0.41 Yes 
Leon (2005) cohort Yes No Yes Mix Rx EurAA 42.4  0.05 0.47 Yes 
Srivastava (2006) cohort Yes No Yes hospital SCZ Asian 32.3    1 0.46 Yes 
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*Design: cs-cn= matched case-control study 
AIMS= Abnormal Involuntary Movement Scale 
 S-K criteria: Schooler-Kane criteria 
 Underlying condition: SCZ+ Rx=patients with chronic schizophrenia with history of antipsychotic use; SCZ= only required schizophrenia as a 
comorbidity; = as long as on antipsychotic use. 
 Ancestry: EUR= European; ASI= Asian 
 HWE= Hardy-Weinberg equilibrium 
**: Average age and percent female were abstracted from the control group 
 
Table 4.1.3 Homogeneity test p-values, funnel plot symmetry test p-values, and summary prevalence odds ratio 
(POR) estimates and 95% confidence intervals (CI) with and without trim and fill imputation, by inheritance model, 
from 13 studies of DRD3 rs6280 and tardive dyskinesia (TD). 
Symmetry test Summary 
Homogen-
eity test 
Summary No. of resultsPOR (95% CI) ______p-value____ 
POR (95% CI) Model and Imputed by 
trim and fill
without 
contrast p-value_ imputation _Begg_ _Egger _ with imputation_ 
General model 
0.3 1.02 (0.76, .37) 0.2 0.1 1 0.99 (0.74, 1.34) Gly/Gly vs. Ser/Ser 
Ser/Gly vs. Ser/Ser 0.1 1.19 (0.99, 1.42) 0.1 0.05 4 1.03 (0.87, 1.21) 
 
Dominant model 
Gly+ vs. Gly- 0.2 1.16 (0.98, 1.38) 0.003 0.004 5 1.02 (0.87, 1.19) 129
Recessive model 
Gly/Gly vs. others 0.2 0.93 (0.70, 1.23) 0.5 0.3 0 0.93 (0.70, 1.23) 
 
 129
Table 4.1.4 Stratified and meta-regression analyses of methodological and population study characteristics  
in 13 studies of DRD3 rs6280 and summary prevalence odds ratio (POR) of tardive dyskinesia (TD).  
Homogeneity 
p-value
Meta-regression Summary     
OR (95% CI)  Characteristic ___Contrast__ Component Studies OR (95% CI)_  
Enrollment Gly/Gly vs. Ser/Ser Schizophrenia 4 0.1 0.85 (0.39, 1.84) 1.03 (0.64, 1.66)
criteria Ser/Gly vs. Ser/Ser   0.4 0.70 (0.42, 1.17) 1.08 (0.79, 1.46)
 Gly+ vs. Gly-   0.3 0.74 (0.47, 1.16) 1.09 (0.81, 1.45)
 Gly/Gly vs. others   0.09 0.97 (0.47, 2.02) 0.95 (0.61, 1.47)
 Gly/Gly vs. Ser/Ser Antipsychotics 3 0.3 0.73 (0.33, 1.61)  0.89 (0.55, 1.46)
 Ser/Gly vs. Ser/Ser   0.9 0.67 (0.39, 1.14) 1.04 (0.76, 1.42)
 Gly+ vs. Gly-   0.7 0.68 (0.43, 1.09) 1.01 (0.75, 1.36)
 Gly/Gly vs. others   0.3 0.90 (0.42, 1.89) 0.88 (0.55, 1.39)
 
Gly/Gly vs. Ser/Ser 
Schizophrenia 
& 
6 0.4 1.0 1.22 (0.66, 2.26)
 Ser/Gly vs. Ser/Ser Antipsychotics  0.05 1.0 1.53 (1.11, 2.12)
 Gly+ vs. Gly-   0.2 1.0 1.48 (1.08, 2.02)
 Gly/Gly vs. others   0.2 1.0 0.98 (0.54, 1.76)
Study design Gly/Gly vs. Ser/Ser Matched  2 0.3 0.80 (0.21, 3.01) 0.83 (0.23, 2.99)
 Ser/Gly vs. Ser/Ser case-control  0.6 2.21 (1.19, 4.10) 2.43 (1.35, 4.38)
 Gly+ vs. Gly-   0.4 1.91 (1.05, 3.48) 2.09 (1.18, 3.71)
 Gly/Gly vs. others   0.4 0.51 (0.15, 1.80) 0.49 (0.14, 1.67)
 Gly/Gly vs. Ser/Ser Cohort 11 0.2 1.0 1.03 (0.76, 1.40)
 Ser/Gly vs. Ser/Ser   0.3 1.0 1.10 (0.92, 1.33)
 Gly+ vs. Gly-   0.4 1.0 1.10 (0.92, 1.31)
 Gly/Gly vs. others   0.1 1.0 0.96 (0.72, 1.28)
TD Gly/Gly vs.  Ser/Ser Non-S-K criteri 2  0.4 2.01 (0.58, 7.02) 1.96 (0.59, 6.58)
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a classification 
 Ser/Gly vs. Ser/Ser   0.08 1.96 (0.89, 4.35) 2.27 (1.09, 4.75)
 Gly+ vs. Gly-    0.2 1.96 (0.93, 4.13) 2.22 (1.10, 4.49)
 Gly/Gly vs. others    0.2 1.65 (0.52, 5.28) 1.48 (0.48, 4.58)
0.98 (0.72, 1.33) S-K criteria 11  0.2 1.0 Gly/Gly vs. Ser/Ser 
 Ser/Gly vs. Ser/Ser    0.3 1.0 1.14 (0.94, 1.37)
 Gly+ vs. Gly-    0.4 1.0 1.12 (0.94, 1.33)
 Gly/Gly vs. others    0.2 1.0 0.90 (0.67, 1.20)
TD evaluation Gly/Gly vs. Ser/Ser Repeated 5  0.4 0.72 (0.39, 1.35) 0.83 (0.50, 1.36)
 Ser/Gly vs. Ser/Ser    0.4 0.81 (0.52, 1.27) 1.06 (0.80, 1.40)
 Gly+ vs. Gly-    0.4 0.78 (0.52, 1.16) 1.02 (0.78, 1.33)
 Gly/Gly vs. others    0.4 0.84 (0.47, 1.52) 0.83 (0.51, 1.34)131
Non-repeated  0.2 1.0 8 1.14 (0.79, 1.66) Gly/Gly vs. Ser/Ser 
 Ser/Gly vs. Ser/Ser   0.08 1.0 1.29 (1.02, 1.64)
  0.2 1.0  1.28 (1.02, 1.61) Gly+ vs. Gly- 
 0.09 1.0  0.98 (0.69, 1.39) Gly/Gly vs. others 
1997- 2001 0.3 1.92 (0.99, 3.72) 7 1.62 (0.93, 2.84)Publication year Gly/Gly vs. Ser/Ser 
 0.2 1.42 (0.95, 2.12)   1.50 (1.09, 2.04)Ser/Gly vs. Ser/Ser 
 0.3 1.53 (1.06, 2.19)  1.54 (1.15, 2.07) Gly+ vs. Gly- 
 0.2 1.66 (0.88, 3.12)  1.34 (0.78, 2.30) Gly/Gly vs. others 
0.85 (0.60, 1.20) 2002- 2007 6 0.6 1.0 Gly/Gly vs. Ser/Ser 
 Ser/Gly vs. Ser/Ser   0.3 1.0 1.06 (0.84- 1.32)
 Gly+ vs. Gly-   0.6 1.0 1.01 (0.82, 1.25)
 Gly/Gly vs. others   0.4 1.0 0.81 (0.58, 1.12)
< 45 0.4 0.75 (0.41, 1.36) Average age 5 0.89 (0.60, 1.33)Gly/Gly vs. Ser/Ser 
 Ser/Gly vs. Ser/Ser   0.6 0.79 (0.49, 1.25) 1.09 (0.84, 1.41)
 131
 0.8 0.77 (0.51, 1.17)   1.05 (0.82, 1.33)Gly+ vs. Gly- 
 0.4 0.76 (0.43, 1.33)  0.81 (0.57, 1.19) Gly/Gly vs. others 
8 0.2 1.0 1.20 (0.77, 1.86)  ≧ 45 Gly/Gly vs. Ser/Ser 
   0.04 1.0 1.30 (1.00, 1.68)Ser/Gly vs. Ser/Ser 
  0.08 1.0 1.30 (1.01, 1.66) Gly+ vs. Gly- 
  0.1 1.0 1.09 (0.71, 1.66) Gly/Gly vs. others 
1.44 (0.66, 3.11)Percent female < 40% 5 0.3 1.50 (0.65, 2.47) Gly/Gly vs. Ser/Ser 
 Ser/Gly vs. Ser/Ser   0.08 1.31 (0.80, 2.15) 1.48 (1.00, 2.18)
 Gly+ vs. Gly-   0.3 1.33 (0.86, 2.06) 1.47 (1.01, 2.12)
 Gly/Gly vs. others   0.1 1.34 (0.60, 2.99) 1.19 (0.57, 2.50)
 Gly/Gly vs. Ser/Ser ≧ 40% 8 0.2 1.0 0.96 (0.69, 1.32)
 Ser/Gly vs. Ser/Ser   0.3 1.0 1.12 (0.91, 1.37)
 Gly+ vs. Gly-   0.2 1.0 1.09 (0.90, 1.33)
132
132
 Gly/Gly vs. others   0.2 1.0 0.89 (0.66, 1.20)
0.1 1.97 (0.83, 4.68) Ancestry Europeans 4 1.76 (0.82, 3.75)Gly/Gly vs. Ser/Ser 
 Ser/Gly vs. Ser/Ser   0.2 1.08 (0.58, 1.98) 1.35 (0.91, 2.02)
 Gly+ vs. Gly-   0.2 1.25 (0.75,2.09) 1.45 (0.99,2.12)
 Gly/Gly vs. others   0.06 1.82 (0.80, 4.13) 1.46 (0.71, 3.01)
Asians 0.5 1.0 8 0.97 (0.65, 1.44) Gly/Gly vs. Ser/Ser 
 Ser/Gly vs. Ser/Ser   0.08 1.0 1.20 (0.94, 1.52)
 0.2 1.0  1.15 (0.92,1.44) Gly+ vs. Gly- 
 0.4 1.0  0.87 (0.60,1.27) Gly/Gly vs. others 
  Mix N/A N/A 1   N/A 
< 0.1 0.4 0.89 (0.48, 1.66) HWE p value 4 0.95 (0.58, 1.55)Gly/Gly vs. Ser/Ser 
 Ser/Gly vs. Ser/Ser   0.04 1.00 (0.60, 1.65) 1.16 (0.85, 1.58)
 132
 0.1 0.97 (0.62, 1.51)   1.12 (0.84, 1.50)Gly+ vs. Gly- 
 0.3 0.92 (0.51, 1.65)  0.88 (0.55, 1.40) Gly/Gly vs. others 
0.2 1.0 9 1.06 (0.73, 1.54) ≧ 0.1 Gly/Gly vs. Ser/Ser 
 Ser/Gly vs. Ser/Ser   0.3 1.0 1.20 (0.96, 1.50)
 0.3 1.0  1.19 (0.96, 1.47) Gly+ vs. Gly- 
 0.1 1.0  0.96 (0.67, 1.36) Gly/Gly vs. others 
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1.7 Figures 
 
Figure 4.1.1 Funnel plot of prevalence odds ratios (solid circles) from 13 
studies of DRD3 rs6280 and tardive dyskinesia (TD) under the dominant 
model (Gly/Gly and Ser/Gly vs. Ser/Ser). Five estimates imputed by the trim 
and fill procedure are shown as hollow circles. 
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Figure 4.1.2 Prevalence odds ratios and 95% confidence intervals from 13 
studies of TD and rs6280 when comparing Gly/Gly to SerGly+ Ser/Ser 
polymorphism under the recessive model of inheritance. 
 
 
♦
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Figure 4.1.3 Prevalence odds ratios and 95% confidence intervals from 13 
studies of TD and rs6280 under the general inheritance model. The top part of 
the figure contrasts Gly/Gly with Ser/Ser and the bottom part contrasts 
Ser/Gly with Ser/Ser.
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2. Paper II: Association between tardive dyskinesia and dopamine receptor 
genes among patients with chronic schizophrenia: an ancillary study to the 
CATIE trial 
 
2.1 Abstract 
Tardive dyskinesia (TD), an involuntary movement disorder, is a serious and 
potentially irreversible adverse effect in the course of long-term antipsychotic therapy. 
Current understanding about TD pathophysiology is limited. This study investigated 
associations between TD and 54 single nucleotide polymorphisms (SNPs) in 
dopamine receptor genes (DRD1, DRD2, DRD3, DRD4, and DRD5) among 711 
patients with chronic schizophrenia. While several SNPs demonstrated nominal 
associations with TD, after multiple comparison adjustments, no SNPs or haplotype 
in these five dopamine receptor genes showed a statistically significant association 
with TD. 
 
2.2 Introduction 
Tardive dyskinesia (TD), an involuntary movement disorder, is a frequent and 
potentially irreversible side effect of long term antipsychotic treatment. Studies have 
reported a greater than 20% prevalence of TD among patients treated with 
conventional antipsychotic medications (1-3). No effective treatment for TD is 
available so far (4). Fortunately, the introduction of atypical antipsychotic medications 
since 1990s have greatly reduced the risk of TD in long-term antipsychotic treatment 
(5). However, atypical antipsychotics also incur several serious side effects, such as 
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weight gain (6) and changes in glucose and lipid metabolism (7, 8). In addition, 
atypical antipsychotic therapy is, on average, ten times more expensive than 
conventional antipsychotic therapy, greatly increasing the financial burden of 
long-term antipsychotic therapy. Therefore, understanding TD is an important task for 
optimal long-term schizophrenia care. 
Several risk factors for TD have been proposed, including advanced age, 
conventional antipsychotic use, African-American ancestry, anticholinergic 
medication use, female gender, psychiatric diagnosis, and substance abuse (9). 
However, the data on these associations are still inconclusive and only explain a 
small portion of the considerable individual variation in the risk of TD. It has been 
suggested that genetic factors contribute to the pathogenesis of TD. Animal studies 
have reported significant variation in the onset of vacuous chewing movement and 
repetitive jaw movement, similar orofacial symptoms of TD across different genetic 
strains of rats (10, 11). Strong aggregate genetic effects on TD have been recognized 
across multiple populations (12-16), although the identification of specific variants 
has thus far been lacking.   
Several lines of evidence support the evaluation of dopamine receptor genes as 
candidate genes for TD. First, dopamine receptors, particularly DRD2 and DRD3 (17, 
18), have been widely suspected as drug targets for antipsychotic medications. 
Second, TD has been widely suspected to be caused by blockade of dopamine D2 
receptors in the basal ganglia, resulting in hypersensitivity of nigrostriatal dopamine 
pathway in the brain, a system particularly involved in production of movement (19). 
In addition, animal and human studies have demonstrated an association between 
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alternations in gene expression in both DRD1 and DRD2 and the pathogenesis of 
neurological toxicity in long-term antipsychotic use (20, 21). 
However, the current literature on the association between dopamine receptor 
genes and TD has been largely contradictory, which could be due to many factors, 
including inadequate statistical power in most studies (22, 23), absence of 
confounding adjustment (23, 24), reliance on one or a few genetic markers, and 
differences across studies in important study characteristics. This study aimed to 
evaluate the relationship between single nucleotide polymorphisms (SNPs) in five 
dopamine receptor genes (DRD1, DRD2, DRD3, DRD4, and DRD5) and risk of TD, 
while improving upon earlier work, as no study has yet to perform such a 
comprehensive analysis in terms of the coverage of these five genes, the large size 
of the study population, and the careful consideration of multiple confounders.  
 
2.3 Methods 
The study population consisted of 711 subjects who participated in the Clinical 
Antipsychotic Trials of Intervention Effectiveness (CATIE) funded by National Institute 
of Health (NIH) and agreed to provide a sample of their DNA. Inclusion and exclusion 
criteria for CATIE have been detailed previously (25). Briefly, participants in CATIE 
were 18-65 years old, met diagnostic criteria for chronic schizophrenia defined by 
Diagnostic and Statistical Manual of Mental Disorder-Fourth Edition (DSM-IV) (25) 
and had decisional capacity to participate in the study.  
TD was diagnosed using standardized examination procedures and rating scales 
(26). The Abnormal Involuntary Movement Scale (AIMS) is currently the most widely 
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accepted measurement tool for TD in clinical research (27). The AIMS is a 12-item 
questionnaire that measures the severity of involuntary movements in several body 
regions, including: mouth, face, extremities, and trunk. Severity of TD is evaluated on 
a scale ranging from 0 to 4 points with higher scores representing greater severity. 
AIMS scores may be interpreted using different criteria for TD diagnosis; in this study 
we implemented the Schooler-Kane criteria, which defines TD as at least one item 
rated greater than 3 or at least two items rated grater than 2 in item 1 to item 7 (28). 
We did not implement the criterion of at least three months of prior antipsychotic 
exposure.  
AIMS evaluation was repeatedly measured in CATIE, including at baseline, 
every three months during the follow-up, and at the end of each phase of the trial (29). 
This study investigated the association between SNPs in dopamine receptor genes 
and having TD at any time in the CATIE study. TD was considered present if a 
subject met probable TD criteria at least once, either at the baseline evaluation or at 
any time during the 18-months follow-up of the CATIE trial. The reference group was 
composed of participants who never met the Schooler-Kane criteria for probable TD 
at any study assessment.  
Fifty four SNPs for five dopamine receptor genes were selected using TAMAL 
(30) and multiple-marker haplotype r2 statistics (31) based on the HapMap Phase 1 
data (32) were selected using TagIT (31). A minimum r2 of ≥0.85 was required. 
Genotyping was conducted using Illumina GoldenGate technology 
(http://www.illumina.com) according to protocol at the Duke University core facility 
directed by Dr. Kevin Shianna.  
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In order to control confounding from population substructure, 75 ancestry 
informative markers selected using HapMap panels were included in the Illumina 
genotyping runs and genotyped in CATIE study subjects. HapMap samples were then 
used as the prototypes for continental ancestry to which CATIE subjects can be 
compared. We then used the Structure program (33), which uses a Bayesian 
approach and Markov chain Monte Carlo (MCMC) method to determine the posterior 
probability for each study subject being classified into one of three main sources of 
human ancestry (African, East Asian, and European). These three probabilities sum 
to 1.0 and subjects could have had substantial ancestry from each source. The 
probabilities of European and East Asian ancestry were used as covariates as their 
intercorrelation was the lowest. 
Several other covariates were measured in this study, including age, sex, 
antipsychotic use, Years since first antipsychotic use, commitment anticholinergic use, 
and substance use at baseline. Type of antipsychotic use at baseline was classified 
into three categories: no use, only atypical antipsychotic use and conventional 
antipsychotic use. As participants without TD at baseline were randomly assigned to 
all treatment arms in CATIE, only baseline antipsychotic use was considered in 
confounding adjustment (25). Years since first antipsychotic use was also included as 
an approximate measure of age of onset. Substance use, including alcohol and illicit 
drug use, was measured as a dichotomous variable at baseline, using information 
from several indicators, including clinician’s ratings using the Structured Clinical 
Interview for DSM-IV (SCID) (34), and toxological assays of participants’ hair and 
urine. Participants meeting DSM-IV criteria for substance abuse or dependence 
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(excluding nicotine and caffeine) via the SCID or testing positive for any illicit drug 
were classified as having clinically significant substance use. 
 
Analytical Methods  
We first implemented contingency testing using Fisher’s exact test and assuming 
a general inheritance model (2-degree of freedom test) to obtain an overview of 
unadjusted associations between each SNP and TD. For SNPs with cell counts less 
than or equal to 5, we examined the distributions of genotype across TD status using 
Fisher’s exact test to determine whether statistical differences between homozygote 
variant and heterozygote variant were noted. When the Fisher’s exact test was not 
rejected, we grouped the rare homozygote variant and the heterozygote genotypes 
together to examine SNP-TD associations, assuming a dominant model of 
inheritance. These analyses were implemented using SAS 9.0 (SAS Institute Inc., 
Cary, North Carolina).  
Next, we implemented logistic regression analysis. Missing covariate data were 
imputed using the multiple imputation procedure in SAS. To maximize our power to 
detect genetic effects, we considered two different models of covariate adjustment. In 
Model 1, adjustments were made for ancestry only. In Model 2, we screened several 
variables, including baseline age, sex, ancestry, antipsychotic use, substance abuse/ 
dependence, years since first antipsychotic prescription and baseline total Positive 
and Negative Symptom Scale (PANSS) (35) for comprehensive covariate adjustment. 
By using forward model selection procedures (p < 0.10), covariates selected for 
adjustment in model 2 were baseline age, sex, structured-inferred proportion of 
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European and Asian ancestry, antipsychotic use (2df), and baseline total PANSS. 
In addition, to adjust for the multiple testing, we use the false discovery rate 
(FDR) controlling procedure of Storey (36). We set a FDR threshold at 5% to assure 
that on average, up to 5% of the total positive discoveries are false. We then 
estimated the q-value of each test, which reflects the expected proportion of false 
positives occurred when rejecting a particular test and those test whose p-values are 
less than this test.  
The FDR calculation was implemented using the Q-value 1.0 software (36)  
Following genotype-based analyses, we implemented haplotype analyses. 
Haplotype blocks were defined using Gabriel et al’s method (37) as implemented in 
the Haploview program (38). As the structure of linkage disequilibrium differs greatly 
by ancestry (32), we implemented haplotype analyses separately by self-reported 
ancestry as “European-only” or as “African-only”. Haplotype analyses was 
implemented using haplo.stat in R by Schaid et al. (39).  
When the minor allele frequency (MAF) of a SNP varied from 10 - 50%, the 
power to detect a genetic effect for TD with an effect size of 1.75 ranged from 0.43 – 
0.99, respectively. When the effect size was greater than 2 and the MAF of a SNP 
varied from 10 - 50%, the statistical power varied from 0.73 – 0.99, respectively.   
 
2.4 Results 
A total of 765 out of 1410 participants in CATIE provided DNA samples. Fifty four 
participants were excluded because they were missing over 10% of their genotypic 
data (N =33) and because of concerns over site integrity in the CATIE study (N =21).  
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We compared subjects who did and did not provide a DNA sample and found 
that subjects who provided a DNA sample had lower average total PANSS score (74 
versus 77) and lower proportion of African ancestry (29% versus 40%) (Appendix 2A). 
Importantly, however, the participation rate was not associated with TD status – either 
the presence/absence of TD, total AIMS score, or the region-specific AIMS 
components. 
A total of 207 TD cases were identified among 711 participants in this study 
(Table 4.2.1). CATIE subjects with TD were older, had higher total PANSS scores, 
and had a higher prevalence of conventional antipsychotic use and commitment 
anticholinergic use at baseline. In addition, TD participants, on average, had 5-year 
longer history since first antipsychotic prescription and 5% higher proportion of 
African-ancestry.  
In the analyses of individual SNPs under a general model (2 df), 2 SNPs 
displayed nominal associations with TD. However, no statistically significant 
associations were noted after adjustment for multiple comparisons (Table 4.2.2). 
SNPs that showed a moderate association with TD before multiple comparison 
adjustment included DRD1 rs265973 and DRD2 rs4648317. Full results for all 54 
SNPs investigated in this study can be found in Appendix 2B. 
 To assess the feasibility of implementing a dominant model for SNPs with small 
MAFs, we tested for significant deviations in the frequency of TD between individuals 
homozygous and heterozygous for the infrequent minor alleles using Fisher’s exact 
test. No statistical deviations were detected. Therefore, we assessed the association 
between TD and SNPs with small genotype frequency using a dominant model 
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(Appendix 2C). No association between TD and SNPs with small MAFs in DRD 
genes was identified when using a dominant model of inheritance.  
Finally, we conducted multi-marker analyses separately in subjects with 
exclusively European and African ancestry. Of the statistical analyses of 7 and 11 
haplotype compositions in DRD genes in European and African ancestry populations, 
respectively, the global p-values were significant in 1 analysis. Results of haplotype 
analyses showed that subjects with A alleles for DRD3 rs167770 and DRD3 
rs324029 were at increased risk of having TD (Table 4.2.3). However, this association 
was observed only among those participants with African ancestry and was from rare 
haplotype frequency. No other significant haplotype effects were noted (Appendix 2D 
and 2E).  
 
2.5 Discussion 
This study aimed to understand associations between 54 SNPs in DR genes and 
TD in 711 participants of the CATIE trial. Several SNPs showed suggestive 
associations with TD, including DRD1 rs265973 and DRD2 rs4648317. However, 
after adjustment for multiple comparisons, no significant associations with TD were 
noted. The haplotype composition of the DRD3 gene tagged by the minor alleles of 
rs167770-rs324029 presented a potential association with TD among 
African-ancestry participants, but this association should be interpreted with caution 
due to small sample sizes.  
SNPs that demonstrated suggestive associations with TD, including DRD1 
rs265973, DRD2 rs4648317 and DRD3 rs167770-rs324029, are not located in 
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conventionally recognized genomic positions with functional roles (transcript factor 
binding site, enhancer, promoter, coding SNP, or splice site). Instead, these SNPs are 
located in a region predicted to contain a regulatory element (30, 40-42). 
To our best knowledge, associations between TD and DRD1 rs265973 or DRD2 
rs12364283 have not been reported in the literature. In contrast, consistent with our 
study, no association between TD and DRD2 rs4648317 was found in 202 European 
Caucasians (43). Also consistent with our study, no association between DRD1 rs686 
and TD was identified in a recent Indian study of 297 subjects (86 TD and 211 
non-TD) (44). DRD3 rs6280 (Ser9Gly), is the most widely studied SNP for TD 
although results have been inconsistent. A recent meta-analysis of 11 studies of this 
variant concluded that there is no association between DRD3 rs6280 variants and TD 
(45), which is also consistent with findings from this study. Association between 
DRD2 rs1801020 (Ser311Cys) has also been assessed in several studies although 
results have been contradictory. As this study did not include rs1801020 or other SNP 
in high linkage disequilibrium with rs1801020, no further evidence was contributed.  
Non-significant associations between dopamine receptor genes and 
medication-mediated side effect, such as TD, can be explained by a lack of statistical 
power for detection, errors in methodology and truly no effect between investigated 
SNPs and TD. As we indicated earlier, we had at least 80% power to detect an effect 
of 1.75 when the minor allele frequency of a given SNP was over 20%. With an effect 
size ≧ 2, we had at least 80% power with a MAF as low as 10% (Appendix 2F). 
Therefore, negative findings across all 54 SNPs might be mainly due to a small 
genetic effect on TD as 80% and 50%of the SNPs we investigated had a MAF over 
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10% or 20%, respectively. However, for some SNPs, the power to detect genetic 
effects was less than adequate and may explain some of the null associations.  
Methodological shortcomings in investigating risk factors for prevalent disease 
status may also have had the potential to bias study findings toward the null, leading 
to non-significant associations. Commonly observed shortcomings include selection 
bias in participants’ recruitment and inappropriate control of confounding factors. As 
indicated in Appendix 2A, this genetic study only enrolled about 50% of initial CATIE 
participants. In a comparison of characteristics between participants and 
non-participants, African-ancestry patients with schizophrenia were 
under-represented in this study. In addition, participants in this genetic study had less 
severe symptoms of schizophrenia at study baseline than non-participants. 
Nevertheless, providing a DNA sample was not associated with exposure or outcome 
investigated in this study as the distribution of AIMS scores were almost identical 
regardless of participation status. Therefore, potential selection bias resulting from 
the participation process may not be of great concern in this study.  
Mistakenly controlling intermediate factors in the causal pathway of an exposure 
to an outcome could also bias study findings toward the null. This study considered 
biological plausibility and also statistical efficiency in choosing covariates included in 
the fully adjusted model (Model 2). Among the five factors chosen as confounders 
(baseline age, sex, ancestry, type of antipsychotic use, and baseline PANSS score 
for severity of schizophrenia) in Model 2, none of them has been proposed as a 
potential mediator in the pathway of dopamine receptor genes and TD. Finally, it may 
be that these five dopamine receptor genes have no effect on TD.  
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This study has several strengths. First, this study included 711 subjects, which is 
a study sample that is 3-fold larger than any prior study of its kind. Second, this study 
investigated SNP-based and also haplotype-based relationship with TD while 
assessing confounding and while controlling for multiple comparisons. Third, in 
contrast with prior studies, participants in this study were from various clinical sites in 
the US and were not excluded due to their comorbidity of substance abuse or other 
medical illness, except those with life-threatening cardiovascular symptoms. Thus, 
findings from this study should be more applicable to the general population of 
schizophrenic patients than prior studies. 
Some limitations in this study need to be recognized. First, misclassification of 
TD is possible but would occur non-differentially across genotypes, which may bias 
results toward the null. Misclassification of non-TD as TD may occur when other 
clinical conditions produced involuntary movement disorder and was mistaken for TD 
(46). In addition, misclassifying TD as non-TD is also possible as TD symptoms could 
be suppressed or masked when increasing antipsychotic dosage or reinstituting other 
kinds of antipsychotic medications (28). However, as this study classified participants 
with TD as long as they had one AIMS evaluation that met TD criteria, degree of 
misclassifying TD as non-TD should not be of great concern.  
Second, discontinuation of treatment occurred commonly in the CATIE trial due 
to following reasons: inefficacy of antipsychotic treatment (15~28% across all 
treatment arms), occurrence of intolerable side effects (10~19%) and patient’s 
decision (24~34%) (47). However, anticipating its impact on the direction of bias is 
difficult. Third, we had limited ability to account for accumulated antipsychotic 
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exposure, making it difficult to control confounding factors of TD completely. Fourth, 
as our case group was defined as prevalent TD at baseline but also as all those 
participants that developed TD during the CATIE trial, the effect sizes could have 
been attenuated if each sub-group displayed an association that was in opposite 
directions. Finally, as in most other epidemiological studies, competing risk could 
have removed participants from the study prior to the TD onset. 
In summary, this study did not support an association between DR genes and TD. 
Some important implications for future research are suggested below. First, the effect 
of dopamine receptors genes on TD may be very subtle and studies with large 
sample sizes are needed. Second, our current understanding of TD pathophysiology 
and antipsychotic mechanisms may not be adequate for strong candidate gene 
selection. The implementation of a genome-wide association approach should be 
considered in order to efficiently identify promising loci for TD. Lastly, other measures 
of genetic composition, such as copy number variation and gene expression, should 
also be explored to better understand the role of genetic predisposition to TD. 
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2.6 Tables 
Table 4.2.1 Distribution of demographic and clinical characteristics of 
participants in the CATIE study stratified by tardive dyskinesia (TD) status 
across all TD assessments in CATIE study. 
_______________TD status_____________  
____Characteristics___ TD (N=207)Non-TD (n=504) _p-value 
Baseline age (sd in years) 39.15 (10.97) 45.16 (10.06) <.0001 
Gender (% male) 365 (72%) 159 (77%) 0.2270 
Age by gender  
    Female (sd in years) 41.07 (10.52) 46.38 (9.26) 0.0022 
    Male (sd in years) 38.42 (11.08) 44.80 (10.29) <.0001 
Self-reported ancestry  0.2866 
 European ancestry 287 (57%) 112 (54%)  
African ancestry  140 (28%) 69 (33%)  
Other 77 (15%) 26 (13%)  
Baseline total PANSS 72.60 (17.41) 76.55 (17.38) 0.0063 
Baseline clinician rated CGI severity score  
 3.87 (0.98) 4.01 (0.88) 0.0633 
Year since first prescribed 
antipsychotic (sd) 
12.85 (10.40) 17.88 (11.27) <.0001 
Baseline AIMS score   
    total (sd) 0.46 (0.99) 4.46 (4.15) <.0001 
    facial (sd) 0.28 (0.70) 2.94 (2.98) <.0001 
    extremity (sd) 0.16 (0.49) 1.28 (1.56) <.0001 
    trunk (sd) 0.02 (0.18) 0.24 (0.59) <.0001 
Baseline antipsychotic use     
    % no antipsychotic 127 (25%)  43 (21%) 0.0565 
    % taking atypical only 301 (60%) 118 (57%)  
    % taking conventional  76 (15%)  46 (22%)  
Baseline substance abuse/ dependence   
     191 (38%) 84 (41%) 0.5046 
Baseline anticholinergic use 85 (17%) 52 (25%) 0.0112 
 155
Table 4.2.2 Dopamine receptor tagSNPs demonstrating a significant association with tardive dyskinesia (TD) when 
implementing in general model of inheritance: effect estimates, p-values and q-values in ancestry-adjusted and 
full model adjustment models. 
    Ancestry-adjusted effect (Model 1) _Covariates-adjusted effect*_(Model 2)__  
Global-p OR (95% C.I.)Gene/ SNP Genotype Non-TD __TD__  p-value Global-p q-value OR (95% C.I.) p-value
170 (34%) 76 (37%) 0.0478 1  0.0171 0.1413 1  __DRD1__ CC 
rs265973 234 (46%) 106 (51%)  1.04 (0.72, 1.48 ) 0.8496   1.01 (0.69, 1.47) 0.9548CT 
 100 (20%) 25 (12%)  0.56 (0.33, 0.95) 0.0299   0.49 (0.28, 0.84) 0.0097TT 
          
rs686 163 (32%) 83 (40%) 0.0268 1  0.1069 0.1413 1  AA 
 240 (48%) 78 (38%)  0.60 (0.41, 0.87) 0.0072   0.65 (0.44, 0.97) 0.0346AG 
101 (20%) 46 (22%) 0.77 (0.49, 1.22) 0.80 (0.49, 1.29)GG   0.2600    0.3525
          156 356 (71%) 145 (71%)CC 0.0171 1  0.0260 0.1413 1  __DRD2__ 
rs4648317 137 (27%)  49 (24%)  0.95 (0.65, 1.39) 0.7813   1.10 (0.73, 1.65) 0.6475CT 
 9 (2%)    9 (5%)  4.78 (1.59, 4.39) 0.0054   4.82 (1.54, 15.11) 0.0069TT 
 missing 2 4        
*Covariate-adjusted model adjusted for age at baseline, sex, baseline antipsychotic use (3 levels), and proportion of European and Asian ancestry.  
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Table 4.2.3 Haplotypes shown statistically significant association with tardive dyskinesia (TD) among 
participants of this ancillary study to the CATIE trial. 
Gene __Haplotype name and loci_ ___Haplotype frequency_____ Global p-value* OR (95%C.I.)** 
__rs167770__DRD3  __rs324029__ _non-TD (n=140) _TD (n=69)_     
 G A 0.66 0.62 0.0002 1 
 A G 0.33 0.30   1.15 (0.69, 1.92) 
 A A 0.01 0.08  24.77 (4.44, 138.19) 
Note: This haplotype was identified only among African-ancestry population 
* after 10000 times of permutation 
** OR was obtained in additive model to approximate the effect in general model 
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CHAPTER V.  
SIGNIFICANCE OF THIS STUDY 
1. Improving medication care of schizophrenia 
     TD is a serious side effect of long-term antipsychotic therapy leading to 
therapeutic intolerability and discontinuation. Although the wide usage of ATY has 
greatly reduced TD prevalence among patients with chronic schizophrenia, ATY use 
has several serious side effects, such as weight gain and changes in glucose and 
lipid metabolism. In addition, ATY is on average, ten times more expensive than 
conventional ATY.Thus, understanding TD is an important task for optimal long-term 
schizophrenia care.  
 
2. Advancing knowledge about factors associated with TD prevalence 
    The current understanding about the factors associated with TD prevalence is 
limited. Published studies assessing the association between dopamine receptor 
genes and TD have been inconclusive. Such conflicting findings may be due to small 
sample sizes in individual studies or differences in key study characteristics across 
stuides. Finding form first part of this work identified several study characteristics, 
which may explain factors leading to heterogeneous POR estimates of TD across 
studies. 
In addition, such conflicting findings may also be related to methodolgical 
inadequacecies such as lack of adjustment for confounding or multiple comparisions 
in individual study. The work conducted for second part of this dissertation project 
improves upon previous studies by 1) using a relatively large sample size (n=711) 
with less restriction of comorbidity of substance and other medical illness and 2) 
assessing a comprehensive SNPs-based and also haplotype-based relationship 
between SNPs in DR genes and TD while assessing confounding and while 
controlling for multiple comparisions. Thus, findings from this study should be more 
applicable to the general population of schizophrenic patients than prior studies.
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CHAPTER VI.  
CONCLUSIONS 
TD is one of most frequent, distressing and potentially persistent side effects 
emerging from the course of long-term antipsychotic use. Since effective and safe 
reatment for TD is unavailable, understanding factors associated with its prevalence 
is crucial in order to reduce the disease burden from TD. This study investigated the 
relationship between TD and SNPs in DR genes and concluded no apparent 
relationship between these factors. Future research should consider other measures 
of genetic composition, such as copy number variation and gene expression, when 
selecting dopamine receptor genes as candidate genes for TD. It is also important to 
recognize current understaning of TD pathophysiology and antipsychotic 
mechanisms may not be adequate for strong candidate gene selections. The 
implementation of genome-wide association approach should be considered in order 
to efficiently identify promising loci for genotype-TD associationi studies.
APPENDICES 
 
Appendix 1. Analyses of symmetry of funnel plots by study characteristics from 13 studies of DRD3 rs6280 and 
summary prevalence odds ratio (POR) of tardive dyskinesia (TD). 
Symmetry 
test_p-values
Imputed effect 
estimates:  
No. of 
results 
imputed
 Summary      
_ OR (95% CI)_  _Characteristic ____Contrast___ Component _Begg Egger  _ OR (95% CI)__
Enrollment Gly/Gly vs. Ser/Ser Schizophrenia  0.3 0.1 2 0.81 (0.53, 1.25) 1.03 (0.64, 1.66)
Criteria   1.0 0.5 2 0.84 (0.66, 1.08) 1.08 (0.79, 1.46)Ser/Gly vs. Ser/Ser 
  0.09 0.1 2 0.94 (0.73, 1.21) 1.09 (0.81, 1.45)Gly+ vs. Gly- 
  0.09 0.1 0 0.95 (0.61, 1.47) 0.95 (0.61, 1.47)Gly/Gly vs. others 
 Antipsychotics  1.0 0.8 0  0.89 (0.55, 1.46) 0.89 (0.55, 1.46)Gly/Gly vs. Ser/Ser 
    0.3 0.5 0 1.04 (0.76, 1.42) 1.04 (0.76, 1.42)Ser/Gly vs. Ser/Ser 
   0.3 0.5 0 1.01 (0.75, 1.36) 1.01 (0.75, 1.36)
166 Gly+ vs. Gly- 
   1.0 0.9 0 0.88 (0.55, 1.39) 0.88 (0.55, 1.39)Gly/Gly vs. others 
 Schizophrenia  1.0 0.6 0 1.22 (0.66, 2.26) 1.22 (0.66, 2.26)Gly/Gly vs. Ser/Ser 
 &  0.3 0.3 1 1.37 (1.00, 1.87) 1.53 (1.11, 2.12)Ser/Gly vs. Ser/Ser 
 Antipsychotics  0.3 0.2 2 1.19 (0.90, 1.57) 1.48 (1.08, 2.02)Gly+ vs. Gly- 
   0.7 0.8 0 0.98 (0.54, 1.76) 0.98 (0.54, 1.76)Gly/Gly vs. others 
 1.0 N/A Study design Matched  0 0.83 (0.23, 2.99) 0.83 (0.23, 2.99)Gly/Gly vs. Ser/Ser 
 1.0 N/A  case-control 0 2.43 (1.35, 4.38) 2.43 (1.35, 4.38)Ser/Gly vs. Ser/Ser 
 1.0 N/A   0 2.09 (1.18, 3.71) 2.09 (1.18, 3.71)Gly+ vs. Gly- 
 1.0 N/A   0 0.49 (0.14, 1.67) 0.49 (0.14, 1.67)Gly/Gly vs. others 
 Cohort 0.04 0.04 2 0.93 (0.69, 1.26) 1.03 (0.76, 1.40)Gly/Gly vs. Ser/Ser 
   0.3  0.1 3 0.98 (0.82, 1.16) 1.10 (0.92, 1.33)Ser/Gly vs. Ser/Ser 
  0.01 0.02 4 0.99 (0.84, 1.17) 1.10 (0.92, 1.31)Gly+ vs. Gly- 
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  0.09 0.08 1 0.94 (0.70, 1.25) 0.96 (0.72, 1.28)Gly/Gly vs. others 
Non-S-K  1.0 N/A 0 TD classification 1.96 (0.59, 6.58) 1.96 (0.59, 6.58)Gly/Gly vs. Ser/Ser 
 1.0 N/A criteria  1 1.20 (0.66, 2.20) 2.27 (1.09, 4.75)Ser/Gly vs. Ser/Ser 
 1.0 N/A   1 1.48 (0.82, 2.64) 2.22 (1.10, 4.49)Gly+ vs. Gly- 
 1.0 N/A   0 1.48 (0.48, 4.58) 1.48 (0.48, 4.58)Gly/Gly vs. others 
 S-K criteria  0.2  0.1 1 0.95 (0.70, 1.29) 0.98 (0.72, 1.33)Gly/Gly vs. Ser/Ser 
   0.3  0.1 2 1.05 (0.87, 1.25) 1.14 (0.94, 1.37)Ser/Gly vs. Ser/Ser 
  0.008 0.03 4 0.99 (0.84, 1.17) 1.12 (0.94, 1.33)Gly+ vs. Gly- 
   0.4  0.2 0 0.90 (0.67, 1.20) 0.90 (0.67, 1.20)Gly/Gly vs. others 
TD evaluation Repeated  0.5  0.8 0 0.83 (0.50, 1.36) 0.83 (0.50, 1.36)Gly/Gly vs. Ser/Ser 
 0.2  0.1 2   0.90 (0.71, 1.15) 1.06 (0.80, 1.40)Ser/Gly vs. Ser/Ser 
 Gly+ vs. Gly-  0.09 0.06 2 0.91 (0.71, 1.15) 1.02 (0.78, 1.33)
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 0.5  0.6 0   0.83 (0.51, 1.34) 0.83 (0.51, 1.34)Gly/Gly vs. others 
Non-repeated 0.06 0.03 4  0.89 (0.64, 1.26) 1.14 (0.79, 1.66)Gly/Gly vs. Ser/Ser 
 0.3  0.2 0   1.29 (1.02, 1.64) 1.29 (1.02, 1.64)Ser/Gly vs. Ser/Ser 
 0.02 0.04 4  1.07 (0.88, 1.31) 1.28 (1.02, 1.61)Gly+ vs. Gly- 
  0.2  0.1 1  0.95 (0.67, 1.34) 0.98 (0.69, 1.39)Gly/Gly vs. others 
Publication year Gly/Gly vs. Ser/Ser 1997- 2001  0.8  1.0 0 1.62 (0.93, 2.84) 1.62 (0.93, 2.84)
   0.4  0.2 0 1.50 (1.09, 2.04) 1.50 (1.09, 2.04)Ser/Gly vs. Ser/Ser 
  0.04 0.05 0 1.54 (1.15, 2.07) 1.54 (1.15, 2.07)Gly+ vs. Gly- 
  1  0.7 0 1.34 (0.78, 2.30) 1.34 (0.78, 2.30)Gly/Gly vs. others 
 1.0  0.5 0 0.85 (0.60, 1.20) 0.85 (0.60, 1.20) 2002- 2007 Gly/Gly vs. Ser/Ser 
 0.5 0.5   0 1.06 (0.84, 1.32) 1.06 (0.84- 1.32)Ser/Gly vs. Ser/Ser 
0.5 0.4   1 0.97 (0.79, 1.20) 1.01 (0.82, 1.25)Gly+ vs. Gly- 
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0.7    0.6 0 0.81 (0.58, 1.22) 0.81 (0.58, 1.12)Gly/Gly vs. others 
< 45  0.5  0.3 1 Average age 0.85 (0.57, 1.27) 0.89 (0.60, 1.33)Gly/Gly vs. Ser/Ser 
 0.8  1.0 0   1.09 (0.84, 1.41) 1.09 (0.84, 1.41)Ser/Gly vs. Ser/Ser 
  0.8  0.7 0  1.05 (0.82, 1.34) 1.05 (0.82, 1.34)Gly+ vs. Gly- 
  0.8  0.3 0  0.82 (0.57, 1.19) 0.82 (0.57, 1.19)Gly/Gly vs. others 
  0.7  0.4 1 1.04 (0.68, 1.59) 1.20 (0.77, 1.86) ≧ 45 Gly/Gly vs. Ser/Ser 
   0.2 0.05 1 1.20 (0.93, 1.54) 1.30 (1.00, 1.68)Ser/Gly vs. Ser/Ser 
  0.02 0.004 4 1.01 (0.82, 1.25) 1.30 (1.01, 1.66)Gly+ vs. Gly- 
   1.0  0.9 0 1.09 (0.71, 1.66) 1.09 (0.71, 1.66)Gly/Gly vs. others 
Percent female < 40%  0.8  0.9 0 1.44 (0.66, 2.11) 1.44 (0.66, 3.11)Gly/Gly vs. Ser/Ser 
   0.5  0.3 1 1.25 (0.87, 1.80) 1.48 (1.00, 2.18)Ser/Gly vs. Ser/Ser 
   0.2  0.2 2 1.19 (0.87, 1.64) 1.47 (1.01, 2.12)
168 Gly+ vs. Gly- 
   1.0  1.0 0 1.19 (0.57, 2.50) 1.19 (0.57, 2.50)Gly/Gly vs. others 
  0.2  0.2 1 0.88 (0.64, 1.21) 0.96 (0.69, 1.32)≧ 40% Gly/Gly vs. Ser/Ser 
   0.5  0.2 0 1.12 (0.91, 1.37) 1.12 (0.91, 1.37)Ser/Gly vs. Ser/Ser 
  0.02 0.04 3 0.98 (0.82, 1.17) 1.09 (0.90, 1.33)Gly+ vs. Gly- 
   0.3  0.3 0 0.89 (0.66, 1.20) 0.89 (0.66, 1.20)Gly/Gly vs. others 
Ancestry Europeans 0.7 0.5 1 1.20 (0.60, 2.38) 1.76 (0.82, 3.75)Gly/Gly vs. Ser/Ser 
   0.7  0.8 0 1.35 (0.91, 2.02) 1.35 (0.91, 2.02)Ser/Gly vs. Ser/Ser 
   0.7  0.4 2 1.06 (0.77, 1.46) 1.45 (0.99,2.12)Gly+ vs. Gly- 
   0.7  0.8 0 1.46 (0.71, 3.01) 1.46 (0.71, 3.01)Gly/Gly vs. others 
Asians   0.3  0.3 0 0.97 (0.65, 1.44) 0.97 (0.65, 1.44)Gly/Gly vs. Ser/Ser 
   0.1 0.08 2 1.06 (0.85, 1.32) 1.20 (0.94, 1.52)Ser/Gly vs. Ser/Ser 
  0.03 0.04 2 1.05 (0.85, 1.30) 1.15 (0.92,1.44)Gly+ vs. Gly- 
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   0.5  0.5 0 0.87 (0.60,1.27) 0.87 (0.60,1.27)Gly/Gly vs. others 
  Mix  N/A  N/A N/A N/A  N/A 
HWE p value < 0.1  0.3  0.2 2 0.83 (0.53, 1.31) 0.95 (0.58, 1.55)Gly/Gly vs. Ser/Ser 
   0.7  0.4 1 1.03 (0.76, 1.38) 1.16 (0.85, 1.58)Ser/Gly vs. Ser/Ser 
  0.3  0.3 1  1.02 (0.77, 1.35) 1.12 (0.84, 1.50)Gly+ vs. Gly- 
  0.7  0.5 1  0.82 (0.52, 1.30) 0.88 (0.55, 1.40)Gly/Gly vs. others 
 0.3  0.4 0  1.06 (0.73, 1.54) 1.06 (0.73, 1.54)≧ 0.1 Gly/Gly vs. Ser/Ser 
 0.6  0.1 0   1.20 (0.96, 1.50) 1.20 (0.96, 1.50)Ser/Gly vs. Ser/Ser 
 0.03 0.02 4  1.02 (0.84, 1.23) 1.19 (0.96, 1.47)Gly+ vs. Gly- 
  0.8  0.5 0  0.96 (0.67, 1.36) 0.96 (0.67, 1.36)Gly/Gly vs. others 
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Appendix 2A. Comparisons of population characteristics and clinical condition between participants and 
non-participants of CATIE subjects in this study. 
 Excluded 
CATIE subjects Participants participants 
(n= 54)_
Non-participants 
________Characteristics________  ___(n= 1410)__    __(n= 711)_  Global p-value_____(n=695 )__
Baseline age (sd in years) 40.6 (11.1) 40.9 (11.1) 40.1 (11.2)41.3 (10.8) 0.3900 
Gender (% male) 1079 (74%) 559 (73%) 521 (75%)34 (63%) 0.1500 
Self-reported ancestry <0.0001
European ancestry only 722 (49%) 399 (56%) 292 (42%)31 (57%)
African ancestry only 506 (35%) 209 (29%) 280 (40%)17 (32%)
Others 232 (16%) 103 (15%) 6 (11%) 123 (18%)170
Baseline total PANSS 75.7 (17.6) 73.8 (17.5) 77.2 (17.5)81.4 (16.6) <0.0001
Year since first antipsychotic use (sd) 14.6 (10.7) 14.5 (10.8) 13.7 (9.9) 14.7 (10.6) 0.7582 
Baseline AIMS score 
total score (sd) 1.6 (3.1) 1.6 (3.0) 1.4 (2.5) 1.6 (3.2) 0.8587 
facial (sd) 1.1 (2.1) 1.1 (2.1) 1.0 (2.0) 1.1 (2.2) 0.9085 
extremity (sd) 0.5 (1.1) 0.5 (1.1) 0.3 (0.9) 0.4 (1.1) 0.5038 
trunk (sd) 0.1 (0.4) 0.1 (0.4) 0.1 (0.3) 0.1 (0.5) 0.6837 
CATIE: Clinical Antipsychotic Trial of Intervention Effectiveness; sd= standard deviation 
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Appendix 2B. Relationship between tardive dyskinesia (TD) and single nucleotide polymorphisms (SNPs) in 
dopamine receptors genes (DRD) among participants of this ancillary study to the CATIE trial. 
    Ancestry-adjusted effect(Model 1) __Covariates-adjusted effect*_(Model 2)__
Gene/ SNP Genotype _Non-TD_ ___TD__ Global-p OR (95% C.I.) p-value Global-p q value OR (95% C.I.) p-value
___DRD1__ CC 104 (21%) 48 (23%) 0.5914 1.20 (0.75, 1.92) 0.4368 0.3483 0.1363 1.36 (0.83, 2.22) 0.2265
rs2453737 CT 237 (47%) 102 (49%)  1.21 (0.83, 1,78) 0.3283   1.31 (0.88, 1.97) 0.1864
 TT 162 (32%) 57 (28%)  1    1  
 missing 1 0        
          
rs265973 CC 170 (34%)  76 (37%) 0.0478 1  0.0171 0.1413 1  
 CT 234 (46%) 106 (51%)  1.04 (0.72, 1.48) 0.8496   1.01 (0.69, 1.47) 0.9548
 TT 100 (20%)  25 (12%)  0.56 (0.33, 0.95) 0.0299   0.49 (0.28, 0.84) 0.0097
           
rs265974 AA 170 (34%) 59 (28%)  1    1  
 AG 208 (41%) 86 (42%) 0.6755 1.15 (0.77, 1,72) 0.4854 0.8345 0.1676 1.01 (0.67, 1.55) 0.9469
 GG 126 (25%) 62 (30%)  1.24 (0.75, 2.05) 0.3990   1.15 (0.68, 1.95) 0.5948
           
rs265976 GG 275 (55%) 108 (52%) 0.8662 1  0.6119 0.1654 1  
 GT 178 (35%) 73 (35%)  0.93 (0.64, 1.34) 0.6877   0.85 (0.58, 1.26) 0.4162
 TT  51 (10%) 26 (13%)  1.06 (0.60, 1.86) 0.8485   1.08 (0.60, 1.95) 0.8046
           
rs686 AA 163 (32%)  83 (40%) 0.0268 1  0.1069 0.1413 1  
 AG 240 (48%)  78 (38%)  0.60 (0.41, 0.87) 0.0072   0.65 (0.44, 0.97) 0.0346
 GG 101 (20%)  46 (22%)  0.77 (0.49, 1.22) 0.2600    0.80 (0.49, 1.29) 0.3525
          
rs5326* AA 13 (3%) 5 (2%) 0.8277 See appendix 2C 0.8082 0.1676 See appendix 2C 
 AG 112 (22%) 41 (20%)        
 GG 379 (75%) 161 (78%)        
           
rs2168631 AA 27 (5%) 12 (6%) 0.4440 1.20 (0.58, 2.47) 0.6294 0.6013 0.1654 1.16 (0.54, 2.49) 0.7060 
 AG 159 (32%) 74 (36%)  1.25 (0.88, 1.78) 0.2116   1.21 (0.83, 1.74) 0.3227
 GG 318 (63%) 121 (58%)  1    1  
             
rs267418 CC 68 (14%) 31 (15%) 0.5275 1.06 (0.63, 1.79) 0.8199 0.7179 0.1675 0.97 (0.56, 1.69) 0.9247
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 CG 224 (44%) 79 (38%)  0.84 (0.57, 1.23) 0.3642   0.85 (0.57, 1.28) 0.4399
 GG 212 (42%) 97 (47%)  1    1  
           
__DRD2__ AA 304 (60%) 109 (53%) 0.0375 1  0.1007 0.1363 1  
rs2734848 AG 181 (36%) 82 (40%)  1.18 (0.83, 1.68) 0.3648   1.18 (0.81, 1.71) 0.3855
 GG 19 (4%) 16 (8%)  2.11 (1.02, 4.38) 0.0451   2.31 (1.06, 5.01) 0.0343
           
rs17115461
* 
AA 442 (88%) 173 (84%)        
 AG 56 (11%) 30 (14%) 0.7479 See appendix 2C 0.6978 0.1675 See appendix 2C 
 GG 6 (1%) 4 (2%)        
           
rs1800497 CC 264 (52%) 106 (51%) 0.4728 1  0.3481 0.1363 1  
 CT 191 (38%) 87 (42%)  1.13 (0.80, 1.59) 0.5016   1.21 (0.84, 1.74) 0.2977
 TT 48 (10%) 14 (7%)  0.76 (0.40, 1.46) 0.4093   0.78 (0.40, 1.53) 0.4692
 missing    1     0        
             
rs6279 CC 87 (17%) 35 (17%) 0.1750 1.09 (0.63, 1.87) 0.7689 0.1550  0.1363 1.10 (0.62, 1.93) 0.7475
 CG 228 (45%) 110 (53%)  1.40 (0.96, 2.04) 0.0815   1.44 (0.97, 2.15) 0.070 
 GG 189 (38%) 62 (30%)  1    1  
           
rs1079594* GG 27 (5%) 5 (2%) 0.4292 See appendix 2C 0.3016 0.1676 See appendix 2C 
 GT 129 (26%) 54 (26%)        
 TT 348 (69%) 148 (72%)        
           
rs6277 CC 211 (42%) 85 (41%) 0.3555 1  0.3805 0.1363 1  
 CT 208 (41%) 94 (46%)  1.20 (0.81, 1.77) 0.3715   1.18 (0.78, 1.79) 0.4351
 TT 85 (17%) 27 (13%)  0.85 (0.49, 1.50) 0.5807   0.83 (0.46, 1.50) 0.5315
 missing    0    1        
             
rs6275 CC 197 (39%) 68 (33%) 0.3050 1  0.2314 0.1363 1  
 CT 219 (44%) 104 (50%)  1.31 (0.90, 1.90) 0.1629   1.38 (0.93, 2.04) 0.1119
 TT 87 (17%) 35 (17%)  1.03 (0.60, 1.76) 0.9084   1.07 (0.61, 1.87) 0.8241
 missing    1    0        
           
172
 173
rs2734836 AA 24 (5%) 6 (3%) 0.7089 0.72 (0.28, 1.82) 0.4822 0.5764 0.1654 0.60 (0.23, 1.57) 0.2940 
 AG 141 (28%) 52 (25%)  0.90 (0.62, 1.32) 0.5979   0.97 (0.65, 1.44) 0.8729
 GG 339 (67%) 149 (72%)  1    1  
             
rs1800498 CC 184 (37%) 67 (33%) 0.2154 1  0.1355 0.1363 1  
 CT 214 (42%) 102 (49%)  1.40 (0.94, 2.10) 0.1024   1.51 (0.98, 2.33) 0.0595
 TT 106 (21%) 38 (18%)  1.12 (0.66, 1.89) 0.685   1.16 (0.66, 2.04) 0.6014
           
rs2234690 AA 184 (37%) 67 (32%) 0.2154 1  0.1355 0.1363 1  
 AT 214 (42%) 102 (49%)  1.40 (0.94, 2.10) 0.1024   1.51 (0.98, 2.33) 0.0595
 TT 106 (21%) 38 (18%)  1.12 (0.66, 1.89) 0.685   1.16 (0.66, 2.04) 0.6014
           
rs2587548 CC 184 (37%) 68 (33%) 0.2662 1  0.1631 0.1363 1  
 CG 214 (42%) 101 (49%)  1.36 (0.91, 2.05) 0.1338   1.48 (0.96, 2.28) 0.0744
 GG 106 (21%) 38 (18%)  1.09 (0.64, 1.85) 0.7417   1.14 (0.65, 2.00) 0.6427
           
rs4986918 CC 488 (97%) 199 (96%) 0.9778 1  0.8097 0.1676 1  
 CT  16 (3%) 8 (4%)  1.01 (0.41, 2.49) 0.9777   1.13 (0.42, 3.03) 0.8097
           
rs1079596 AA 29 (6%) 6 (3%) 0.3762 0.59 (0.24, 1.47) 0.2582 0.1685 0.1363 0.49 (0.19, 1.26) 0.1365
 AG 148 (29%) 66 (32%)  1.13 (0.79, 1.61) 0.5082   1.20 (0.82, 1.75) 0.3456
 GG 327 (65%) 135 (65%)  1    1  
           
rs7103679* CC 341 (68%) 154 (74%)        
 CT 154 (30%) 50 (24%)  See appendix 2C 0.5875 0.1654 See appendix 2C 
 TT 9 (2%) 3 (2%)        
           
rs4586205 GG 84 (17%) 38 (18%) 0.6805 1.13 (0.66, 1.96) 0.6532 0.6572 0.1675 1.01 (0.57, 1.80) 0.9745
 GT 217 (43%) 97 (47%)  1.18 (0.81, 1.72) 0.3801   1.18 (0.79, 1.75) 0.4161
 TT 203 (40%) 72 (35%)  1    1  
         
rs7125415* CC 367 (73%) 162 (78%) 0.1797 See appendix 2C 0.1822 0.1363 See appendix 2C 
 CT 128 (25%) 44 (21%)        
 TT 9 (2%) 1 (1%)        
           
173
 174
rs4648318 AA 226 (45%) 86 (41%) 0.4674 1  0.5267 0.1654 1  
 AG 211 (42%) 97 (47%)  1.14 (0.80, 1.62) 0.4727   1.13 (0.78, 1.64) 0.5094
 GG 67 (13%) 24 (12%)  0.82 (0.46, 1.46) 0.5035   0.83 (0.46, 1.51) 0.5431
               
rs7109897 CT 32 (6%) 13 (6%) 0.4168 0.74 (0.36, 1.53) 0.417 0.3434 0.1363 0.69 (0.32, 1.48) 0.3434
 TT 472 (94%) 194 (94%)  1    1  
             
rs4581480 CC 39 (8%) 17 (8%) 0.7901 0.74 (0.36, 1.53) 0.533 0.7205 0.1675 0.75 (0.36, 1.55) 0.4368
 CT 155 (31%) 67 (32%)  0.80 (0.40, 1.61) 0.6154   0.98 (0.64, 1.50) 0.9339
 TT 310 (61%) 123 (59%)  1    1  
           
rs4648317 CC 356 (71%) 145 (71%) 0.0171 1  0.0260  0.1161 1  
 CT 137 (27%) 49 (24%)  0.95 (0.65, 1.39) 0.7813   1.10 (0.73, 1.65) 0.6475
 TT 9 (2%) 9 (5%)  4.78(1.59,14.39) 0.0054   4.82 (1.54, 15.11) 0.0069
 missing 2 4        
           
rs1799978* AA 424 (84%) 173 (84%) 0.9688 See appendix 2C 0.8678 0.1676 See appendix 2C 
 AG 75 (15%) 32 (15%)        
 GG 4 (1%) 2 (1%)        
 missing 1 0        
             
rs12364283
* 
AA 457 (91%) 181 (87%) 0.3488 See appendix 2C 0.2018 0.1363 See appendix 2C 
 AG 45 (9%) 25 (12%)        
 GG 2 (0%) 1 (1%)        
              
rs6589377 AA 265 (53%) 97 (47%) 0.2419 1  0.3083 0.1363 1  
 AG 195 (39%) 86 (41%)  1.23 (0.87, 1.76) 0.2429   1.26 (0.86, 1.82) 0.2345
 GG 44 (8%) 24 (12%)  1.55 (0.88, 2.73) 0.1282   1.49 (0.82, 2.72) 0.1920 
               
__DRD3__ AA 427 (85%) 166 (80%) 0.7684 See appendix 2C 0.7371 0.1676 See appendix 2C 
rs6808291* AT 68 (13%) 36 (17%)        
 TT 9 (2%) 5 (3%)        
              
rs1486012 AA 102 (20%) 41 (20%) 0.7799 0.86 (0.53, 1.39) 0.5351 0.7116 0.1676 0.84 (0.50, 1.39) 0.4889
174
 175
 AT 272 (54%) 107 (52%)  0.89 (0.60, 1.30) 0.5398   0.86 (0.57, 1.29) 0.4530 
 TT 130 (26%) 58 (28%)  1    1  
 missing 0 1        
           
rs2399496 AA 104 (21%) 38 (18%) 0.3517 1.11 (0.68,1.82) 0.6711 0.3675 0.1363 1.17 (0.69, 1.97) 0.5580
 AT 245 (48%) 113 (55%)  1.31 (0.90, 1.93) 0.1609   1.33 (0.89, 1.99) 0.1599
 TT 155 (31%) 56 (27%)  1    1  
           
rs9824856 AA 416 (83%) 157 (76%) 0.4421 1  0.2750  0.1363 1  
 AC 69 (14%) 41 (20%)  1.37 (0.84, 2.25) 0.2083   1.51 (0.90, 2.53) 0.1224
 CC 17 (3%) 8 (4%)  1.05 (0.42, 2.66) 0.9140   0.98 (0.37, 2.61) 0.9674
 missing     2     1        
           
rs2134655 AA 20 (4%) 12 (6%) 0.2478 1.78 (0.83, 2.82) 0.1394 0.5799 0.1654 1.32 (0.59, 2.95) 0.4992
 AG 163 (32%) 70 (34%)  1.22 (0.85, 1.77) 0.2799   1.2 (0.82, 1.77) 0.3560
 GG 321 (64%) 125 (60%)  1    1  
           
rs2251177* CC 2 (1%) 1 (1%) 0.0932 See appendix 2C 0.1852 0.1363 See appendix 2C 
 CT 24 (4%) 22 (11%)        
 TT 478 (95%) 184 (89%)        
           
rs963468 AA 54 (11%) 18 (9%) 0.6990 0.89 (0.48, 1.65) 0.7099 0.8132 0.1676 0.89 (0.47, 1.70) 0.7317
 AG 195 (39%) 80 (39%)  1.12 (0.76, 1.65) 0.5637   1.08 (0.72, 1.63) 0.7022
 GG 255 (51%) 109 (53%)  1    1  
           
rs3773678 CC 292 (58%) 114 (55%) 0.7624 1  0.7641 0.1676 1  
 CT 152 (30%) 62 (30%)  0.86 (0.55, 1.34) 0.5091   0.89 (0.56, 1.41) 0.6155
 TT 59 (12%) 31 (15%)  0.98 (0.52, 1.85) 0.9445   0.78 (0.40, 1.54) 0.4726
 missing    1    0        
           
rs2630349 AA 14 (3%) 7 (4%) 0.9305 1.05 (0.40, 2.76) 0.9262 0.8881 0.1675 0.78 (0.28, 2.17) 0.6364
 AG 99 (20%) 44 (21%)  0.92 (0.59, 1.45) 0.7322   1.01 (0.63, 1.61) 0.9845
 GG 391 (77%) 156 (75%)  1    1  
           
rs167771 AA 244 (48%) 102 (49%) 0.3408 1  0.2533 0.1363 1  
175
 176
 AG 156 (31%) 56 (27%)  0.74 (0.49, 1.12) 0.1564   0.82 (0.53, 1.26) 0.3641
 GG 104 (21%) 49 (24%)  0.73 (0.40, 1.34) 0.3097   0.59 (0.31, 1.11) 0.0987
           
rs167770 AA 179 (35%) 75 (36%) 0.4964 1  0.3213 0.1363 1  
 AG 226 (45%) 94 (45%)  0.91 (0.62, 1.32) 0.6049   1.06 (0.71, 1.58) 0.7716
 GG 99 (20%) 38 (18%)  0.73 (0.43, 1.23) 0.2379   0.73 (0.42, 1.26) 0.2558
           
rs324029 AA 101 (20%) 48 (23%) 0.7944 0.98 (0.59, 1.63) 0.9256 0.9744 0.1804 1.01 (0.59, 1.73) 0.9773
 AG 224 (44%) 86 (42%)  0.89 (0.60, 1.30) 0.5330    1.04 (0.70, 1.57) 0.8349
 GG 179 (36%) 73 (35%)  1    1  
           
rs10934256 AA 22 (4%) 8 (4%) 0.9158 1.01 (0.43, 2.34) 0.9860 0.4024 0.1388 1.16 (0.48, 2.80) 0.7441
 AC 135 (27%) 56 (27%)  1.08 (0.75, 1.57) 0.6769   1.31 (0.88, 1.95) 0.1795
 CC 347 (69%) 143 (69%)  1    1  
           
rs1486009* AA 435 (86%) 188 (91%) 0.3435 See appendix 2C 0.3816 0.1363 See appendix 2C 
 AG 67 (13%) 19 (9%)        
 GG 2 (1%) 0 (0%)        
           
rs3732783* AA 425 (84%) 181 (87%) 0.4866 See appendix 2C 0.6069 0.1654 See appendix 2C 
 AG 76 (15%) 25 (12%)        
 GG 3 (1%) 1 (1%)        
           
rs6280 CC 119 (24%) 53 (26%) 0.6937 0.84 (0.51, 1.41) 0.5157 0.8843 0.1676 0.93 (0.54, 1.59) 0.7777
 CT 223 (44%) 86 (41%)  0.85 (0.57, 1.26) 0.4120    1.04 (0.69, 1.58) 0.8492
 TT 162 (32%) 68 (33%)  1    1  
           
rs9825563 AA 222 (44%) 91 (44%) 0.9362 1  0.8633 0.1676 1  
 AG 222 (44%) 89 (43%)  0.94 (0.66, 1.34) 0.7497   1.03 (0.71, 1.49) 0.8800 
 GG 60 (12%) 27 (13%)  1.01 (0.60, 1.72) 0.9609   1.17 (0.67, 2.05) 0.5886
           
__DRD4__ CC 15 (3%) 7 (3%) 0.4125 1.19 (0.47, 3.01) 0.7212 0.3078 0.1363 1.04 (0.39, 2.78) 0.9420 
rs3758653 CT 166 (33%) 57 (28%)  0.80 (0.56, 1.14) 0.2185   0.75 (0.51, 1.09) 0.1303
 TT 323 (64%) 143 (69%)  1    1  
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rs1800443** GT 16 (3%) 1 (0.5%) 0.0417 0.12 (0.02, 0.92)  0.0693 0.1363 0.15 (0.02, 1.17) 0.0693
 TT 488 (97%) 206 
(99.5%) 
 1    1  
           
rs11246226 AA 103 (20%) 48 (23%) 0.4326 1.21 (0.76, 1.93) 0.4127 0.5792 0.1654 1.21 (0.74, 1.98) 0.4410 
 AC 250 (50%) 94 (46%)  0.92 (0.63, 1.35) 0.6645   0.98 (0.64, 1.43) 0.8342
 CC 151 (30%) 65 (31%)  1    1  
           
rs936465 CC 135 (27%) 56 (27%) 0.3644 1  0.3585 0.1363 1  
 CG 254 (50%) 96 (46%)  0.93 (0.63, 1.38) 0.7121   0.95 (0.62, 1.43) 0.7874
 GG 115 (23%) 55 (27%)  1.24 (0.79, 1.96) 0.3527   1.28 (0.79, 2.07) 0.3097
           
AA 455 (91%) 183 (88%) 0.9875 0.6939 0.1675 __DRD5__ See appendix 2C See appendix 2C 
rs4516717* AG 40 (8%) 21 (10%)        
 GG 6 (1%) 3 (2%)        
 missing 2 0        177            
rs2867383 AA 86 (17%) 29 (14%) 0.2482 0.90 (0.54, 1.49) 0.6727 0.2074 0.1363 0.90 (0.53, 1.52) 0.6853
 AG 213 (42%) 102 (49%)  1.27 (0.89, 1.82) 0.1911   1.31 (0.90, 1.92) 0.1569
 GG 204 (41%) 76 (37%)  1    1  
 missing 1 0        
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Appendix 2C. Relationship between TD and single nucleotide polymorphisms (SNPs) in dopamine receptor genes 
1, 2, 3, 4, and 5 (DRD1, DRD2, DRD3, DRD4, DRD5) with genotype count less than or equal to 5 in dominant model 
of inheritance. 
     _Ancestry-adjusted effect_ _Covariates-adjusted effect*
OR (95% C.I.)_Gene ___SNP__ Genotype Non-TD  ___TD___  p-value _OR (95% C.I.) p-value 
rs5326 AA+ AG 125 (25%) 46 (22%) 0.89 (0.60, 1.31) 0.5546 0.88 (0.58, 1.32) 0.5259DRD1 
 GG 379 (%) 161 (78%) 1  1  
     
rs17115461 AA 442 (88%) 173 (84%) 1  1 DRD2 
 AG+ GG 62 (12%) 34 (16%) 1.22 (0.70, 2.11) 0.4801 1.23 (0.69, 2.20) 0.4843 
     
rs1079594 GG+ GT 156 (31%) 59 (29%) 1.00 (0.69, 1.44) 0.9874 1.01 (0.68, 1.48) 0.9774 
 TT 348 (69%) 148 (72%) 1  1  
     
rs2734836 AA+ AG 165 (33%) 58 (28%) 0.88 (0.61, 1.27) 0.4921 0.91 (0.62, 1.34) 0.6420  178  GG 339 (67%) 149 (72%) 1  1  
     
rs1079596 AA+ AG 177 (35%) 72 (35%) 1.05 (0.74, 1.48) 0.7814 1.08 (0.75, 1.55) 0.6885 
 GG 327 (65%) 135 (65%) 1  1  
     
rs7103679 CC 341 (68%) 154 (74%) 1  1  
 CT+ TT 163 (32%) 53 (26%) 0.79 (0.54, 1.14) 0.2117 0.81 (0.55, 1.20) 0.3039 
     
rs7125415 CC 367 (73%) 162 (78%) 1  1  
 CT+ TT 137 (27%) 45 (22%) 0.72 (0.49, 1.07) 0.1003 0.74 (0.49, 1.12) 0.1488 
     
rs4648317 CC 356 (71%) 145 (70%) 1  1  
 CT+ TT 146 (29%) 58 (28%) 1.07 (0.74, 1.55) 0.7141 1.23 (0.83, 1.81) 0.3008 
 missing 2 4    
     
rs1799978 AA 424 (84%) 173 (84%) 1  1  
 AG+ GG 79 (16%) 34 (16%) 1.0 (0.63, 1.57) 0.9871 0.88 (0.55, 1.42) 0.6034 
 missing 1 0    
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rs12364283 AA 457 (91%) 181 (87%) 1  1  
 AG+ GG 47 (9%) 26 (13%) 1.47 (0.87, 2.45) 0.1469 1.64 (0.95, 2.84) 0.0755 
     
rs6808291 AA 427 (85%) 166 (80%) 1  1 DRD3 
 AT+ TT 77 (15%) 41 (20%) 1.19 (0.74, 1.92) 0.4682 1.22 (0.74, 2.00) 0.4371 
     
rs9824856 AA 416 (83%) 157 (76%) 1  1  
 AC+ CC 86 (17%) 49 (24%) 1.32 (0.82, 2.12) 0.2539 1.41 (0.86, 2.32) 0.1778 
     
rs2251177 CC+ CT 26 (5%) 23 (11%) 2.01 (1.05, 3.84) 0.0349 1.78 (0.90, 3.52) 0.0988 
 TT 478 (95%) 184 (89%) 1  1  
     
rs2630349 AA+ AG 113 (22%) 51 (25%) 0.94 (0.61, 1.45) 0.7725 0.97 (0.62, 1.54) 0.9119 
 GG 391 (78%) 156 (75%) 1  1  
     
rs10934256 AA+ AC 157 (31%) 64 (31%) 1.07 (0.75, 1.53) 0.6992 1.29 (0.88, 1.89) 0.1865 178
179
179  CC 347 (69%) 143 (69%) 1  1  
     
rs1486009 AA 435 (86%) 188 (91%) 1  1  
 AG+ GG 69 (14%) 19 (9%) 0.65 (0.38, 1.11) 0.1145 0.66 (0.38, 1.16) 0.1490  
     
rs3732783 AA 425 (84%) 181 (87%) 1  1  
 AG+ GG 79 (16%) 26 (13%) 0.75 (0.46, 1.21) 0.2321 0.78 (0.47, 1.28) 0.3190  
     
rs3758653 CC+ CT 181 (36%) 64 (31%) 0.83 (0.58, 1.17) 0.2844 0.77 (0.53, 1.11) 0.1603DRD4 
 TT 323 (64%) 143 (69%) 1  1  
     
rs4516717 AA 455 (91%) 183 (88%) 1  1 DRD5 
  AG+ GG 46 (9%) 24 (12%) 1.03 (0.57, 1.86) 0.9300 1.16 (0.62, 2.17) 0.6426
   missing 3 0  
*Covariate-adjusted model adjusted for baseage, sex, baseline antipsycohtic use (3 levels), proportion of European and Asian ancestry 
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Appendix 2D. Association between TD and haplotypes in dopamine receptor 
genes 1, 2, 3, 4, and 5 (DRD1, DRD2, DRD3, DRD4, DRD5) in European ancestry 
population.   
  ___Haplotype frequency___  
non-TD (n=287) TD (n=112)Gene Haplotype name and loci  __Global p-value*__ 
G G 0.38 0.37 0.7753 DRD1 
A A 0.15 0.15   
A G  0.46 0.48    
*SNP order: rs686 ,rs5326     
     
A G 0.17  0.16  0.8082  
G G 0.38  0.38    
G C  0.45  0.46     
* SNP order: rs2168631 , rs267418      
     
G T T C 0.51  0.50  0.9142 DRD2 
G G C C 0.18  0.18    
C T C T 0.29  0.30    
C T C C  0.01  0.02     
* SNP order:  rs6279 , rs1079594 , rs6277 , rs6275     
     
G T T G C G C G C G 0.02  NA 0.4360   
G C A C C G C G T G 0.11  0.09    
A C A C C A T T C A 0.17  0.16    
A C A C C A C T C A 0.01  0.01    
G T T G C G C T C A 0.54  0.57    
G C A C C G C G C G 0.13  0.16     
* SNP order: rs2734836, rs1800498, rs2234690, rs2587548, rs4986918, rs1079596, 
rs7103679, rs4586205, rs7125415, rs4648318  
     
A C G T T C  0.46  0.46  DRD3 
A T G T T C  0.05  0.04   
A T G G C C  0.18  0.18   
A C C T C T  0.29  0.30   
A C C T C C   0.01  0.02   
* SNP order: rs1486012, rs2399496, rs9824856, rs2134655, rs2251177, rs963468  
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G C G C G C  0.02  NA  
C C G C G T  0.11  0.09   
C C A C T C  0.01  0.01   
C C A T T C  0.17  0.16   
G C G C T C  0.55  0.57   
C C G C G C   0.14  0.17   
* SNP order: rs167770, rs324029, rs10934256, rs1486009, rs3732783, rs6280  
     
C A  0.81  0.79  DRD4 
C G  0.05  0.05   
T A   0.14  0.15   
C A  0.81  0.79   
  
 
 * SNP order: rs11246226, rs936465 
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Appendix 2E. Association between TD and haplotypes in dopamine receptor 
genes 1, 2, 3, 4, and 5 (DRD1, DRD2, DRD3, DRD4, DRD5) in African ancestry 
population.   
  ___Haplotype frequency___  
Gene Haplotype name and loci  global p-value*non-TD (n=140) TD (n=69)
G G 0.28  0.24  0.5528 DRD1 
A G 0.25  0.25    
G T  0.46  0.51     
SNP order: rs265974, rs265976     
     
G G 0.61  0.51  0.1261  
A A 0.10  0.07    
A G 0.29  0.41     
SNP order: rs686, rs5326      
     
G G 0.11  0.09  0.4039 DRD2 
C T 0.63  0.62    
G T 0.26  0.30    
SNP order: rs6279, rs1079594    
     
C T 0.25  0.23  0.6185  
C C 0.63  0.62    
T C  0.12  0.15     
SNP order: rs6277, rs6275    
     
C A C 0.83  0.78  0.2064  
T T G  0.17  0.22     
SNP order: rs1800498, rs2234690, rs2587548   
     
C G 0.81  0.80  0.8717  
C A 0.14  0.14    
T A  0.06  0.06     
SNP order: rs4986918, rs1079596    
      
T G 0.19  0.15  0.4533  
C G 0.33  0.34    
C A  0.47  0.51     
 182
SNP order: rs7125415, rs4648318     
      
C C 0.52  0.49  0.2726  
T C 0.36  0.36    
T T  0.12  0.15     
SNP order:  rs4581480, rs4648317    
     
T G G 0.34  0.31  0.7651 DRD3 
C G G 0.15  0.12    
C G A 0.24  0.22    
T A G  0.27  0.35     
SNP order: rs3773678, rs2630349, rs167771    
     
C C 0.59  0.57  0.3272 DRD4 
A G 0.34  0.35    
C G  0.07  0.09     
SNP order: rs11246226, rs936465    
     
A A 0.47 0.43 0.5586 DRD5 
G G 0.17 0.18   
 A G 0.36 0.39  
  SNP order: rs4516717, rs2867383     
*The global-p value were obtained from 10,000 times of permutation  
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Appendix 2F. Power calculation on aditive model among 207 TD and 504 
non-TD across different minor allele frequency of single nucleotide 
polymorphisms (SNPs) in dopamine receptor genes 1, 2, 3, 4, and 5 (DRD1, 
DRD2, DRD3, DRD4, DRD5). 
MAF* _Effect Size (OR), at alpha-level= 0.001 % of MAF in total 711 participants
  _1.25_ _1.50_ _1.75_ _2.00_ _2.25_ % range of MAF_ _ % in CATIE__ 
0.01 0.2% 0.6%  1%  3%   5% <0.01 --- 
0.05 0.8%  5% 16% 34%  55% 0.01~ <0.05 7% 
0.1  2% 14% 43% 73%  90% 0.05~ <0.1 13% 
0.2  4% 34% 77% 96%  99% 0.1~ <0.2 20% 
0.3  7% 48% 89% 99% 100% 0.2~ <0.3 17% 
0.4  8% 55% 92% 99% 100% 0.2~ <0.4 13% 
0.5  8% 56% 92% 99% 100% 0.4~ <0.5 30% 
*MAF: Minor allele frequency    
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